BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Non-Small Cell Lung Cancer readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Non-Small Cell Lung C
 ancer\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05532696-2326@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Gozanertinib: Phase 1/2 readout est. (NCT05532696)
DESCRIPTION:Gozanertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients\nEs
 timated primary completion: November 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gozanertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05532696
URL:https://assetmemo.bio/drug/gozanertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04958811-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04958811)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 ragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advance
 d Non-squamous NSCLC\nEstimated primary completion: November 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04958811
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04958811-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT04958811)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tir
 agolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced
  Non-squamous NSCLC\nEstimated primary completion: November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04958811
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107686-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT06107686)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Selected Patients With Advanced Solid Tumors\nE
 stimated primary completion: November 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06107686
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07336732-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Andamertinib: Phase 2 readout est. (NCT07336732)
DESCRIPTION:Andamertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: An
 damertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-d
 oublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutatio
 ns\nEstimated primary completion: November 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/andamertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07336732
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448312-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06448312)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Pembro
 lizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lun
 g Cancer\nEstimated primary completion: November 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06448312
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06704620)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Re
 ceptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small
  Cell Lung Cancer\nEstimated primary completion: November 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06704620-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06704620)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Tislelizumab and Platinum-based Chemotherapy Combination Wit
 h H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic No
 n-Small Cell Lung Cancer\nEstimated primary completion: November 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06704620
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  CIMAvax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With
  Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEst
 imated primary completion: 25 November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: CIM
 Avax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With Adv
 anced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEstimat
 ed primary completion: 25 November 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Multiple Therapies in Biomarker-selected Participants With Resect
 able Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04302025)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of Multiple Therapies in Biomarker-selected Participants Wit
 h Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 30 November 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/alectinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04223596-2024@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Brigatinib: Phase 2 readout est. (NCT04223596)
DESCRIPTION:Brigatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Clin
 ical Utility of Liquid Biopsy in Brigatinib ALK+ Patients\nEstimated prima
 ry completion: 30 November 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/brigatinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04223596
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2217@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Divarasib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Divarasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Multiple Therapies in Biomarker-selected Participants With Resectabl
 e Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary comp
 letion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/divarasib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04302025
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2220@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Entrectinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Entrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Multiple Therapies in Biomarker-selected Participants With Resecta
 ble Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/entrectinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04302025-2227@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Pralsetinib: Phase 2 readout est. (NCT04302025)
DESCRIPTION:Pralsetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Multiple Therapies in Biomarker-selected Participants With Resecta
 ble Stages IB-III Non-small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pralsetinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04302025
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256509-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07256509)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Al
 one as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resect
 able Non-squamous Non-small Cell Lung Cancer\nEstimated primary completion
 : 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 simertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07256509
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07256509-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:CPO301: Phase 2 readout est. (NCT07256509)
DESCRIPTION:CPO301\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuva
 nt Therapy for Patients With EGFR Mutation-positive Resectable Non-squamou
 s Non-small Cell Lung Cancer\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07256509
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749886-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06749886)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: An
  Exploratory Study of Tislelizumab in Combination with Chemotherapy in Imm
 uno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC in the
  Second-line Setting\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122687-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07122687)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chem
 otherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous No
 n-Small Cell Lung Cancer\nEstimated primary completion: 30 November 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122687-2254@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:IBI363: Phase 2 readout est. (NCT07122687)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 C
 ombined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as N
 eoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 November 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07122687
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749886-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06749886)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: An Exploratory Study of Tislelizumab in Combination with Chemotherap
 y in Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCL
 C in the Second-line Setting\nEstimated primary completion: 30 November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06749886-11057@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Denosumab (Xgeva): Phase 2 readout est. (NCT06749886)
DESCRIPTION:Denosumab (Xgeva)\, phase 2\, Non-Small Cell Lung Cancer.\nStud
 y: An Exploratory Study of Tislelizumab in Combination with Chemotherapy i
 n Immuno-experienced Patients with EGFR/ALK/ROS1-negative Advanced NSCLC i
 n the Second-line Setting\nEstimated primary completion: 30 November 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/denosumab-xgeva#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06749886
URL:https://assetmemo.bio/drug/denosumab-xgeva#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429463-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectabl
 e Squamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 
 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pa
 clitaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05429463
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05429463-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Sintilimab: Phase 3 readout est. (NCT05429463)
DESCRIPTION:Sintilimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Sq
 uamous Cell NSCLC（neoSCORE Ⅱ）\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054
 29463
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949606-2065@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 1/2 readout est. (NCT05949606)
DESCRIPTION:Danvilostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Adv
 anced or Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/da
 nvilostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05949606
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949606-2265@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 1/2 readout est. (NCT05949606)
DESCRIPTION:Izalontamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advan
 ced or Metastatic Non-small Cell Lung Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05949606
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06114511-2282@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab brengitecan: Phase 1/2 readout est. (NCT06114511)
DESCRIPTION:Trastuzumab brengitecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER
 2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06114511
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05736731-2310@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:A2B530: Phase 1/2 readout est. (NCT05736731)
DESCRIPTION:A2B530\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B530\, a Logic-gated CAR T\, in
  Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Ex
 pression\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/a2b530#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05736731
URL:https://assetmemo.bio/drug/a2b530#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546268-2661@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:MRT-2359: Phase 1/2 readout est. (NCT05546268)
DESCRIPTION:MRT-2359\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Oral MRT-2359 in Selected Cancer Patients\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mr
 t-2359#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05546268
URL:https://assetmemo.bio/drug/mrt-2359#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05024214-994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Envafolimab: Phase 1/2 readout est. (NCT05024214)
DESCRIPTION:Envafolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tu
 mors\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05024214
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04691817-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04691817)
DESCRIPTION:Atezolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic
  Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhib
 itor-Based Therapy\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04691817
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-2087@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AK129: Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:AK129\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: AK129 C
 ombination Therapy for Advanced Solid Tumors\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ak12
 9#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 943820
URL:https://assetmemo.bio/drug/ak129#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 i
 n Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05482568
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-2207@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Pyrotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A T
 rial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in 
 Subjects With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05482568
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05473156-2349@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AP203: Phase 1/2 readout est. (NCT05473156)
DESCRIPTION:AP203\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate the Safety\, Pharmacokinetics\, and Clinical Activity of A
 P203 in Patients with Locally Advanced or Metastatic Solid Tumors\, and Ex
 pansion to Selected Malignancies\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ap203#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05473156
URL:https://assetmemo.bio/drug/ap203#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07151040-2766@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:TH9619: Phase 1/2 readout est. (NCT07151040)
DESCRIPTION:TH9619\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase 
 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors\nEs
 timated primary completion: December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/th9619#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07151040
URL:https://assetmemo.bio/drug/th9619#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05482568-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab rezetecan: Phase 1/2 readout est. (NCT05482568)
DESCRIPTION:Trastuzumab rezetecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or 
 SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer\nEstimated p
 rimary completion: December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05482568
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03909334-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03909334)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Osimertinib With and Without Ramucirumab in Locally Advan
 ced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03909334
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03965468-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03965468)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy\, Chemotherapy\, Radiotherapy and Surgery for Synchronous Oligo-
 metastatic NSCLC\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03965468
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000710-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05000710)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Conc
 omitant Radiotherapy\, Tremelimumab & Durvalumab for Advanced NSCLC Patien
 ts Progressing on First-line Immunotherapy\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05000710
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03786692)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizu
 mab in Stage IV NSCLC\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03915678-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03915678)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients W
 ith Advanced Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03915678
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246110-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06246110)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in 
 Patients With Stage 4 NSCLC\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03527108-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03527108)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab Plus Ramucirumab in Patients With Recurrent\, Advanced\, Metastatic N
 SCLC\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03527108
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03786692)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizum
 ab in Stage IV NSCLC\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03527108-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT03527108)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Niv
 olumab Plus Ramucirumab in Patients With Recurrent\, Advanced\, Metastatic
  NSCLC\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03527108
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03909334-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT03909334)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Osimertinib With and Without Ramucirumab in Locally Advanced or Meta
 static Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ramucir
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03909334
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03965468-2015@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03965468)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Im
 munotherapy\, Chemotherapy\, Radiotherapy and Surgery for Synchronous Olig
 o-metastatic NSCLC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03965468
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000710-2015@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05000710)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncomitant Radiotherapy\, Tremelimumab & Durvalumab for Advanced NSCLC Pati
 ents Progressing on First-line Immunotherapy\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trem
 elimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05000710
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246110-2115@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Resiquimod: Phase 2 readout est. (NCT06246110)
DESCRIPTION:Resiquimod\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Pat
 ients With Stage 4 NSCLC\nEstimated primary completion: December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/resiquimod#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03786692-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03786692)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- At
 ezolizumab in Stage IV NSCLC\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03786692
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246110-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06246110)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemothera
 py in Patients With Stage 4 NSCLC\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06246110
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250777-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT06250777)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer P
 atients With Asymptomatic Brain Metastases\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastu
 zumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06250777
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890182-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06890182)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resecta
 ble Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC\nEstimated primary comple
 tion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06890182
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06198907-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06198907)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Goli
 docitinib in Combination With Sintilimab for PD-L1 Selected Treatment Loca
 lly Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06198907
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890182-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06890182)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for R
 esectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC\nEstimated primary 
 completion: December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06890182
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623656-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06623656)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Preo
 perative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06623656
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06652048-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06652048)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanc
 ed NSCLC After Disease Progression on Third-generation EGFR-TKI\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06652048
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844474-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06844474)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844474
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally 
 Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcino
 ma and Other Solid Tumors\nEstimated primary completion: December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT059
 56587
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05956587-2065@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Danvilostomig: Phase 2 readout est. (NCT05956587)
DESCRIPTION:Danvilostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced o
 r Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcinoma and Oth
 er Solid Tumors\nEstimated primary completion: December 2026. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/danvilostomig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05956587
URL:https://assetmemo.bio/drug/danvilostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06864624-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT06864624)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06864624
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844474-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06844474)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study of SHR-1826 for Injection in Patients With NSCLC\nE
 stimated primary completion: December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844474
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456256-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05456256)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers Wi
 th Advanced Lung Adenocarcinoma\nEstimated primary completion: December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05456256
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456256-2598@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dimesna: Phase 2 readout est. (NCT05456256)
DESCRIPTION:Dimesna\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced 
 Lung Adenocarcinoma\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/dimesna#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05456256
URL:https://assetmemo.bio/drug/dimesna#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in 
 Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative 
 Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06711900-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06711900)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Pembrolizumab Versus Chemot
 herapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1
  Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06711900
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06382129)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unrese
 ctable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung C
 ancer(PANKU-Lung02)\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06671379-2181@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT06671379)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-muta
 ted\, Advanced or Metastatic NSCLC\nEstimated primary completion: December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rez
 etecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06671379
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06382129-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06382129)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresecta
 ble Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Canc
 er(PANKU-Lung02)\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06382129
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive ctDNA-Based Personalization of Treatment During Consolidation Therapy
  in NSCLC\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05654454-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT05654454)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 afety and Efficacy Study of Bevacizumab\, Paclitaxel\, Carboplatin Compare
 d to Avastin® in Non-Small Cell Lung Cancer\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05654454
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2015@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Tremelimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 aptive ctDNA-Based Personalization of Treatment During Consolidation Thera
 py in NSCLC\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04585490)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Adaptive ctDNA-Based Personalization of Treatment During Consolidatio
 n Therapy in NSCLC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754644-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06754644)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate Efficacy\, and Safety of QL2107 Plus Chemo and Co
 mpare With Keytruda in Participants With IV nqNSCLC\nEstimated primary com
 pletion: December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06754644
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088771-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cemiplimab: Phase 1/2 readout est. (NCT06088771)
DESCRIPTION:Cemiplimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable
  NSCLC\nEstimated primary completion: 1 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06088771
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05713006-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT05713006)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Alectinib Pharmacokinetic in Patients With NSCLC\nEstimated primar
 y completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/alectinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05713006
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05825625-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05825625)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05825625
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05463224-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05463224)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Laze
 rtinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patient
 s\nEstimated primary completion: 1 December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05463224
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04268550-2209@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Retevmo (Selpercatinib): Phase 2 readout est. (NCT04268550)
DESCRIPTION:Retevmo (Selpercatinib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cel
 l Lung Cancer (A LUNG-MAP Treatment Trial)\nEstimated primary completion: 
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/selp
 ercatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04268550
URL:https://assetmemo.bio/drug/selpercatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683703-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06683703)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Uti
 delone Injection Combined with Bevacizumab Injection for Non-small Cell Lu
 ng Cancer Patients with Brain Metastases\nEstimated primary completion: 1 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaci
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06683703
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07035392-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07035392)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC\nEstim
 ated primary completion: 1 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07035392
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683703-2272@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Utidelone: Phase 2 readout est. (NCT06683703)
DESCRIPTION:Utidelone\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Utide
 lone Injection Combined with Bevacizumab Injection for Non-small Cell Lung
  Cancer Patients with Brain Metastases\nEstimated primary completion: 1 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/utidelon
 e#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 683703
URL:https://assetmemo.bio/drug/utidelone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06192849-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06192849)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 o Assess the Efficacy and Safety of Furmonertinib in Patients With Epiderm
 al Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small 
 Cell Lung Carcinoma\, Following Complete Tumour Resection With or Without 
 Adjuvant Chemotherapy\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06192849
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06714708-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06714708)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low 
 Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant
  Therapy for Stage II-III NSCLC\nEstimated primary completion: 1 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06714708
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06426511-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06426511)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ctD
 NA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06426511
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04285671-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04285671)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Necitumumab and Trastuzumab in Combination With Osimertinib for 
 the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutate
 d Stage IV Non-small Cell Lung Cancer\nEstimated primary completion: 2 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4285671
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04285671-2026@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261202
DTEND;VALUE=DATE:20261203
SUMMARY:Necitumumab: Phase 1/2 readout est. (NCT04285671)
DESCRIPTION:Necitumumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: N
 ecitumumab and Trastuzumab in Combination With Osimertinib for the Treatme
 nt of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV 
 Non-small Cell Lung Cancer\nEstimated primary completion: 2 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/necitumumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04285671
URL:https://assetmemo.bio/drug/necitumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04245514-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04245514)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mult
 imodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)\nEstim
 ated primary completion: 7 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04245514
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151574-2274@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261210
DTEND;VALUE=DATE:20261211
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT06151574)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) 
 Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations 
 Compared With Standard Treatment\nEstimated primary completion: 10 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zongertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06151
 574
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT07376382)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimerti
 nib in Patients With Locally Advanced or Metastatic NSCLC\nEstimated prima
 ry completion: 12 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07376382
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376382-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:CPO301: Phase 3 readout est. (NCT07376382)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients 
 With Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 1
 2 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo3
 01#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7376382
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06430866-2085@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261214
DTEND;VALUE=DATE:20261215
SUMMARY:Abp 234: Phase 3 readout est. (NCT06430866)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pharmac
 okinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)\nEstima
 ted primary completion: 14 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/abp-234#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06430866
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669430-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembro
 lizumab in Participants With Solid Tumor Malignancies\nEstimated primary c
 ompletion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05669430
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669430-2037@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:GV20-0251: Phase 1/2 readout est. (NCT05669430)
DESCRIPTION:GV20-0251\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizu
 mab in Participants With Solid Tumor Malignancies\nEstimated primary compl
 etion: 15 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05669430
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-2704@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:rezatapopt: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:rezatapopt\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a
  TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezatapopt#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0458575
 0
URL:https://assetmemo.bio/drug/rezatapopt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747169-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin 
 in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small C
 ell Lung Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated prim
 ary completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06747169
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747169-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in L
 ocally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell 
 Lung Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated primary 
 completion: 17 December 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747169
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747169-2160@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Endostar: Phase 2 readout est. (NCT06747169)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effica
 cy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Loc
 ally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lu
 ng Cancer: a Single-arm\, Multicenter Clinical Study\nEstimated primary co
 mpletion: 17 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/endostar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06747169
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung 
 Cancer With Oncogenic Mutation\nEstimated primary completion: 24 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0432289
 0
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-1966@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Crizotinib: Phase 2 readout est. (NCT04322890)
DESCRIPTION:Crizotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trea
 tment Strategies and Survival Outcome for Non-small Cell Lung Cancer With 
 Oncogenic Mutation\nEstimated primary completion: 24 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04322890
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06783647)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Trial of LBL-024 Combination Drug in Patients With Advanced Solid 
 Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06783647
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung Ca
 ncer With Oncogenic Mutation\nEstimated primary completion: 24 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04322890
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322890-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT04322890)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Treatment Strategies and Survival Outcome for Non-small Cell Lung 
 Cancer With Oncogenic Mutation\nEstimated primary completion: 24 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0432289
 0
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06783647)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Clinical Trial of LBL-024 Combination Drug in Patients With Advance
 d Solid Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 Dece
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 83647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-2588@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Opamtistomig: Phase 2 readout est. (NCT06783647)
DESCRIPTION:Opamtistomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid
  Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/opamtistomig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06783647
URL:https://assetmemo.bio/drug/opamtistomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06783647-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261224
DTEND;VALUE=DATE:20261225
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06783647)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Clinical Trial of LBL-024 Combination Drug in Patients With Advanc
 ed Solid Tumours[Substudy 01(NSCLC)]\nEstimated primary completion: 24 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 83647
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525350-2222@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Glumetinib: Phase 2 readout est. (NCT06525350)
DESCRIPTION:Glumetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of the Combination of Glumetinib a
 nd Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-ov
 erexpressed Non-small Cell Lung Cancer\nEstimated primary completion: 25 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/glumeti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06525350
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525350-2506@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Docetaxel (HB1801): Phase 2 readout est. (NCT06525350)
DESCRIPTION:Docetaxel (HB1801)\, phase 2\, Non-Small Cell Lung Cancer.\nStu
 dy: A Study to Evaluate the Efficacy and Safety of the Combination of Glum
 etinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment o
 f MET-overexpressed Non-small Cell Lung Cancer\nEstimated primary completi
 on: 25 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /docetaxel-hb1801#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06525350
URL:https://assetmemo.bio/drug/docetaxel-hb1801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06525350-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261225
DTEND;VALUE=DATE:20261226
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06525350)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Evaluate the Efficacy and Safety of the Combination of Gl
 umetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment
  of MET-overexpressed Non-small Cell Lung Cancer\nEstimated primary comple
 tion: 25 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06525350
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06792435-2360@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:ASP546C: Phase 1/2 readout est. (NCT06792435)
DESCRIPTION:ASP546C\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XNW27
 011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.\
 nEstimated primary completion: 30 December 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/asp546c#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06792435
URL:https://assetmemo.bio/drug/asp546c#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109558-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT06109558)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: The Efficacy and Safety of LMV-12 Combined With Osimertinib in N
 SCLC\nEstimated primary completion: 30 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06109558
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699123-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04699123)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 he Study of NC318 Alone or in Combination With Pembrolizumab in Patients W
 ith Advanced Non-small Cell Lung Cancer\nEstimated primary completion: 30 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembro
 lizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04699123
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319950-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06319950)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-dose Furmonertinib Versus Osimertinib in Advanced EGFRm NSCLC Patients
  With Brain Metastases\nEstimated primary completion: 30 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06319950
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108816-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07108816)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Single-center\, Phase II Clinical Trial Evaluating the Efficacy
  of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvan
 t Therapy for PD-L1-positive\, Resectable Stage II to IIIB Non-small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 30 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071088
 16
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982924-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06982924)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Study on the Efficacy and Safety of the Combination of Limertinib 
 and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.\nEsti
 mated primary completion: 30 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06982924
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086326-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07086326)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Che
 motherapy in Resectable NSCLC\nEstimated primary completion: 30 December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07086326
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07108816-2581@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tagitanlimab: Phase 2 readout est. (NCT07108816)
DESCRIPTION:Tagitanlimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Single-center\, Phase II Clinical Trial Evaluating the Efficacy of Sacituz
 umab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy f
 or PD-L1-positive\, Resectable Stage II to IIIB Non-small Cell Lung Cancer
  (NSCLC)\nEstimated primary completion: 30 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tagitanlimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07108816
URL:https://assetmemo.bio/drug/tagitanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06982924-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Limertinib: Phase 2 readout est. (NCT06982924)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study on the Efficacy and Safety of the Combination of Limertinib a
 nd Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.\nEstim
 ated primary completion: 30 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06982924
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06467500-1994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06467500)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective\, Open-label\, Single-center\, Single-arm Phase II Clinical Stu
 dy of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patien
 ts With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and
  Failed Immunotherapy\nEstimated primary completion: 30 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06467500
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169552-2129@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:HC010: Phase 2 readout est. (NCT07169552)
DESCRIPTION:HC010\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: HC010 in 
 First-line PD-L1 Positive Advanced NSCLC Patients\nEstimated primary compl
 etion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/hc010#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07169552
URL:https://assetmemo.bio/drug/hc010#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772287-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Toripalimab: Phase 3 readout est. (NCT04772287)
DESCRIPTION:Toripalimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adj
 uvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage I
 I-IIIB(N2) NSCLC (LungMate-008)\nEstimated primary completion: 30 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT047722
 87
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of 
 Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04140526
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04180371-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2
  Expression\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04180371
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-2413@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Gotistobart: Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Gotistobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety\, PK and Efficacy of ONC-392 in Monotherapy and in Combination of An
 ti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/got
 istobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04140526
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04180371-2421@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nuzefatide pevedotin: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nuzefatide pevedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Study BT5528-100 in Patients With Advanced Solid Tumors Associated
  With EphA2 Expression\nEstimated primary completion: 31 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nuzefatide-pevedotin#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041803
 71
URL:https://assetmemo.bio/drug/nuzefatide-pevedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04140526-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04140526)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Safety\, PK and Efficacy of ONC-392 in Monotherapy and in Combinat
 ion of Anti-PD-1 in Advanced Solid Tumors and NSCLC\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04140526
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06343064-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Vebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplifi
 cation or MET Overexpression Following EGFR-TKI\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/andamertinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06343064
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06343064-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT06343064)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: V
 ebreltinib Plus PLB1004 in EGFR-mutated\, Advanced NSCLC With MET Amplific
 ation or MET Overexpression Following EGFR-TKI\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vebreltinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06343064
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05340309-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05340309)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Su
 bcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05340309
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04625647-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Sotorasib: Phase 2 readout est. (NCT04625647)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Testi
 ng the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced 
 Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)\nEsti
 mated primary completion: 31 December 2026. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04625647
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02912949-2821@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Bizengri (Zenocutuzumab): Phase 2 readout est. (NCT02912949)
DESCRIPTION:Bizengri (Zenocutuzumab)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumor
 s Harboring an NRG1 Fusion (eNRGy)\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenocutuzum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 2912949
URL:https://assetmemo.bio/drug/zenocutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05597800-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05597800)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients Wi
 th HIV\, HBV\, HCV and Long Covid Syndrome\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05597800
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05597800-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05597800)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients W
 ith HIV\, HBV\, HCV and Long Covid Syndrome\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 ilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05597800
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07402070-2254@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:IBI363: Phase 2 readout est. (NCT07402070)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 a
 s Neoadjuvant Therapy in Resectable Stage II-III Non-Small Cell Lung Cance
 r\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07402070
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271602-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07271602)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Phase 2 Randomized\, Controlled Trial of QL1706 Plus Chemo
 therapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lun
 g Cancer.\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07271602
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322783-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07322783)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Combined With Savolitinib in the Treatment of NSCLC Wi
 th Low Copy Number MET Amplification\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7322783
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330037-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07330037)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: TA
 LENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectab
 le NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy\nEstimated prima
 ry completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07330037
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05798845-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Toripalimab: Phase 2 readout est. (NCT05798845)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage I
 I-IIIA (N+) Non Small Cell Lung Cancer\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripal
 imab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05798845
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769295-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06769295)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemother
 apy in Patients with NSCLC\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06769295
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322783-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT07322783)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Combined With Savolitinib in the Treatment of NSCLC Wi
 th Low Copy Number MET Amplification\nEstimated primary completion: 31 Dec
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7322783
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751018-2207@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT05751018)
DESCRIPTION:Pyrotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-am
 plified/Mutated Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pyrotinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05751018
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04136535-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04136535)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride fo
 r Osimertinib-resistant Non-squamous NSCLC\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04136535
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05805631-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05805631)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant N
 SCLC\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05805631
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440954-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06440954)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal
  Metastases\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06440954
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330050-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07330050)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant 
 Advanced NSCLC\nEstimated primary completion: 31 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07330050
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT05059522)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cont
 inued Access Study for Participants Deriving Benefit in Pfizer-Sponsored A
 velumab Parent Studies That Are Closing\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorlat
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05059522
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07162883-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07162883)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 harmacokinetic Study of QL2107 Versus Keytruda® for Adjuvant Therapy of N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 162883
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04841811-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT04841811)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MD
 T-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance i
 n EGFRm+ Unresectable Stage III NSCLC (APPROACH)\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04841811
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05059522-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05059522)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Continued Access Study for Participants Deriving Benefit in Pfizer-Sp
 onsored Avelumab Parent Studies That Are Closing\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05059522
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06674343-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06674343)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib 160mg as First-line Treatment in Locally Advanced or Metastat
 ic NSCLC With EGFR Classical Mutations\nEstimated primary completion: 31 D
 ecember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06674343
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561362-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04561362)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignanci
 es\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04561362
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879717-2162@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dostarlimab: Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:Dostarlimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Wi
 thout Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dostarlimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/dostarlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879717-2712@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:roginolisib: Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:roginolisib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Wi
 thout Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/roginolisib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/roginolisib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06879717-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06879717)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Roginolisib (IOA-244) in Combination With Dostarlimab W
 ith or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) 
 Patients\nEstimated primary completion: January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06879717
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208773-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\nEstimate
 d primary completion: January 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07208773-2817@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tambotatug pelitecan: Phase 1/2 readout est. (NCT07208773)
DESCRIPTION:Tambotatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors\
 nEstimated primary completion: January 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07208773
URL:https://assetmemo.bio/drug/tambotatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05206812-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05206812)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Wind
 ow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynami
 cs in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05206812
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493980-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07493980)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resecta
 ble Stage II-III Non-small Cell Lung Cancer Patients\nEstimated primary co
 mpletion: January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/toripalimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07493980
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07493980-2147@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:JSKN016: Phase 2 readout est. (NCT07493980)
DESCRIPTION:JSKN016\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study o
 n the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable 
 Stage II-III Non-small Cell Lung Cancer Patients\nEstimated primary comple
 tion: January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/j
 skn016#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07493980
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04467723-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Atezolizumab: Phase 1/2 readout est. (NCT04467723)
DESCRIPTION:Atezolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCL
 C\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04467723
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07341737-2732@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:SL-28: Phase 1/2 readout est. (NCT07341737)
DESCRIPTION:SL-28\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SL-28 f
 or Advanced Solid Tumours\nEstimated primary completion: 1 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sl-28#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07341737
URL:https://assetmemo.bio/drug/sl-28#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083687-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07083687)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib in ROS1+ NSCLC With Brain Metastasis\nEstimated primary completion:
  1 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lorl
 atinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07083687
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06971406)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexe
 d in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptome
 ningeal Metastasis\nEstimated primary completion: 1 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06971406)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hig
 h-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed 
 in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeni
 ngeal Metastasis\nEstimated primary completion: 1 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06971406-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06971406)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pem
 etrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With L
 eptomeningeal Metastasis\nEstimated primary completion: 1 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06971406
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Di
 clofenac for the Treatment of Patients With Metastatic Non-small Cell Lung
  Cancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731270
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D
 iclofenac for the Treatment of Patients With Metastatic Non-small Cell Lun
 g Cancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06731270
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Diclo
 fenac for the Treatment of Patients With Metastatic Non-small Cell Lung Ca
 ncer on Single Agent Immunotherapy\nEstimated primary completion: 1 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673127
 0
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Dicl
 ofenac for the Treatment of Patients With Metastatic Non-small Cell Lung C
 ancer on Single Agent Immunotherapy\nEstimated primary completion: 1 Janua
 ry 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06731
 270
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05221840-2157@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Oleclumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Oleclumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Glo
 bal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab
  With Monalizumab Following Concurrent Chemoradiation in Patients With Sta
 ge III Unresectable Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 leclumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05221840
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05221840-2257@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270108
DTEND;VALUE=DATE:20270109
SUMMARY:Monalizumab: Phase 3 readout est. (NCT05221840)
DESCRIPTION:Monalizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A G
 lobal Study to Assess the Effects of Durvalumab With Oleclumab or Durvalum
 ab With Monalizumab Following Concurrent Chemoradiation in Patients With S
 tage III Unresectable Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: 8 January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /monalizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05221840
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06417814)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or
  Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in 
 Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 11 January 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417814-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06417814)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Dato-DXd With or Wi
 thout Osimertinib Compared With Platinum Based Doublet Chemotherapy in Par
 ticipants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 11 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06417814
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan i
 n Combination With Pembrolizumab for Participants With Metastatic Non-smal
 l Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tum
 or Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary completi
 on: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05609968
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT05609968)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Gov
 itecan in Combination With Pembrolizumab for Participants With Metastatic 
 Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD
 -L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)\nEstimated primary 
 completion: 12 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/sacituzumab-govitecan#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05609968
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06752408-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06752408)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Au
 molertinib Versus Osimertinib As First-line Therapy for Patients with EGFR
  Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer\nEstima
 ted primary completion: 16 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06752408
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05374603)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Savo
 litinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Meta
 static NSCLC\nEstimated primary completion: 18 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT05374603)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Adva
 nced or Metastatic NSCLC\nEstimated primary completion: 18 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Alecensa (Alectinib): Phase 3 readout est. (NCT05170204)
DESCRIPTION:Alecensa (Alectinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study Evaluating the Efficacy and Safety of Multiple Therapies in 
 Cohorts of Participants With Locally Advanced\, Unresectable\, Stage III N
 on-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0517020
 4
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05170204-2220@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Entrectinib: Phase 3 readout est. (NCT05170204)
DESCRIPTION:Entrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts o
 f Participants With Locally Advanced\, Unresectable\, Stage III Non-Small 
 Cell Lung Cancer (NSCLC)\nEstimated primary completion: 19 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/entrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05170204
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699188-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270125
DTEND;VALUE=DATE:20270126
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT04699188)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS 
 G12C Mutation\nEstimated primary completion: 25 January 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04699188
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743505-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04743505)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Safety and Efficacy of Combining APL-101 With Frontline Osimerti
 nib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 31 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04743505
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Combination Therapy With Amivantamab and Cetrelimab in Participa
 nts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completi
 on: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05908734
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743505-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT04743505)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of Combining APL-101 With Frontline Osimertinib in Pati
 ents With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 31 January 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04743505
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2285@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cetrelimab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Cetrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Combination Therapy With Amivantamab and Cetrelimab in Participan
 ts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05908734
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07202364-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Beruzatatug pelitecan: Phase 2 readout est. (NCT07202364)
DESCRIPTION:Beruzatatug pelitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of YL202 in Patients With Advanced Solid Tumors\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/beruzatatug-pelitecan#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07202364
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06269211-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06269211)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cel
 l Lung Cancer with EGFR Mutation and PD-L1 Positive Expression\nEstimated 
 primary completion: 31 January 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06269211
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Maligna
 ncies Affecting the Lungs\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172802-2495@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:GI-108: Phase 1/2 readout est. (NCT07172802)
DESCRIPTION:GI-108\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y of GI-108\, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein\, as Mo
 notherapy in Patients With Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: February 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/gi-108#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07172802
URL:https://assetmemo.bio/drug/gi-108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-2575@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:KB707: Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:KB707\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Af
 fecting the Lungs\nEstimated primary completion: February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/kb707#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/kb707#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06228326-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06228326)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study Assessing KB707 for the Treatment of Advanced Solid Tumor 
 Malignancies Affecting the Lungs\nEstimated primary completion: February 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06228326
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04716946-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04716946)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trea
 ting Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation 
 Therapy\nEstimated primary completion: February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04716946
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05798663-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT05798663)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unr
 esectable Stage III NSCLC\nEstimated primary completion: February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05798663
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04499053-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04499053)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Durv
 alumab and Tremelimumab in Combination With Chemotherapy in HIV-infected P
 atients With Non-small Cell Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 499053
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696782-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05696782)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Quic
 k Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lu
 ng Cancer\nEstimated primary completion: February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05696782
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05241028-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT05241028)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-sm
 all Cell Lung Cancer\nEstimated primary completion: February 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05241028
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04499053-2015@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04499053)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Du
 rvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected
  Patients With Non-small Cell Lung Cancer\nEstimated primary completion: F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremeli
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04499053
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463665-2654@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Olvimulogene nanivacirepvec: Phase 2 readout est. (NCT06463665)
DESCRIPTION:Olvimulogene nanivacirepvec\, phase 2\, Non-Small Cell Lung Can
 cer.\nStudy: Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-d
 oublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Doc
 etaxel in NSCL Cancer\nEstimated primary completion: February 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/olvimulogene-nanivacirepvec
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064
 63665
URL:https://assetmemo.bio/drug/olvimulogene-nanivacirepvec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06939595-2443@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P51: Phase 3 readout est. (NCT06939595)
DESCRIPTION:CT-P51\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Prev
 iously Untreated Metastatic Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ct-p51#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069395
 95
URL:https://assetmemo.bio/drug/ct-p51#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031154-2014@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Apatinib: Phase 2 readout est. (NCT07031154)
DESCRIPTION:Apatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Sing
 le-arm\, Multicenter\, Prospective Clinical Study of Adebrelimab Combined 
 With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cance
 r\nEstimated primary completion: 1 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/apatinib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07031154
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031154-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07031154)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 ingle-arm\, Multicenter\, Prospective Clinical Study of Adebrelimab Combin
 ed With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Ca
 ncer\nEstimated primary completion: 1 February 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07031154
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323641-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07323641)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progres
 sive\, Incurable\, Non Small Cell Lung Cancer\nEstimated primary completio
 n: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/o
 simertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07323641
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323641-2230@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Telisotuzumab Vedotin: Phase 2 readout est. (NCT07323641)
DESCRIPTION:Telisotuzumab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Telisotuzumab Vedotin and Osimertinib for the Treatment of Progress
 ive\, Incurable\, Non Small Cell Lung Cancer\nEstimated primary completion
 : 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/te
 lisotuzumab-vedotin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07323641
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinatio
 n With Intravenous Ipilimumab and Chemotherapy in Participants With Previo
 usly Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinati
 on With Intravenous Ipilimumab and Chemotherapy in Participants With Previ
 ously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06946797)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in 
 Combination With Intravenous Ipilimumab and Chemotherapy in Participants W
 ith Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cance
 r (NSCLC)\nEstimated primary completion: 5 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467863-2114@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270214
DTEND;VALUE=DATE:20270215
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07467863)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Dual-Target CAR-NK Cells Directed Against MSLN\, EGFR\, or HER
 2 in Advanced NSCLC\nEstimated primary completion: 14 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dual-target-car-nk-cells#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07467
 863
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06140836-2264@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:Repotrectinib: Phase 3 readout est. (NCT06140836)
DESCRIPTION:Repotrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Repotrectinib Versus Crizotinib in Participants With Locally Adv
 anced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive N
 on-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)\nEstimated primary completio
 n: 16 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 repotrectinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06140836
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117890-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT07117890)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Un
 common Mutations\nEstimated primary completion: 20 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sunvozertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07117890
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06248606-2025@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Krazati (Adagrasib): Phase 2 readout est. (NCT06248606)
DESCRIPTION:Krazati (Adagrasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC 
 With Untreated Brain Metastases\nEstimated primary completion: 25 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/adagrasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06248606
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897046-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270225
DTEND;VALUE=DATE:20270226
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT06897046)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Perioperative Study of Iparomlimab and Tuvonralimab in Resec
 table NSCLC\nEstimated primary completion: 25 February 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06897046
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R
 α Binding\, in Patients With Unresectable Locally Advanced or Metastatic 
 Cancer\nEstimated primary completion: 28 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 afety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gli
 oblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 
 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bev
 acizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06047379
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sa
 fety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glio
 blastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 2
 8 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipil
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06047379
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-2364@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Imneskibart: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Imneskibart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-
 2Rα Binding\, in Patients With Unresectable Locally Advanced or Metastati
 c Cancer\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/imneskibart#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/imneskibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-2638@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:NEO212: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:NEO212\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glioblas
 toma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/neo212#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047
 379
URL:https://assetmemo.bio/drug/neo212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623136-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06623136)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of ES102 in Combination With Toripalimab in Subjects With Advanced No
 n-small Cell Lung Cancer\nEstimated primary completion: 28 February 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06623136
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623136-2546@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Ordastobart: Phase 2 readout est. (NCT06623136)
DESCRIPTION:Ordastobart\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of ES102 in Combination With Toripalimab in Subjects With Advanced No
 n-small Cell Lung Cancer\nEstimated primary completion: 28 February 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06623136
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Sacituzumab Tirumotecan Combined With Toripalimab for Re
 sectable Stage II-IIIB NSCLC\nEstimated primary completion: 28 February 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirum
 otecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07438600
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Sacituzumab Tirumotecan Combined With Toripalimab for Rese
 ctable Stage II-IIIB NSCLC\nEstimated primary completion: 28 February 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7438600
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07438600-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07438600)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Sta
 ge II-IIIB NSCLC\nEstimated primary completion: 28 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07438600
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06275360-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06275360)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Repos
 itioning Immunotherapy in VetArans With Lung Cancer\nEstimated primary com
 pletion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06275360
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Clinical Trial of TB511 in Advanced Solid Tumors\nEstimated primary compl
 etion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06400160
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06400160-2758@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TB511: Phase 1/2 readout est. (NCT06400160)
DESCRIPTION:TB511\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Clinica
 l Trial of TB511 in Advanced Solid Tumors\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tb511#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06400160
URL:https://assetmemo.bio/drug/tb511#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288205-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid 
 Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0528820
 5
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altere
 d Malignancies\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05288205-2238@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sitneprotafib: Phase 1/2 readout est. (NCT05288205)
DESCRIPTION:Sitneprotafib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Sol
 id Tumors Harboring KRAS p.G12C Mutation\nEstimated primary completion: Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sitneprotaf
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5288205
URL:https://assetmemo.bio/drug/sitneprotafib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05443126-2472@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Lunbotinib: Phase 1/2 readout est. (NCT05443126)
DESCRIPTION:Lunbotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Maligna
 ncies\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/lunbotinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05443126
URL:https://assetmemo.bio/drug/lunbotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05186974)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Sacituzumab Govitecan Combinations in First-line Treatment of Part
 icipants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05186974
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05186974-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05186974)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Sacituzumab Govitecan Combinations in First-line Treatment
  of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: March 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05186974
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992739-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06992739)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGF
 R-mutated\, Advanced Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06992739
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05765877-2231@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Iruplinalkib: Phase 2 readout est. (NCT05765877)
DESCRIPTION:Iruplinalkib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Ce
 ll Lung Cancer\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/iruplinalkib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05765877
URL:https://assetmemo.bio/drug/iruplinalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06315010-2264@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Repotrectinib: Phase 2 readout est. (NCT06315010)
DESCRIPTION:Repotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: R
 epotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Act
 ive Brain Metastasis\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/repotrectinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06315010
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06014827-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06014827)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body
  Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive
  Oncogenic Positive Non-Small Cell Lung Carcinoma\nEstimated primary compl
 etion: 9 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06014827
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07641023-2114@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270314
DTEND;VALUE=DATE:20270315
SUMMARY:Dual-target Car-nk Cells: Phase 1/2 readout est. (NCT07641023)
DESCRIPTION:Dual-target Car-nk Cells\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Dual-Target CAR-NK Cells Targeting MSLN\, EGFR\, or HER2 in Ad
 vanced NSCLC\nEstimated primary completion: 14 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07641023
URL:https://assetmemo.bio/drug/dual-target-car-nk-cells#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380348-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06380348)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: JMT101 in Combination With Osimertinib\, Versus Cisplatin-pemetrex
 ed in Participants With Locally Advanced or Metastatic Non-small Cell Lung
  Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) 
 Exon 20ins Mutations\nEstimated primary completion: 26 March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06380348-2224@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270326
DTEND;VALUE=DATE:20270327
SUMMARY:Becotatug: Phase 3 readout est. (NCT06380348)
DESCRIPTION:Becotatug\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JMT10
 1 in Combination With Osimertinib\, Versus Cisplatin-pemetrexed in Partici
 pants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCL
 C) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mu
 tations\nEstimated primary completion: 26 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/becotatug#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06380348
URL:https://assetmemo.bio/drug/becotatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550920-2061@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07550920)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Relatrilfa-α Plus Single-Agent Chemotherapy as Neoadjuvant Therapy for 
 Resectable Stage II-III NSCLC (Phase 2)\nEstimated primary completion: 30 
 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/retlirafu
 sp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07550920
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab 
 With or Without Bevacizumab\, in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab
  With or Without Bevacizumab\, in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 31 March 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427941-2390@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:BGB-B2033: Phase 1/2 readout est. (NCT06427941)
DESCRIPTION:BGB-B2033\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 1/2 Study of BGB-B2033\, Alone or in Combination With Tislelizumab Wi
 th or Without Bevacizumab\, in Participants With Advanced or Metastatic So
 lid Tumors\nEstimated primary completion: 31 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/bgb-b2033#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06427941
URL:https://assetmemo.bio/drug/bgb-b2033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810544-2771@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:TNG456: Phase 1/2 readout est. (NCT06810544)
DESCRIPTION:TNG456\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Tolerability of TNG456 Alone and in Combination With Abemaciclib in P
 atients With Solid Tumors With MTAP Loss\nEstimated primary completion: 31
  March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tng456#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06810
 544
URL:https://assetmemo.bio/drug/tng456#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310007-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04310007)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Testi
 ng the Addition of the Pill Chemotherapy\, Cabozantinib\, to the Standard 
 Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small C
 ell Lung Cancer\nEstimated primary completion: 31 March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04310007
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310007-2031@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT04310007)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Addition of the Pill Chemotherapy\, Cabozantinib\, to the Standa
 rd Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-smal
 l Cell Lung Cancer\nEstimated primary completion: 31 March 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04310007
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04701476-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04701476)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 ATE and Pembrolizumab (MK3475) in mCRC and NSCLC\nEstimated primary comple
 tion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04701476
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492342-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07492342)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fulz
 erasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for
  Resectable KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0749234
 2
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492342-2487@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07492342)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Th
 erapy for Resectable KRAS G12C-Mutant NSCLC\nEstimated primary completion:
  31 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulze
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07492342
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab and Ipilimumab With or Without Local Consolidation Therapy in Treatin
 g Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03391869
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Ipilimumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Ipilimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab and Ipilimumab With or Without Local Consolidation Therapy in Treati
 ng Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03391869
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (K
 RAS G12C)\nEstimated primary completion: April 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-2053@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS
  G12C)\nEstimated primary completion: April 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04956640-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04956640)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of LY3537982 in Cancer Patients With a Specific Genetic Mutat
 ion (KRAS G12C)\nEstimated primary completion: April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04956640
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Q
 LS5132 Combination Therapy in Advanced Solid Tumors\nEstimated primary com
 pletion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07453394
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 1/2\, Non-Small Cell Lung 
 Cancer.\nStudy: QLS5132 Combination Therapy in Advanced Solid Tumors\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07453394
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07453394-7615@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:QLS5132: Phase 1/2 readout est. (NCT07453394)
DESCRIPTION:QLS5132\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: QLS51
 32 Combination Therapy in Advanced Solid Tumors\nEstimated primary complet
 ion: April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qls5
 132#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07453394
URL:https://assetmemo.bio/drug/qls5132#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087223-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Furmonertinib: Phase 1/2 readout est. (NCT07087223)
DESCRIPTION:Furmonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients Wit
 h c-Met Amplification After EGFR-TKI Failure\nEstimated primary completion
 : April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furmone
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07087223
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07087223-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT07087223)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With 
 c-Met Amplification After EGFR-TKI Failure\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebreltin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7087223
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903377-2822@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nilvanstomig: Phase 1/2 readout est. (NCT06903377)
DESCRIPTION:Nilvanstomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nilvanstomig#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06903377
URL:https://assetmemo.bio/drug/nilvanstomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04946968-1969@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dacomitinib PF-00299804: Phase 2 readout est. (NCT04946968)
DESCRIPTION:Dacomitinib PF-00299804\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced S
 olid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomark
 ers\nEstimated primary completion: April 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04946968
URL:https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139041-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07139041)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing 
 Conversion to Resectability in Initially Unresectable Stage III NSCLC\nEst
 imated primary completion: April 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07139041
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03410043-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03410043)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib\, Surgery\, and Radiation Therapy in Treating Patients
  With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations\, NO
 RTHSTAR Study\nEstimated primary completion: 1 April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03410043
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04317534-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04317534)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 djuvant Pembrolizumab vs Observation Following Curative Resection for Stag
 e I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm\
 nEstimated primary completion: 8 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04317534
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D
 ISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary 
 completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06364917
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DISCE
 RN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary comp
 letion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06364917
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DISC
 ERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary com
 pletion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06364917
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06364917)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated pr
 imary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06364917
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488314-1968@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Capmatinib: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Capmatinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Me
 tastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apri
 l 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/capmatinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054883
 14
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05488314-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT05488314)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Capmatinib Combination Therapy in Unresectable M
 etastatic Non-small Cell Lung Cancer\nEstimated primary completion: 28 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0548
 8314
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06799065-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06799065)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 irst-in-Human Study of ATX-295\, an Oral Inhibitor of KIF18A\, as Monother
 apy and in Combination With Anticancer Therapy in Patients With Advanced o
 r Metastatic Solid Tumors\, Including Ovarian Cancer\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06799065
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944470-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06944470)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC\
 nEstimated primary completion: 30 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06944470
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06944470-2239@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:JS207: Phase 2 readout est. (NCT06944470)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207 Com
 bined With Chemotherapy in Subjects With Stage II-III NSCLC\nEstimated pri
 mary completion: 30 April 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/js207#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06944470
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936644-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06936644)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter\, Single-arm Phase II Study to Evaluate the Efficacy and Safety
  of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) in First-
 line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Patien
 ts With KRAS G12C Mutation\nEstimated primary completion: 30 April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06936644
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554859-2279@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:GFH375: Phase 2 readout est. (NCT07554859)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: GFH375 M
 onotherapy and Combination Therapy as First-Line Treatment for Advanced KR
 AS G12D-Mutant Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0755
 4859
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936644-2487@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT06936644)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Multicenter\, Single-arm Phase II Study to Evaluate the Efficacy an
 d Safety of Fulzerasib (IBI351) in Combination With Ivonescimab (AK-112) i
 n First-line Treatment of Advanced or Metastatic Non-small Cell Lung Cance
 r Patients With KRAS G12C Mutation\nEstimated primary completion: 30 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fulzerasib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0693664
 4
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03694236-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03694236)
DESCRIPTION:Durvalumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resec
 table Stage III NSCLC\nEstimated primary completion: May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03694236
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03896074-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03896074)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: At
 ezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Pat
 ients (BEAT)\nEstimated primary completion: May 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03896074
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03896074-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03896074)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ate
 zolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Pati
 ents (BEAT)\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT03896074
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014215-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07014215)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PD-1
  Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced 
 NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy\nEstimated primary 
 completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07014215
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014215-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07014215)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PD-
 1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced
  NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy\nEstimated primary
  completion: May 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07014215
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07009925-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07009925)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Pacl
 itaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07009925
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04410796-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT04410796)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancer
 s\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04410796
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05589818-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05589818)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab for Advanced NSCLC and PS 2-3\nEstimated primary completion: 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5589818
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04410796-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04410796)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers\n
 Estimated primary completion: May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04410796
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06670196-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06670196)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of SKB264 in Combination With Osimertinib Versus Osimerti
 nib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations\, L
 ocally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06670196
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928389-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06928389)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Can
 cer\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06928389
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951464-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06951464)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage
  II-IIIB NSCLC\nEstimated primary completion: 5 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06951464
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951464-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06951464)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 and Almonertinib in Patients With Resectable 
 EGFR+ Stage II-IIIB NSCLC\nEstimated primary completion: 5 May 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069514
 64
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04380636)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by P
 embrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Can
 cer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion: 5 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0438
 0636
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04380636)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followe
 d by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lu
 ng Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)\nEstimated primary completion:
  5 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4380636
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06074588)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previous
 ly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (
 NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)\nEst
 imated primary completion: 10 May 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06074588
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06424899-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06424899)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafte
 r Compared With Immunoconsolidation After Radical Chemoradiotherapy for St
 age III Potentially Resectable NSCLC\nEstimated primary completion: 19 May
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT064248
 99
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05973773-2070@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:Zipalertinib: Phase 3 readout est. (NCT05973773)
DESCRIPTION:Zipalertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RE
 ZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumo
 rs)\nEstimated primary completion: 27 May 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05973773
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644068-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT04644068)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study of AZD5305 as Monotherapy and in Combination With Anti-can
 cer Agents in Patients With Advanced Solid Malignancies\nEstimated primary
  completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/trastuzumab-deruxtecan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04644068
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590531-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07590531)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 MT-116 in Combination With AK112 in Patients With Lung Cancer\nEstimated p
 rimary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07590531
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07590531-2088@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:AMT-116: Phase 1/2 readout est. (NCT07590531)
DESCRIPTION:AMT-116\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: AMT-1
 16 in Combination With AK112 in Patients With Lung Cancer\nEstimated prima
 ry completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/amt-116#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07590531
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551414-2300@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Zorifertinib: Phase 2 readout est. (NCT07551414)
DESCRIPTION:Zorifertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Zo
 rifertinib Plus Intra-Ommaya CSF Chemotherapy for Leptomeningeal Progressi
 on in NSCLC After Third-Generation EGFR-TKI\nEstimated primary completion:
  30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zorifer
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07551414
URL:https://assetmemo.bio/drug/zorifertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06421298)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Prospective\, Single-arm\, Phase II Clinical Trial to Evaluate the Effic
 acy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in
  Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell 
 Lung Cancer After Failure of First-line Immunotherapy.\nEstimated primary 
 completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06421298
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06421298)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pr
 ospective\, Single-arm\, Phase II Clinical Trial to Evaluate the Efficacy 
 and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Pat
 ients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung
  Cancer After Failure of First-line Immunotherapy.\nEstimated primary comp
 letion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06421298
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06421298-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06421298)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Prospective\, Single-arm\, Phase II Clinical Trial to Evaluate the
  Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemother
 apy in Patients With Advanced or Metastatic Driver Gene-negative Non-small
  Cell Lung Cancer After Failure of First-line Immunotherapy.\nEstimated pr
 imary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06421298
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05379985-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT05379985)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RMC-6236 in Patients With Advanced Solid Tumors Harbor
 ing Specific Mutations in RAS\nEstimated primary completion: 31 May 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05379985
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enha
 nced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth
  Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated
  First-line With Amivantamab Plus Lazertinib\nEstimated primary completion
 : 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06120140
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120140-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06120140)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Enh
 anced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growt
 h Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treate
 d First-line With Amivantamab Plus Lazertinib\nEstimated primary completio
 n: 31 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiva
 ntamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06120140
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02595944-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT02595944)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab After Surgery and Chemotherapy in Treating Patients With Stage IB-III
 A Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)\nEstimated pri
 mary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02595944
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05085028-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05085028)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab 
 immuNothErapy for First-line Treatment of Patients With Advanced Non-small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05085028
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metasta
 tic Solid Tumors\nEstimated primary completion: June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastat
 ic Solid Tumors\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-2236@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Dabrafenib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-2540@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atebimetinib: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Atebimetinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastati
 c Solid Tumors\nEstimated primary completion: June 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atebimetinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-7671@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Gemcitabine: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Gemcitabine\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Comb
 ination in PDAC & NSCLC Patients\nEstimated primary completion: June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-1997@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2073@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combin
 ation in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/vopimetostat#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutat
 ed NSCLC\nEstimated primary completion: June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study to Evaluate the Safety\, Tolerability & Efficacy of TNG46
 2 in Combination in PDAC & NSCLC Patients\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/daraxonrasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 922591
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated N
 SCLC\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070440-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: DZD6008 Combination Therapy in Patients With Locally Advanced or Me
 tastatic NSCLC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetr
 exed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07070440
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070440-2251@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:DZD6008: Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:DZD6008\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: DZD60
 08 Combination Therapy in Patients With Locally Advanced or Metastatic NSC
 LC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dzd6008#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07070440
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05706129-2302@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:177Lu-DPI-4452: Phase 1/2 readout est. (NCT05706129)
DESCRIPTION:177Lu-DPI-4452\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Assess Safety\, Tolerability and Imaging Characteristics of [
 68Ga]Ga-DPI-4452 and to Assess Safety\, Tolerability\, and Efficacy of [17
 7Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Meta
 static Solid Tumors\nEstimated primary completion: June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/177lu-dpi-4452#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05706129
URL:https://assetmemo.bio/drug/177lu-dpi-4452#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06162221-2827@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06162221)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06162221
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06922591-2827@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT06922591)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate the Safety\, Tolerability & Efficacy of TNG462 in Combina
 tion in PDAC & NSCLC Patients\nEstimated primary completion: June 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/zoldonrasib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06922591
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070440-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07070440)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: DZD6008 Combination Therapy in Patients With Locally Advanced or M
 etastatic NSCLC With EGFR Mutation (TIAN-SHAN7)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docet
 axel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07070440
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498986-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06498986)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Table
 ts in Patients With Locally Advanced or Metastatic Non-small Cell Lung Can
 cer\nEstimated primary completion: June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06498986
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015724-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06015724)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pa
 ncreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06015724
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498986-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06498986)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tabl
 ets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Ca
 ncer\nEstimated primary completion: June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06498986
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276789-2599@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cronexitide lanocianine: Phase 2 readout est. (NCT07276789)
DESCRIPTION:Cronexitide lanocianine\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence
  Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cance
 r Resection for Non Small Cell Lung Cancer\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cronexitid
 e-lanocianine#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07276789
URL:https://assetmemo.bio/drug/cronexitide-lanocianine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244926-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07244926)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced No
 n-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07244926
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244926-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07244926)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sac
 -TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous N
 on-Small Cell Lung Cancer\nEstimated primary completion: June 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07244926
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485452-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07485452)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Boosting Osimertinib Blood Brain Barrier Penetration\nEstimated pr
 imary completion: June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07485452
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05742607-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05742607)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IPH5
 201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer 
 (MATISSE)\nEstimated primary completion: June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05742607
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06475300)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Ca
 rcinoma and Other Solid Tumors\nEstimated primary completion: June 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengiteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 475300
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514027-2100@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:BEBT-109: Phase 2 readout est. (NCT06514027)
DESCRIPTION:BEBT-109\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon
  20 Insertion Mutations\nEstimated primary completion: June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bebt-109#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06514027
URL:https://assetmemo.bio/drug/bebt-109#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06475300-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06475300)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally
  Advanced or Metastatic Non-small Cell Lung Cancer\, Nasopharyngeal Carcin
 oma and Other Solid Tumors\nEstimated primary completion: June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06475300
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06514027-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06514027)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carryin
 g EGFR Exon 20 Insertion Mutations\nEstimated primary completion: June 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06514027
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659782-2279@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:GFH375: Phase 2 readout est. (NCT07659782)
DESCRIPTION:GFH375\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung 
 Cancer\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07659782
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05742607-11151@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:IPH5201: Phase 2 readout est. (NCT05742607)
DESCRIPTION:IPH5201\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IPH5201
  and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MA
 TISSE)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/iph5201#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05742607
URL:https://assetmemo.bio/drug/iph5201#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310020-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04310020)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-s
 mall Cell Lung Cancer Patients\nEstimated primary completion: 1 June 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04310020
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07560111-8738@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:GC101: Phase 2 readout est. (NCT07560111)
DESCRIPTION:GC101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Study of GC101 in NSCLC\nEstimated primary completion: 1 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/gc101#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07560111
URL:https://assetmemo.bio/drug/gc101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012031-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Sotorasib: Phase 1/2 readout est. (NCT07012031)
DESCRIPTION:Sotorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Sot
 orasib in Combination With Trastuzumab Deruxtecan for the Treatment of Loc
 ally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C M
 utation\nEstimated primary completion: 14 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07012031
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07012031-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270614
DTEND;VALUE=DATE:20270615
SUMMARY:Trastuzumab Deruxtecan: Phase 1/2 readout est. (NCT07012031)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Sotorasib in Combination With Trastuzumab Deruxtecan for the Tre
 atment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With 
 a KRAS G12C Mutation\nEstimated primary completion: 14 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07012031
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480136-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT06480136)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Fa
 iled the Previous Standard First-line Treatment\nEstimated primary complet
 ion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06480136
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06480136-2726@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270615
DTEND;VALUE=DATE:20270616
SUMMARY:Tizetatug rezetecan: Phase 2 readout est. (NCT06480136)
DESCRIPTION:Tizetatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCL
 C Who Failed the Previous Standard First-line Treatment\nEstimated primary
  completion: 15 June 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/tizetatug-rezetecan#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06480136
URL:https://assetmemo.bio/drug/tizetatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2039@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:HLX43: Phase 2 readout est. (NCT07253142)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subj
 ects With Advanced Lung Cancer\nEstimated primary completion: 18 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07253142
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253142-2161@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270618
DTEND;VALUE=DATE:20270619
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07253142)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab i
 n Subjects With Advanced Lung Cancer\nEstimated primary completion: 18 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07253
 142
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07343479-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07343479)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Ra
 diotherapy for EGFR-Mutant NSCLC Brain Metastases\nEstimated primary compl
 etion: 20 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sacituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07343479
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734182-994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Envafolimab: Phase 2 readout est. (NCT06734182)
DESCRIPTION:Envafolimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable 
 HER2-Mutant Non-Small-Cell Lung Cancer\nEstimated primary completion: 22 J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/envafolimab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT067
 34182
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06734182-2454@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270622
DTEND;VALUE=DATE:20270623
SUMMARY:Disitamab Vedotin: Phase 2 readout est. (NCT06734182)
DESCRIPTION:Disitamab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\nStud
 y: Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resec
 table HER2-Mutant Non-Small-Cell Lung Cancer\nEstimated primary completion
 : 22 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/disit
 amab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06734182
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05651022-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05651022)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of DECOY20 With or Without Tislelizumab in Patients With Advanced So
 lid Tumors\nEstimated primary completion: 30 June 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05651022
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03392246-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03392246)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase 2 Study of Osimertinib in Combination With Selumetinib in 
 EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer\nEstimated primary 
 completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03392246
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05198830-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05198830)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Test
 ing the Addition of an Anti-Cancer Drug\, TRC102\, to the Usual Chemothera
 py Treatment (Pemetrexed\, Cisplatin or Carboplatin) During Radiation Ther
 apy for Stage III Non-Squamous Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05198830
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05198830-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05198830)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of an Anti-Cancer Drug\, TRC102\, to the Usual C
 hemotherapy Treatment (Pemetrexed\, Cisplatin or Carboplatin) During Radia
 tion Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05198830
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06977828-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06977828)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Prospective\, Single-arm\, Phase II Clinical Study of Tislelizumab Combine
 d With Anlotinib and Platinum-based Doublet Perioperative Therapy for Rese
 ctable Stage II-IIIB Driver Gene-negative NSCLC\nEstimated primary complet
 ion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ti
 slelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06977828
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845916-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07845916)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Qu
 ad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemoth
 erapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07845916
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06775483-2147@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JSKN016: Phase 2 readout est. (NCT06775483)
DESCRIPTION:JSKN016\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Evaluat
 ion of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a
  Phase II Clinical Study\nEstimated primary completion: 30 June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/jskn016#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06775483
URL:https://assetmemo.bio/drug/jskn016#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845916-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07845916)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based 
 Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07845916
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03191149-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03191149)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Testing Osimertinib as a Treatment for Lung Cancers With an EGFR E
 xon 20 Change\nEstimated primary completion: 30 June 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03191149
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05642572)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Comparing Combinations of Targeted Drugs for Advanced Non-Small Ce
 ll Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Tr
 ial)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-1968@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Capmatinib: Phase 2 readout est. (NCT05642572)
DESCRIPTION:Capmatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Comp
 aring Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Canc
 er That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/capmatinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/capmatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953843-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06953843)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy on the Optimal Combination Pattern of the Combined Treatment of Radioth
 erapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Can
 cer (NSCLC) With Multiple Metastases\nEstimated primary completion: 30 Jun
 e 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06953
 843
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06877299-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06877299)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lo
 w-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in
  Stage ⅡA-ⅢB Non-small Cell Lung Cancer\nEstimated primary completion:
  30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislel
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06877299
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07050056-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07050056)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for 
 Resectable NSCLC\nEstimated primary completion: 30 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07050056
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05642572-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT05642572)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 paring Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Can
 cer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)\nEstim
 ated primary completion: 30 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05642572
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07308106-2066@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SKB571: Phase 2 readout est. (NCT07308106)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase 
 II Clinical Study of SKB571 as Monotherapy in Patients With Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer With MET Abnormalities\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/skb571#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07308106
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863506-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Befotertinib: Phase 2 readout est. (NCT06863506)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Clinical Study of Befotertinib in EGFR Non-classical Mutant NSCLC\n
 Estimated primary completion: 30 June 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/befotertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06863506
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Atezolizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Atezolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies
  as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nE
 stimated primary completion: 30 June 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT05096663)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] P
 lus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell
  Lung Cancer (A Lung-MAP Treatment Trial)\nEstimated primary completion: 3
 0 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05096663
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Bevacizumab: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Bevacizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alecensa (Alectinib): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alecensa (Alectinib)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/alectinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05096663-2051@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2/3 readout est. (NCT
 05096663)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2/3\, Non-Small 
 Cell Lung Cancer.\nStudy: Testing the Use of Combination Immunotherapy Tre
 atment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment fo
 r Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05096663
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2217@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Divarasib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Divarasib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as
  Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 30 June 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2220@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Entrectinib: Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Entrectinib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies 
 as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)\nEs
 timated primary completion: 30 June 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/entrectinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/entrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Evaluate the Efficacy and Safety of Multiple Targeted Th
 erapies as Treatments for Participants With Non-Small Cell Lung Cancer (NS
 CLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03178552-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT03178552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Multiple Targeted T
 herapies as Treatments for Participants With Non-Small Cell Lung Cancer (N
 SCLC)\nEstimated primary completion: 30 June 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03178552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05920356-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Sotorasib: Phase 3 readout est. (NCT05920356)
DESCRIPTION:Sotorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab 
 Platinum Doublet Combination as a Front-Line Therapy in Participants With 
 Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers 
 (CodeBreaK 202)\nEstimated primary completion: 30 June 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05920356
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956690-2470@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:ENV-501: Phase 1/2 readout est. (NCT06956690)
DESCRIPTION:ENV-501\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2 Clinical Trial to Assess the Safety\, Tolerability\, Pharmacokineti
 cs and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing S
 olid Tumors\nEstimated primary completion: July 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/env-501#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06956690
URL:https://assetmemo.bio/drug/env-501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05880706-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05880706)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib M
 esylate Tablets in Patients With Locally Advanced or Metastatic Non-small 
 Cell Lung Cancer\nEstimated primary completion: July 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05880706
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05880706-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT05880706)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib 
 Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small
  Cell Lung Cancer\nEstimated primary completion: July 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05880706
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07084610-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07084610)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Metab
 olic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07084610
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01639508-2031@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT01639508)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ca
 bozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lu
 ng Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increase
 d MET or AXL Activity\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cabozantinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT01639508
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362459-2721@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SCTB14: Phase 3 readout est. (NCT07362459)
DESCRIPTION:SCTB14\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in
  Non-Small Cell Lung Cancer.\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sctb14#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07362459
URL:https://assetmemo.bio/drug/sctb14#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07789444-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07789444)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EG
 FR+ NSCLC With Brain Mets\nEstimated primary completion: 1 July 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07789
 444
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630077-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07630077)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tra
 stuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally
  Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abn
 ormalities\nEstimated primary completion: 1 July 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07630077
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07630077-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07630077)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) 
 in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER
 2 Gene Abnormalities\nEstimated primary completion: 1 July 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07630077
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05570825-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05570825)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 X-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stag
 e IIIC or IV Non-Small Cell Lung Cancer\nEstimated primary completion: 1 J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5570825
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04077099-2702@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270706
DTEND;VALUE=DATE:20270707
SUMMARY:Davutamig: Phase 1/2 readout est. (NCT04077099)
DESCRIPTION:Davutamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition 
 Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer\nEstimated primar
 y completion: 6 July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/davutamig#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04077099
URL:https://assetmemo.bio/drug/davutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205706-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  BI-1910 as a Single Agent and in Combination With Pembrolizumab for the T
 reatment of Advanced Solid Tumors\nEstimated primary completion: 14 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062057
 06
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06205706-2394@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:BI-1910: Phase 1/2 readout est. (NCT06205706)
DESCRIPTION:BI-1910\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: BI-19
 10 as a Single Agent and in Combination With Pembrolizumab for the Treatme
 nt of Advanced Solid Tumors\nEstimated primary completion: 14 July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bi-1910#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06205706
URL:https://assetmemo.bio/drug/bi-1910#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07070518-2037@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:GV20-0251: Phase 1/2 readout est. (NCT07070518)
DESCRIPTION:GV20-0251\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of GV20-0251 in Participants With Solid Tumor Malignancies\nEstimated p
 rimary completion: 16 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/gv20-0251#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07070518
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503888-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Almonertinib: Phase 1/2 readout est. (NCT05503888)
DESCRIPTION:Almonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment 
 of Relapsed or Advanced Non-small Cell Lung Cancer\nEstimated primary comp
 letion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05503888
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05503888-2061@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Retlirafusp alfa: Phase 1/2 readout est. (NCT05503888)
DESCRIPTION:Retlirafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStu
 dy: Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatm
 ent of Relapsed or Advanced Non-small Cell Lung Cancer\nEstimated primary 
 completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05503888
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198321-2492@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07198321)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Sing
 le-Arm\, Open-Label\, Multicenter Phase I/II Clinical Study of GFH276 in P
 atients With RAS-Mutant Advanced Solid Tumors\nEstimated primary completio
 n: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gfh2
 76#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7198321
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-1985@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06448754)
DESCRIPTION:Volrustomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Vol
 rustomig Priming Regimens Exploratory Phase II Platform Study\nEstimated p
 rimary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/volrustomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06448754)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Vol
 rustomig Priming Regimens Exploratory Phase II Platform Study\nEstimated p
 rimary completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06448754-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06448754)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Volrustomig Priming Regimens Exploratory Phase II Platform Study\nEst
 imated primary completion: 30 July 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06448754
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06635824-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06635824)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 rial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Ove
 r Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC
 -06)\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06635824
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362940-2458@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07362940)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dosit
 inib\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07362940
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362940-2490@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:GEN-725: Phase 1/2 readout est. (NCT07362940)
DESCRIPTION:GEN-725\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib\nEstim
 ated primary completion: 31 July 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gen-725#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07362940
URL:https://assetmemo.bio/drug/gen-725#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784791-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06784791)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pre
 operative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment 
 in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic
  EGFR Mutations (NEOpredict-EGFR)\nEstimated primary completion: 31 July 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06784791
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06784791-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06784791)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Tr
 eatment in Patients With Resectable Non-small-cell Lung Cancer Harboring O
 ncogenic EGFR Mutations (NEOpredict-EGFR)\nEstimated primary completion: 3
 1 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrex
 ed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6784791
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908304-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06908304)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment
  in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06908304
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908304-2297@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Ateganosine (THIO): Phase 3 readout est. (NCT06908304)
DESCRIPTION:Ateganosine (THIO)\, phase 3\, Non-Small Cell Lung Cancer.\nStu
 dy: A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line T
 reatment in Advanced/Metastatic NSCLC\nEstimated primary completion: 31 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/ateganosine-
 thio#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06908304
URL:https://assetmemo.bio/drug/ateganosine-thio#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05081609-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05081609)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alo
 ne or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or 
 Other Anticancer Therapies in Adult Participants With Locally Advanced or 
 Metastatic Solid Tumor Malignancies\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05081
 609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05276726-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT05276726)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and ST
 K11 Co-mutation and Wild-type KEAP1\nEstimated primary completion: August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05276726
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865339-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06865339)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Thor
 acic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced No
 n-Small Cell Lung Cancer\nEstimated primary completion: August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06865339
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06582771-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sotorasib: Phase 2 readout est. (NCT06582771)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Sotorasib in People With Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: August 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/sotorasib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06582771
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05894889-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05894889)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC\nEstimated pri
 mary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05894889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463171-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Almonertinib: Phase 2 readout est. (NCT06463171)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Can
 cer\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06463171
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05120349-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT05120349)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Global Study to Assess the Effects of Osimertinib in Participant
 s With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection\nEsti
 mated primary completion: 2 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05120349
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089199-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07089199)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Tislelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectab
 le Non-small Cell Lung Cancer : A Prospective\, Single-Arm\, Phase II Stud
 y\nEstimated primary completion: 10 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07089199
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07089199-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07089199)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Anlotinib and Nab-paclitaxel in II-III Resectable
  Non-small Cell Lung Cancer : A Prospective\, Single-Arm\, Phase II Study\
 nEstimated primary completion: 10 August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07089199
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07486817)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: B
 eamion 44: A Study to Test How Well Zongertinib is Tolerated by People Wit
 h Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Co
 mbination With Chemotherapy With or Without Pembrolizumab\nEstimated prima
 ry completion: 12 August 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07486817)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by Peop
 le With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given
  in Combination With Chemotherapy With or Without Pembrolizumab\nEstimated
  primary completion: 12 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486817-2274@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270812
DTEND;VALUE=DATE:20270813
SUMMARY:Hernexeos (Zongertinib): Phase 2 readout est. (NCT07486817)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion 44: A Study to Test How Well Zongertinib is Tolerated by 
 People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When G
 iven in Combination With Chemotherapy With or Without Pembrolizumab\nEstim
 ated primary completion: 12 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/zongertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07486817
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Lazertinib: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Participants With Advanced or Metastatic Solid Tumor
 s Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell
  Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05498428)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Participants With Advanced or Metastatic Solid Tumo
 rs Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cel
 l Lung Cancer\nEstimated primary completion: 17 August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498428-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05498428)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Amivantamab in Participants With Advanced or Metastatic So
 lid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-S
 mall Cell Lung Cancer\nEstimated primary completion: 17 August 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05498428
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951399-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06951399)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 racking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanc
 ed Non-Small Cell Lung Cancer\nEstimated primary completion: 30 August 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06951399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778745-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07778745)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective Phase II Clinical Trial Evaluating the Efficacy and Safety of A
 debrelimab in Combination With Trastuzumab Rezetecan for Patients With Sta
 ge III Unresectable HER2-Positive NSCLC\nEstimated primary completion: 30 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebreli
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07778745
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07283198-2572@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:JSKN033: Phase 2 readout est. (NCT07283198)
DESCRIPTION:JSKN033\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  II Clinical Study to Evaluate the Safety\, Efficacy\, Pharmacokinetics/Ph
 armacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Ca
 ncer\nEstimated primary completion: 30 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/jskn033#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07283198
URL:https://assetmemo.bio/drug/jskn033#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778745-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07778745)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Prospective Phase II Clinical Trial Evaluating the Efficacy and S
 afety of Adebrelimab in Combination With Trastuzumab Rezetecan for Patient
 s With Stage III Unresectable HER2-Positive NSCLC\nEstimated primary compl
 etion: 30 August 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07778745
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07669779)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase II Study of AK146D1 in Combination With AK112 in Advanced 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 30 August 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925866-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07925866)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure
  of First-Line Immunotherapy\nEstimated primary completion: 30 August 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07925866
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669779)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small C
 ell Lung Cancer\nEstimated primary completion: 30 August 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669779-2336@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:AK146D1: Phase 2 readout est. (NCT07669779)
DESCRIPTION:AK146D1\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase
  II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell 
 Lung Cancer\nEstimated primary completion: 30 August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ak146d1#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07669779
URL:https://assetmemo.bio/drug/ak146d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07925866-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07925866)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After
  Failure of First-Line Immunotherapy\nEstimated primary completion: 30 Aug
 ust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07925
 866
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777278-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Orpathys (Savolitinib): Phase 1/2 readout est. (NCT05777278)
DESCRIPTION:Orpathys (Savolitinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wild
 type NSCLC With MET Overexpression\nEstimated primary completion: 31 Augus
 t 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05777
 278
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05777278-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05777278)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildty
 pe NSCLC With MET Overexpression\nEstimated primary completion: 31 August 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05777278
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07329322)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osim
 ertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Gr
 owth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07329322-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07329322)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Study of Sacituzumab Tirumotecan in Combination With Osi
 mertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer\nEstimated
  primary completion: 31 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07329322
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07306624-2637@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nelmastobart: Phase 2 readout est. (NCT07306624)
DESCRIPTION:Nelmastobart\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 lmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer\nEs
 timated primary completion: 31 August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nelmastobart#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07306624
URL:https://assetmemo.bio/drug/nelmastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07306624-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07306624)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Ca
 ncer\nEstimated primary completion: 31 August 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07306624
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05671510-2413@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Gotistobart: Phase 3 readout est. (NCT05671510)
DESCRIPTION:Gotistobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ONC
 -392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 In
 hibitors\nEstimated primary completion: 31 August 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/gotistobart#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05671510
URL:https://assetmemo.bio/drug/gotistobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04465968-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04465968)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of CRT\, Durvalumab and Surgery for SST\nEstimated primary
  completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04465968
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05487391-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05487391)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 Combined With Platinum-containing Chemothe
 rapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer Aft
 er Complete Surgical Resection.\nEstimated primary completion: 31 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-
 tuvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05487391
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361174-2555@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:IOV-4001: Phase 1/2 readout est. (NCT05361174)
DESCRIPTION:IOV-4001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in A
 dult Participants With Unresectable or Metastatic Melanoma or Stage III or
  IV Non-small-cell Lung Cancer\nEstimated primary completion: September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iov-4001#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05361174
URL:https://assetmemo.bio/drug/iov-4001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05592626-2742@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Invikafusp alfa: Phase 1/2 readout est. (NCT05592626)
DESCRIPTION:Invikafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStud
 y: A Study of a Selective T Cell Receptor (TCR) Targeting\, Bifunctional A
 ntibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumor
 s\nEstimated primary completion: September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05592626
URL:https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05592626-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05592626)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of a Selective T Cell Receptor (TCR) Targeting\, Bifunctio
 nal Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid 
 Tumors\nEstimated primary completion: September 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05592626
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003321-2130@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07003321)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Ce
 ll Lung Cancer\nEstimated primary completion: September 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/hrs-4508#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07003321
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483983-2183@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Setidegrasib: Phase 2 readout est. (NCT07483983)
DESCRIPTION:Setidegrasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non
 -small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC
 )\, With Biomarker Analysis to Characterize Response/Resistance\nEstimated
  primary completion: September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/setidegrasib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07483983
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07198841-2487@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07198841)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Ca
 ncer With KRAS G12C Mutation\nEstimated primary completion: September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/fulzerasib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07198841
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05528458-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05528458)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib to Suppress the Progression of Remaining GGN for EGFR 
 Mutation-positive Stage IB-IIIA Lung Adenocarcinoma\nEstimated primary com
 pletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05528458
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pi
 lot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cel
 l Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primary
  completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small C
 ell Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated prima
 ry completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 ilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Ce
 ll Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primar
 y completion: 1 September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT04253964)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pilo
 t Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell 
 Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated primary c
 ompletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549061-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07549061)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing 
 NSCLC\nEstimated primary completion: 1 September 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07549061
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04253964-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04253964)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-sm
 all Cell Lung Cancer Patients Treated With Chemo/Immunotherapy\nEstimated 
 primary completion: 1 September 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04253964
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06945705-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06945705)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Tre
 atment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastas
 is\nEstimated primary completion: 2 September 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06945705
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153770-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270920
DTEND;VALUE=DATE:20270921
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07153770)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Boz
 itinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC 
 MET-Altered Non-Small Cell Lung Cancer\nEstimated primary completion: 20 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebrel
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07153770
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05785767-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05785767)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemipli
 mab Alone is More Effective for Adult Participants With Advanced Non-Small
  Cell Lung Cancer (NSCLC)\nEstimated primary completion: 28 September 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05785767
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Participants 
 With Advanced/Metastatic Solid Malignancies\nEstimated primary completion:
  29 September 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/r
 ilvegostomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05123482
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05123482-2375@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Puxitatug samrotecan: Phase 1/2 readout est. (NCT05123482)
DESCRIPTION:Puxitatug samrotecan\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase I/IIa Study of AZD8205 Given Alone or Combined\, in Partic
 ipants With Advanced/Metastatic Solid Malignancies\nEstimated primary comp
 letion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/puxitatug-samrotecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05123482
URL:https://assetmemo.bio/drug/puxitatug-samrotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339839-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07339839)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: G
 lecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-
 mutated NSCLC\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07339839
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339839-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glecirasib: Phase 1/2 readout est. (NCT07339839)
DESCRIPTION:Glecirasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Gl
 ecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-m
 utated NSCLC\nEstimated primary completion: 30 September 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/glecirasib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07339839
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03667820-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03667820)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in
  EGFR Mutant NSCLC\nEstimated primary completion: 30 September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03667820
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884282-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04884282)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effic
 acy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Thera
 py in Metastatic Non-small-cell Lung Cancer Progressing After First-line C
 hemo-immunotherapy (Combi-TED)\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04884282
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208944-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05208944)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: THIO
  Sequenced With Cemiplimab in Advanced NSCLC\nEstimated primary completion
 : 30 September 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05208944
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703228-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07703228)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced D
 river Gene-Negative Non-Squamous NSCLC\nEstimated primary completion: 30 S
 eptember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacitu
 zumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07703228
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05208944-2297@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ateganosine (THIO): Phase 2 readout est. (NCT05208944)
DESCRIPTION:Ateganosine (THIO)\, phase 2\, Non-Small Cell Lung Cancer.\nStu
 dy: THIO Sequenced With Cemiplimab in Advanced NSCLC\nEstimated primary co
 mpletion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ateganosine-thio#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05208944
URL:https://assetmemo.bio/drug/ateganosine-thio#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884282-2663@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:OSE2101: Phase 2 readout est. (NCT04884282)
DESCRIPTION:OSE2101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Efficac
 y of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy
  in Metastatic Non-small-cell Lung Cancer Progressing After First-line Che
 mo-immunotherapy (Combi-TED)\nEstimated primary completion: 30 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/ose2101#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04884282
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884282-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT04884282)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second
 -line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After F
 irst-line Chemo-immunotherapy (Combi-TED)\nEstimated primary completion: 3
 0 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doc
 etaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04884282
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908733-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06908733)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: In
 tegrating Surgery and Radiotherapy Following Tislelizumab-based Conversion
  Therapy in N3-Stage III NSCLC\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06908
 733
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156604-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT07156604)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vebreltinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071
 56604
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT03793179)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 esting the Timing of Pembrolizumab Alone or With Chemotherapy as First Lin
 e Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated prima
 ry completion: 30 September 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03793179-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT03793179)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Timing of Pembrolizumab Alone or With Chemotherapy as Fir
 st Line Treatment and Maintenance in Non-small Cell Lung Cancer\nEstimated
  primary completion: 30 September 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT03793179
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CPO301: Phase 3 readout est. (NCT07633873)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemothera
 py for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC
 （SYNSTAR 04）\nEstimated primary completion: 30 September 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633873-2291@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07633873)
DESCRIPTION:Enlonstobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SY
 S6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chem
 otherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic N
 SCLC（SYNSTAR 04）\nEstimated primary completion: 30 September 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/enlonstobart#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07633873
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06244771-2485@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:FMC-376: Phase 1/2 readout est. (NCT06244771)
DESCRIPTION:FMC-376\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fmc-376#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06244771
URL:https://assetmemo.bio/drug/fmc-376#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134413-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07134413)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QL1
 706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC\nEstimated 
 primary completion: October 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07134413
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204548-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07204548)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  IVO-LUNG Study\nEstimated primary completion: October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07204548
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07134413-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07134413)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous 
 NSCLC\nEstimated primary completion: October 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07134413
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207395-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07207395)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Orally Administered JBI-802 Alone or in Combination With Pembrol
 izumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation
 .\nEstimated primary completion: October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07207395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264673-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07264673)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ra
 ndomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintena
 nce Therapy in ctDNA Positive NSCL. The Cemited Study.\nEstimated primary 
 completion: October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07264673
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07392658-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07392658)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC P
 atients With EGFR exon20 Insertion Mutations.\nEstimated primary completio
 n: October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07392658
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264673-2663@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:OSE2101: Phase 2 readout est. (NCT07264673)
DESCRIPTION:OSE2101\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Rando
 mized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance
  Therapy in ctDNA Positive NSCL. The Cemited Study.\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ose2101#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07264673
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05801029)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate Safety and Efficacy of Osimertinib and Amiv
 antamab in Participants With Non-small Cell Lung Cancer With Common Epider
 mal Growth Factor Receptor Mutations\nEstimated primary completion: 1 Octo
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT058
 01029
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05801029-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Amivantamab: Phase 2 readout est. (NCT05801029)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy to Investigate Safety and Efficacy of Osimertinib and Amivantamab in 
 Participants With Non-small Cell Lung Cancer With Common Epidermal Growth 
 Factor Receptor Mutations\nEstimated primary completion: 1 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05801029
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05012254)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Canc
 er With Brain Metastases\nEstimated primary completion: 15 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05012254
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT05012254)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivo
 lumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Can
 cer With Brain Metastases\nEstimated primary completion: 15 October 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05012254
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05012254)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV
  Lung Cancer With Brain Metastases\nEstimated primary completion: 15 Octob
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05012
 254
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118854-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05118854)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carb
 oplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamo
 us Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation\nEstimated prima
 ry completion: 20 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/sotorasib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05118854
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118854-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05118854)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplat
 in or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB 
 Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation\nEstim
 ated primary completion: 20 October 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05118854
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06452277-2723@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Hyrnuo (Sevabertinib): Phase 3 readout est. (NCT06452277)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn More About How Well Sevabertinib Works and How Saf
 e it is Compared With Standard Treatment\, in Participants Who Have Advanc
 ed Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epiderma
 l Growth Factor Receptor 2 (HER2)\nEstimated primary completion: 28 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sevabertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0645
 2277
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07482605-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07482605)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion\nEsti
 mated primary completion: 30 October 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07482605
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06604351-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06604351)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With
  Central Airway Obstruction\nEstimated primary completion: 31 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06604351
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06604351-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06604351)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Bron
 choscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Cen
 tral Airway Obstruction\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06604351
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309952-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07309952)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCL
 C\nEstimated primary completion: 31 October 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07309952
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07249372-2111@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sirpiglenastat: Phase 2 readout est. (NCT07249372)
DESCRIPTION:Sirpiglenastat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer\n
 Estimated primary completion: 31 October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sirpiglenastat#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07249372
URL:https://assetmemo.bio/drug/sirpiglenastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309952-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07309952)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Posi
 tive NSCLC\nEstimated primary completion: 31 October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07309952
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154368-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07154368)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive P
 atients Previously Treated With ROS1-TKIs.\nEstimated primary completion: 
 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07154368
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154368-2440@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Fudotinib: Phase 3 readout est. (NCT07154368)
DESCRIPTION:Fudotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JYP03
 22 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Pr
 eviously Treated With ROS1-TKIs.\nEstimated primary completion: 31 October
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fudotinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07154368
URL:https://assetmemo.bio/drug/fudotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-2356@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ASKC202: Phase 3 readout est. (NCT07109531)
DESCRIPTION:ASKC202\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC202
  Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment 
 of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpress
 ion After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31 Oc
 tober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/askc202#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07109
 531
URL:https://assetmemo.bio/drug/askc202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109531-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Limertinib: Phase 3 readout est. (NCT07109531)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatme
 nt of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpr
 ession After Failure of EGFR-TKI Therapy\nEstimated primary completion: 31
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07109531
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Budigalimab: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Budigalimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuz
 umab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in 
 Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No 
 Prior Treatment for Advanced Disease\, and No Actionable Genomic Alteratio
 ns\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisot
 uzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor i
 n Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With N
 o Prior Treatment for Advanced Disease\, and No Actionable Genomic Alterat
 ions\nEstimated primary completion: November 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) T
 elisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhib
 itor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC 
 With No Prior Treatment for Advanced Disease\, and No Actionable Genomic A
 lterations\nEstimated primary completion: November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Telisotuzumab Adizutecan: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study to Evaluate Adverse Events and Efficacy of Intravenous (
 IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint 
 Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous N
 SCLC With No Prior Treatment for Advanced Disease\, and No Actionable Geno
 mic Alterations\nEstimated primary completion: November 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874984-2740@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SSGJ-706: Phase 2 readout est. (NCT07874984)
DESCRIPTION:SSGJ-706\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SPGL00
 8 in Combination With SSGJ-706 ± Chemotherapy for Advanced Non-small Cell
  Lung Cancer\nEstimated primary completion: November 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/ssgj-706#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07874984
URL:https://assetmemo.bio/drug/ssgj-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06901817-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06901817)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via In
 traventricular Injection for the Treatment of Refractory Non-squamous Non-
 small Cell Lung Cancer with Leptomeningeal Metastases\nEstimated primary c
 ompletion: November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06901817
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06901817-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06901817)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of the Safety and Efficacy of Pemetrexed Combined with Nivolu
 mab Via Intraventricular Injection for the Treatment of Refractory Non-squ
 amous Non-small Cell Lung Cancer with Leptomeningeal Metastases\nEstimated
  primary completion: November 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06901817
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119581-2053@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06119581)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without
  Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lu
 ng Cancer\nEstimated primary completion: November 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06119581
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1966@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Crizotinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Crizotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/crizotinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667167-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06667167)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irst Line Therapy for Extensive SCLC Patients\, Treated with Chemo+Keytrud
 a Followed by Keytuda+Trodelvy\nEstimated primary completion: 1 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT066671
 67
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III
  NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0656399
 9
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-1979@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Trametinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Trametinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667167-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06667167)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: First Line Therapy for Extensive SCLC Patients\, Treated with Chemo
 +Keytruda Followed by Keytuda+Trodelvy\nEstimated primary completion: 1 No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzu
 mab-govitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06667167
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06702826-1994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06702826)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cad
 onilimab Combined With Stereotactic Radiotherapy as Second-line Treatment 
 for Brain Metastases\nEstimated primary completion: 1 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cadonilimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06702826
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Orpathys (Savolitinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Orpathys (Savolitinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage II
 I NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 Novembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/savolitinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06563
 999
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Glecirasib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/glecirasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage 
 III NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sunvozertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6563999
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2207@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pyrotinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Pyrotinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harbo
 ring Rare Mutations.\nEstimated primary completion: 1 November 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pyrotinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2227@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Pralsetinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Pralsetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Har
 boring Rare Mutations.\nEstimated primary completion: 1 November 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pralsetinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/pralsetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2236@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Dabrafenib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2586@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Larotrectinib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Larotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC H
 arboring Rare Mutations.\nEstimated primary completion: 1 November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/larotrectinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/larotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e III\, Open-label\, First-line Study of Dato-DXd in Combination With Durv
 alumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alter
 ations\nEstimated primary completion: 1 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, First-line Study of Dato-DXd in Combinati
 on With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable G
 enomic Alterations\nEstimated primary completion: 1 November 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06567015-2745@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:STX-241: Phase 1/2 readout est. (NCT06567015)
DESCRIPTION:STX-241\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EG
 FR TKIs\nEstimated primary completion: 20 November 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/stx-241#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06567015
URL:https://assetmemo.bio/drug/stx-241#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288177-2708@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271122
DTEND;VALUE=DATE:20271123
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 2 readout est. (NCT07288177)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 2\, Non-Small Cell Lung C
 ancer.\nStudy: Study to Assess the Efficacy and Safety of Rina-S in Partic
 ipants With Non-small Cell Lung Cancer\nEstimated primary completion: 22 N
 ovember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rinatab
 art-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07288177
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03838159-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03838159)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: NADIM
  II: Neo-Adjuvant Immunotherapy\nEstimated primary completion: 30 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03838159
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06142617)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Prospective Study of Pembrolizumab Combining Chemotherapy in Adv
 anced NSCLC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary 
 completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06142617
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06142617)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSC
 LC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary completio
 n: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06142617
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231575-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07231575)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resecta
 ble EGFR Wild-type NSCLC\nEstimated primary completion: 30 November 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07231575
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07241819-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07241819)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Ad
 juvant Therapy for Resectable Non-small Cell Lung Cancer\nEstimated primar
 y completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07241819
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06142617-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06142617)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanc
 ed NSCLC Patients With EGFR Exon 21 Point Mutation.\nEstimated primary com
 pletion: 30 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06142617
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 This is a Multicenter\, Open-label\, Phase I/II Study to Explore the Safet
 y\, Tolerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy of GFH
 276 in Patients With Advanced NSCLC Harboring a RAS Mutation.\nEstimated p
 rimary completion: December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07846358
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: This is a Multicenter\, Open-label\, Phase I/II Study to Explore th
 e Safety\, Tolerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy
  of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07846358
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07846358-2492@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:GFH276: Phase 1/2 readout est. (NCT07846358)
DESCRIPTION:GFH276\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: This i
 s a Multicenter\, Open-label\, Phase I/II Study to Explore the Safety\, To
 lerability\, Pharmacokinetics (PK)\, and Preliminary Efficacy of GFH276 in
  Patients With Advanced NSCLC Harboring a RAS Mutation.\nEstimated primary
  completion: December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/gfh276#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07846358
URL:https://assetmemo.bio/drug/gfh276#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 m
 Ab\, Administered Alone and in Combination With a PD-1 Inhibitor or Chemot
 herapy (the MORNINGSTAR Study)\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0543127
 0
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556228-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA O
 verexpression Driven Solid Tumors or Lymphoma\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03556228
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mA
 b\, Administered Alone and in Combination With a PD-1 Inhibitor or Chemoth
 erapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: F
 iH Study to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040
  in Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06303505
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mAb
 \, Administered Alone and in Combination With a PD-1 Inhibitor or Chemothe
 rapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06754930-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 1/2 readout est. (NCT06754930)
DESCRIPTION:Adebrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SHR-1826 for Injection in Combination With Other Antitumor Thera
 pies in Subjects With NSCLC\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/adebrelimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06754930
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219576-2210@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Retifanlimab: Phase 1/2 readout est. (NCT07219576)
DESCRIPTION:Retifanlimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Retifanlimab and Ruxolitinib In Solid Malignancies\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/retifanlimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07219576
URL:https://assetmemo.bio/drug/retifanlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-C
 D73 mAb\, Administered Alone and in Combination With a PD-1 Inhibitor or C
 hemotherapy (the MORNINGSTAR Study)\nEstimated primary completion: Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 70
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07189871-2293@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:177Lu-BetaBart: Phase 1/2 readout est. (NCT07189871)
DESCRIPTION:177Lu-BetaBart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : 177Lu-BetaBart in Patients With Relapsed/Refractory\, Locally Advanced I
 noperable\, or Metastatic Solid Tumors\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/177lu-beta
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07189871
URL:https://assetmemo.bio/drug/177lu-betabart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-2614@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Mavrostobart: Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Mavrostobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-CD73 mAb
 \, Administered Alone and in Combination With a PD-1 Inhibitor or Chemothe
 rapy (the MORNINGSTAR Study)\nEstimated primary completion: December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/mavrostobart#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05431270
URL:https://assetmemo.bio/drug/mavrostobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06303505-2785@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:TUB-040: Phase 1/2 readout est. (NCT06303505)
DESCRIPTION:TUB-040\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: FiH S
 tudy to Investigate Safety\, PK and Efficacy of the NaPi2b ADC TUB-040 in 
 Patients With PROC or r/r Adenocarcinoma NSCLC\nEstimated primary completi
 on: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tu
 b-040#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06303505
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556228-2799@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:VMD-928: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:VMD-928\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: VMD-9
 28 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexp
 ression Driven Solid Tumors or Lymphoma\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vmd-928#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03556
 228
URL:https://assetmemo.bio/drug/vmd-928#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05431270-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05431270)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Dose Escalation/Expansion Study of Mavrostobart (PT199)\, an Anti-
 CD73 mAb\, Administered Alone and in Combination With a PD-1 Inhibitor or 
 Chemotherapy (the MORNINGSTAR Study)\nEstimated primary completion: Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054312
 70
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384626-10952@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:neladalkib: Phase 1/2 readout est. (NCT05384626)
DESCRIPTION:neladalkib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other So
 lid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-
 1)\nEstimated primary completion: December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05384626
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05676931-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05676931)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Study With Various Immunotherapy Treatments in Participants With Lun
 g Cancer\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05676931
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07038460)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Multicenter Phase II Randomized Trial of Limertinib Followed by 
 Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chem
 otherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NS
 CLC\nEstimated primary completion: December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07038460)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Phase II Randomized Trial of Limertinib Followed by Sintilimab a
 nd Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as 
 Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281209-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07281209)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Re
 sectable HER2-Altered Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07281209
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07874282)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Phase II Study to Evaluate Telisotuzumab Adizutecan in Combinati
 on With RC148(ABBV-1480) as First-Line Treatment for Patients With Non-Squ
 amous Non-Small-Cell Lung Cancer\nEstimated primary completion: December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-ad
 izutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07874282
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2698@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 2 readout est. (NCT07874282)
DESCRIPTION:RC148\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II 
 Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-
 1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cel
 l Lung Cancer\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07874282
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07038460-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Limertinib: Phase 2 readout est. (NCT07038460)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Phase II Randomized Trial of Limertinib Followed by Sintilimab a
 nd Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as 
 Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07038460
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281209-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07281209)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Ther
 apy for Resectable HER2-Altered Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07281209
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264816-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07264816)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unre
 sectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous N
 SCLC\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07264816
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449313-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06449313)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non
 -small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features\nEs
 timated primary completion: December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06449313
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232849-2130@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-4508: Phase 2 readout est. (NCT07232849)
DESCRIPTION:HRS-4508\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tria
 l of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Loc
 ally Advanced or Metastatic Non-small Cell Lung Cancer\nEstimated primary 
 completion: December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hrs-4508#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232849
URL:https://assetmemo.bio/drug/hrs-4508#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082179-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07082179)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Prospective Phase II Clinical Study of Immunotherapy Combi
 ned With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cance
 r\nEstimated primary completion: December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07082179
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05363280-2275@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:AL8326: Phase 2 readout est. (NCT05363280)
DESCRIPTION:AL8326\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase 2 
 Study for the Patient\, Who Has Diagnosed With Small Cell Lung Cancer (SCL
 C) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and
  Finished the First Line Stand Treatment \, Need More Treatment\nEstimated
  primary completion: December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/al8326#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05363280
URL:https://assetmemo.bio/drug/al8326#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07264816-2282@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 2 readout est. (NCT07264816)
DESCRIPTION:Trastuzumab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 in Combination With Pembrolizumab in Patients
  With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-
 Squamous NSCLC\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07264816
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05168566-2749@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutetinib: Phase 2 readout est. (NCT05168566)
DESCRIPTION:Sutetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study
  to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic N
 on-small Cell Lung Cancer\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sutetinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05168566
URL:https://assetmemo.bio/drug/sutetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06010329-2749@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sutetinib: Phase 2 readout est. (NCT06010329)
DESCRIPTION:Sutetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Loc
 ally Advanced or Metastatic NSCLC\nEstimated primary completion: December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sutetinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06010329
URL:https://assetmemo.bio/drug/sutetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06956001-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06956001)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Versus Platinum Based Chemotherapy as First-line Treatment fo
 r NSCLC With EGFR PACC or EGFR l861q Mutation\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fur
 monertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06956001
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800223-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Almonertinib: Phase 3 readout est. (NCT05800223)
DESCRIPTION:Almonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ar
 matinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated
  Non-small Cell Lung Cancer\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/almonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05800223
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07178795-2282@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab brengitecan: Phase 3 readout est. (NCT07178795)
DESCRIPTION:Trastuzumab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in Fir
 st-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
 \nEstimated primary completion: December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07178795
URL:https://assetmemo.bio/drug/trastuzumab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2207@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Pyrotinib: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Pyrotinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced o
 r Metastasis NSCLC With HER2 Mutation\nEstimated primary completion: 1 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pyrotinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT057
 45740
URL:https://assetmemo.bio/drug/pyrotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745740-2454@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Disitamab Vedotin: Phase 1/2 readout est. (NCT05745740)
DESCRIPTION:Disitamab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Ad
 vanced or Metastasis NSCLC With HER2 Mutation\nEstimated primary completio
 n: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 isitamab-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05745740
URL:https://assetmemo.bio/drug/disitamab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-2517@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nezutatug: Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Nezutatug\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cetuximab +/- 
 Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary completion:
  1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nez
 utatug#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05910827
URL:https://assetmemo.bio/drug/nezutatug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cet
 uximab +/- Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary 
 completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05910827
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200947-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07200947)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients Wit
 h SMARCA4-Deficient\, Locally Advanced or Metastatic Non-Small Cell Lung C
 ancer.\nEstimated primary completion: 1 December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07200947
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07450183-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07450183)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Peri
 operative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High P
 D-L1\nEstimated primary completion: 1 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07450183
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06684873-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06684873)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter\, Single-arm\, Open-label Study Evaluating the Safety and Effic
 acy of AK112 Combined With Chemotherapy as First-line Treatment for Non-sq
 uamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO
  BRAIN)\nEstimated primary completion: 1 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06684873
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672068-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06672068)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patient
 s With Mutated Epidermal Growth Factor Receptor NSCLC\nEstimated primary c
 ompletion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06672068
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07200947-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07200947)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Phase II Study of QL1706 and Platinum-Based Chemotherapy i
 n Patients With SMARCA4-Deficient\, Locally Advanced or Metastatic Non-Sma
 ll Cell Lung Cancer.\nEstimated primary completion: 1 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7200947
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06672068-2269@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Asandeutertinib: Phase 2 readout est. (NCT06672068)
DESCRIPTION:Asandeutertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients Wi
 th Mutated Epidermal Growth Factor Receptor NSCLC\nEstimated primary compl
 etion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/asandeutertinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06672068
URL:https://assetmemo.bio/drug/asandeutertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06881784-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Rasonque (Daraxonrasib): Phase 3 readout est. (NCT06881784)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSC
 LC (RASolve 301)\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06881784
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655622-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Furmonertinib: Phase 1/2 readout est. (NCT07655622)
DESCRIPTION:Furmonertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non
 -small Cell Lung Cancer and High PD-L1 Expression\nEstimated primary compl
 etion: 3 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07655622
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07655622-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271203
DTEND;VALUE=DATE:20271204
SUMMARY:Vebreltinib: Phase 1/2 readout est. (NCT07655622)
DESCRIPTION:Vebreltinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: V
 ebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-s
 mall Cell Lung Cancer and High PD-L1 Expression\nEstimated primary complet
 ion: 3 December 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vebreltinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07655622
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07085182-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07085182)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Ce
 ll Lung Cancer：A Prospective\, Single-Arm\, Phase II Study\nEstimated pr
 imary completion: 10 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07085182
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05631249-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271212
DTEND;VALUE=DATE:20271213
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05631249)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sotor
 asib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects W
 ith Mutated KRAS p.G12C\nEstimated primary completion: 12 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05631249
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286942-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07286942)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ste
 reotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (
 QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable 
 Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm\, Singl
 e-centre\, Phase 2 Trial\nEstimated primary completion: 18 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07286942
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286942-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271218
DTEND;VALUE=DATE:20271219
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07286942)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Stereotactic Body Radiotherapy With Sequential Iparomlimab a
 nd Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients
  With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a S
 ingle-arm\, Single-centre\, Phase 2 Trial\nEstimated primary completion: 1
 8 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipar
 omlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07286942
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07016126-1972@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Camrelizumab: Phase 2 readout est. (NCT07016126)
DESCRIPTION:Camrelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: D-
 BACE in Combination With Chemotherapy and Camrelizumab for Resectable II-I
 IIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC\nEstimated primary c
 ompletion: 22 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/camrelizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07016126
URL:https://assetmemo.bio/drug/camrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710132-2612@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:precemtabart tocentecan: Phase 1/2 readout est. (NCT06710132)
DESCRIPTION:precemtabart tocentecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced S
 olid Tumors (PROCEADE PanTumor)\nEstimated primary completion: 23 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/precemtabart-t
 ocentecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06710132
URL:https://assetmemo.bio/drug/precemtabart-tocentecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05275374-1979@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05275374)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XP
 -102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Pat
 ients With a BRAF V600 Mutation\nEstimated primary completion: 30 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trametinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0527537
 4
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195189-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT06195189)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-
 TKI Treatment Failure：Phase I/II\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sunvozertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6195189
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07603791)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Phase II Clinical Study to Evaluate the Safety\, Tolerability\, Ph
 armacokinetics and Antitumor Activity of ALK202 for Injection in Combinati
 on With Drugs in NSCLC Participants.\nEstimated primary completion: 30 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7603791
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197008-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07197008)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generat
 ion EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Met
 astasis\nEstimated primary completion: 30 December 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07197008
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07854509-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07854509)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI F
 ailure\nEstimated primary completion: 30 December 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07854509
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197008-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07197008)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sac
 ituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI
  Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis\nEst
 imated primary completion: 30 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07197008
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07603791)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinet
 ics and Antitumor Activity of ALK202 for Injection in Combination With Dru
 gs in NSCLC Participants.\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07603791
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603791-2341@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:ALK202: Phase 2 readout est. (NCT07603791)
DESCRIPTION:ALK202\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II
  Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinetics a
 nd Antitumor Activity of ALK202 for Injection in Combination With Drugs in
  NSCLC Participants.\nEstimated primary completion: 30 December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/alk202#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07603791
URL:https://assetmemo.bio/drug/alk202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001995-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Limertinib: Phase 2 readout est. (NCT07001995)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lime
 rtinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Tran
 sformation After EGFR-TKI Progression\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7001995
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585477-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04585477)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04585477
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668103-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT06668103)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonerti
 nib\nEstimated primary completion: 30 December 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06668103
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748325-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07748325)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immu
 nochemotherapy and Surgery in High-Risk NSCLC\nEstimated primary completio
 n: 30 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 sintilimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07748325
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416058-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07416058)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PHO
 ENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant\, PD-L1 
 ≥50% Non-Squamous NSCLC\nEstimated primary completion: 30 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07416058
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416058-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07416058)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Res
 istant\, PD-L1 ≥50% Non-Squamous NSCLC\nEstimated primary completion: 30
  December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iparo
 mlimab-and-tuvonralimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07416058
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06668103-2323@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT06668103)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
 \nEstimated primary completion: 30 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/lumipodlin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06668103
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442565-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:CPO301: Phase 3 readout est. (NCT07442565)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SYS6010 
 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase Ⅲ\nE
 stimated primary completion: 30 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cpo301#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07442565
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06123754-994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Envafolimab: Phase 3 readout est. (NCT06123754)
DESCRIPTION:Envafolimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable
  Stage III NSCLC\nEstimated primary completion: 30 December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/envafolimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06123754
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03225664-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03225664)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Trametinib and Pembrolizumab in Treating Patients With Recurrent Non-smal
 l Cell Lung Cancer That Is Metastatic\, Unresectable\, or Locally Advanced
 \nEstimated primary completion: 31 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03225664
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02696993-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02696993)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Niv
 olumab and Radiation Therapy With or Without Ipilimumab in Treating Patien
 ts With Brain Metastases From Non-small Cell Lung Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02696993
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165330-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04165330)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luation of AL3818 in Combination With Nivolumab in Solid Tumors\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04165330
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03225664-1979@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT03225664)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Tr
 ametinib and Pembrolizumab in Treating Patients With Recurrent Non-small C
 ell Lung Cancer That Is Metastatic\, Unresectable\, or Locally Advanced\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT03225664
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02696993-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT02696993)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ni
 volumab and Radiation Therapy With or Without Ipilimumab in Treating Patie
 nts With Brain Metastases From Non-small Cell Lung Cancer\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT02696993
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083857-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06083857)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Ce
 ll Lung Cancer\nEstimated primary completion: 31 December 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06083857
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06083857-2033@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tepmetko (Tepotinib): Phase 1/2 readout est. (NCT06083857)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non
 -small Cell Lung Cancer\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tepotinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06083857
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05764928-2403@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:BLEX 404: Phase 1/2 readout est. (NCT05764928)
DESCRIPTION:BLEX 404\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Eval
 uate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetre
 xed + Cisplatin Therapy\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/blex-404#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05764928
URL:https://assetmemo.bio/drug/blex-404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed
  by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-2340@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alintegimod: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Alintegimod\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followe
 d by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/alintegimod#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/alintegimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231068-2458@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07231068)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study
  of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advan
 ced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07231068
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05118789-2824@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Zidesamtinib: Phase 1/2 readout est. (NCT05118789)
DESCRIPTION:Zidesamtinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Othe
 r Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/zidesamtinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05118789
URL:https://assetmemo.bio/drug/zidesamtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969027-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06969027)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: JS207Combined With Chemotherapy in First-line Treatment of Advanced N
 SCLC\nEstimated primary completion: 31 December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06969027
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06969027-2239@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JS207: Phase 2 readout est. (NCT06969027)
DESCRIPTION:JS207\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS207Comb
 ined With Chemotherapy in First-line Treatment of Advanced NSCLC\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/js207#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06969027
URL:https://assetmemo.bio/drug/js207#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918782-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06918782)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Real-world Experience With Combination Chemotherapy and Osimertini
 b in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06918782
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962189-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT06962189)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The 
 Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion
  for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective\, Sin
 gle-Arm\, Phase II Study\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sintilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06962189
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489703-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07489703)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07489703
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742956-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07742956)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Clinical Study to Evaluate the Safety\, Tolerability\, Pharmacokinet
 ics and Antitumor Activity of ALK201 for Injection in Combination With Ivo
 nescimab Injection in sqNSCLC Participants.\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iv
 onescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07742956
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662473-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07662473)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: The Efficacy and Safety of Trastuzumab Deruxtecan in Advanced or M
 etastatic NSCLC With HER2 Over Expression\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tras
 tuzumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07662473
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07413952-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Limertinib: Phase 2 readout est. (NCT07413952)
DESCRIPTION:Limertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lime
 rtinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/limertinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07413952
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489703-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07489703)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC\nEstima
 ted primary completion: 31 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07489703
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05398094-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Sotorasib: Phase 2 readout est. (NCT05398094)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Clini
 cal Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients a
 nd Ineligible for Chemo-radiotherapy\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT053
 98094
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528274-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07528274)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mi
 crowave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After F
 irst-Line Immunotherapy Failure\nEstimated primary completion: 31 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07528
 274
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472478-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07472478)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemoth
 erapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study)\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07472478
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07398937-2161@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Serplulimab: Phase 2 readout est. (NCT07398937)
DESCRIPTION:Serplulimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 parison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resecta
 ble Stage II-IIIA Squamous NSCLC\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07398
 937
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472478-2488@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Anfangning (Garsorasib): Phase 2 readout est. (NCT07472478)
DESCRIPTION:Anfangning (Garsorasib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab 
 Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIV
 EN Study)\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07472478
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444437-2593@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LM103: Phase 2 readout est. (NCT07444437)
DESCRIPTION:LM103\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lu
 ng Cancer\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/lm103#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07444437
URL:https://assetmemo.bio/drug/lm103#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987734-2747@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cejemly (Sugemalimab): Phase 2 readout est. (NCT06987734)
DESCRIPTION:Cejemly (Sugemalimab)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemal
 imab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer
  Patients\nEstimated primary completion: 31 December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/sugemalimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06987734
URL:https://assetmemo.bio/drug/sugemalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07528274-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07528274)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC
  After First-Line Immunotherapy Failure\nEstimated primary completion: 31 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/doceta
 xel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07528274
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662811-2291@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Enlonstobart: Phase 2/3 readout est. (NCT07662811)
DESCRIPTION:Enlonstobart\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Th
 erapy for Squamous Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 enlonstobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07662811
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 ding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With 
 Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platin
 um Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ramucirumab: Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Ramucirumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
 dding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With
  Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Plati
 num Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)\
 nEstimated primary completion: 31 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616584-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT06616584)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Non-Small Cell Lung Cancer.\
 nStudy: Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for Pe
 ople With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment W
 ith Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatmen
 t Trial)\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06616584
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ve
 breltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patie
 nts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGF
 R-TKI Failure\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970782-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06970782)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patien
 ts With EGFRm\, MET+\, Locally Advanced or Metastatic NSCLC Following EGFR
 -TKI Failure\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06970782
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07242274-2566@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:JMKX001899: Phase 3 readout est. (NCT07242274)
DESCRIPTION:JMKX001899\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or
  Metastatic KRAS G12C-Mutant NSCLC\nEstimated primary completion: 31 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/jmkx001899#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0724
 2274
URL:https://assetmemo.bio/drug/jmkx001899#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416474-2698@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 3 readout est. (NCT07416474)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RC148 Plu
 s Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemothe
 rapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07416474
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686682-2560@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:JAB-8263: Phase 1/2 readout est. (NCT04686682)
DESCRIPTION:JAB-8263\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fi
 rst-in-Human\, JAB-8263 in Adult Patients With Advanced Tumors\nEstimated 
 primary completion: January 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04686682
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07148128-2804@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:WEF-001: Phase 1/2 readout est. (NCT07148128)
DESCRIPTION:WEF-001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  1/2a Study to Assess the Safety\, Tolerability\, Pharmacokinetics\, and P
 reliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Soli
 d Tumours.\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/wef-001#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07148128
URL:https://assetmemo.bio/drug/wef-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04105270-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04105270)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: RMT 
 in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. 
 A Randomized Double Blind Phase II Trial\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 105270
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670013-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07670013)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 Plus Glecirasib in Advanced KRAS G12C-Mutant NSCLC: A Phas
 e II Study\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07670013
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07669051-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07669051)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Clinical Trial of Ivonescimab Plus Third-generation EGFR-TKIs in A
 dvanced Non-small Cell Lung Cancer With Gradual or Potential Progression A
 fter EGFR-TKIs Treatment\nEstimated primary completion: 1 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07669051
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358689-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07358689)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Combined With Platinum-based Chemotherapy With or Without H1 Rece
 ptor Antagonist in the Perioperative Treatment of Resectable Non-small Cel
 l Lung Cancer\nEstimated primary completion: 1 January 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07358689
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07505173-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07505173)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Hippocampus-Protective Radiotherapy Combined With Osimertinib for 
 Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer\nEstimated primar
 y completion: 1 January 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07505173
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants W
 ith Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 10 January 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311721-2085@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Abp 234: Phase 3 readout est. (NCT06311721)
DESCRIPTION:Abp 234\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Ad
 vanced or Metastatic Non-squamous Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abp-234#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06311721
URL:https://assetmemo.bio/drug/abp-234#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548060-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280122
DTEND;VALUE=DATE:20280123
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07548060)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertin
 ib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progr
 essed After EGFR-TKI and Platinum-Based Chemotherapy\nEstimated primary co
 mpletion: 22 January 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07548060
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07548060-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280122
DTEND;VALUE=DATE:20280123
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07548060)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of Sacituzumab Tirumotecan in Combination With F
 urmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who 
 Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy\nEstimated 
 primary completion: 22 January 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07548060
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06345729-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280124
DTEND;VALUE=DATE:20280125
SUMMARY:Calderasib: Phase 3 readout est. (NCT06345729)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants W
 ith KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Ce
 ll Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004
 /KANDLELIT-004)\nEstimated primary completion: 24 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06345729
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 acituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus 
 Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With 
 Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50
 % (MK-2870-007)\nEstimated primary completion: 25 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06170788
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06170788-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06170788)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizum
 ab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NS
 CLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (T
 PS) ≥ 50% (MK-2870-007)\nEstimated primary completion: 25 January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6170788
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05557591-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT05557591)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Tr
 ial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab 
 Works and How Safe the Combination is in Adults With Advanced Non-small Ce
 ll Lung Cancer (EMPOWERVAX Lung 1)\nEstimated primary completion: 26 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05557
 591
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05557591-2104@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280126
DTEND;VALUE=DATE:20280127
SUMMARY:BNT116: Phase 2 readout est. (NCT05557591)
DESCRIPTION:BNT116\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Trial 
 to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Work
 s and How Safe the Combination is in Adults With Advanced Non-small Cell L
 ung Cancer (EMPOWERVAX Lung 1)\nEstimated primary completion: 26 January 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/bnt116#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05557591
URL:https://assetmemo.bio/drug/bnt116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330596-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280128
DTEND;VALUE=DATE:20280129
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07330596)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: QL1706 Combined With Chemotherapy in the Treatment of Immune
 -mediated NSCLC\nEstimated primary completion: 28 January 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073305
 96
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05393466-2105@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:BPI-361175: Phase 1/2 readout est. (NCT05393466)
DESCRIPTION:BPI-361175\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: BP
 I-361175 Tablets in Patients With Advanced Non-Small Cell Lung Cancer (NSC
 LC)\nEstimated primary completion: 30 January 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bpi-361175#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05393466
URL:https://assetmemo.bio/drug/bpi-361175#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02525757-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT02525757)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: MP
 DL3280A With Chemoradiation for Lung Cancer\nEstimated primary completion:
  31 January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ate
 zolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02525757
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568939-2230@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Telisotuzumab Vedotin: Phase 2 readout est. (NCT06568939)
DESCRIPTION:Telisotuzumab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Adverse Events and How Intravenously (IV) Infused
  Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy 
 in Adult Participants With Previously Treated Non-Squamous Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06568939
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728865-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06728865)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luation of the Efficacy and Safety of Befotertinib Combined With Bevacizum
 ab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer Wi
 th Brain Metastases: A Single-Arm\, Open-Label\, Prospective Phase II Clin
 ical Study\nEstimated primary completion: 1 February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06728865
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728865-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Befotertinib: Phase 2 readout est. (NCT06728865)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ev
 aluation of the Efficacy and Safety of Befotertinib Combined With Bevacizu
 mab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer W
 ith Brain Metastases: A Single-Arm\, Open-Label\, Prospective Phase II Cli
 nical Study\nEstimated primary completion: 1 February 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/befotertinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06728865
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07517640-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07517640)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 ombining Furmonertinib With Local Therapy for Inoperable Early-stage Lung 
 Cancer: A Phase II Trial\nEstimated primary completion: 1 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07517640
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133425-2720@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Daxokafusp alfa: Phase 2 readout est. (NCT07133425)
DESCRIPTION:Daxokafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory 
 Non-small Cell Lung Cancer\nEstimated primary completion: 1 February 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/daxokafusp-alfa#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07133425
URL:https://assetmemo.bio/drug/daxokafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06080776-2226@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Rilertinib (SH-1028): Phase 3 readout est. (NCT06080776)
DESCRIPTION:Rilertinib (SH-1028)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage
  II-IIIB NSCLC With Sensitizing EGFR Mutations\nEstimated primary completi
 on: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rilertinib-sh-1028#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06080776
URL:https://assetmemo.bio/drug/rilertinib-sh-1028#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pe
 mbrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated
  primary completion: 15 February 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-2338@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:ALE.P02: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:ALE.P02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P02 as a Monotherapy or in Combination With Pembroli
 zumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated prima
 ry completion: 15 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ale-p02#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/ale-p02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07545213-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07545213)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of SKB264 Plus Anlotinib in EGFR-TKI-Resistan
 t Advanced NSCLC With Liver Metastasis\nEstimated primary completion: 15 F
 ebruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituz
 umab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07545213
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06829459)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate the Efficacy and Safety of Glumetinib Combined
  With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in N
 on-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimate
 d primary completion: 15 February 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06829459
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829459-2222@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Glumetinib: Phase 3 readout est. (NCT06829459)
DESCRIPTION:Glumetinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimer
 tinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cel
 l Lung Cancer Patients After Resistance to EGFR-TKIs\nEstimated primary co
 mpletion: 15 February 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/glumetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06829459
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987644-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT05987644)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Can
 cer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases a
 nd ALK rEarrangements\nEstimated primary completion: 28 February 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05987644
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03586453-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT03586453)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib In EGFR Mutant Lung Cancer\nEstimated primary completi
 on: 28 February 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03586453
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05064280-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05064280)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Study of Pembrolizumab in Combination With Lenvatinib in Patients 
 With TNBC\, NSCLC\, and Other Tumor Types and Brain Metastases\nEstimated 
 primary completion: 28 February 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05064280
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06579196-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06579196)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCL
 C and Positive PD-L1\nEstimated primary completion: March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06579196
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486833-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04486833)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients W
 ith Advanced Lung Cancer Who Progressed on Osimertinib\nEstimated primary 
 completion: March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/osimertinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04486833
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04486833-2205@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Reqorsa (Quaratusugene Ozeplasmid): Phase 1/2 readout est. (NCT0448
 6833)
DESCRIPTION:Reqorsa (Quaratusugene Ozeplasmid)\, phase 1/2\, Non-Small Cell
  Lung Cancer.\nStudy: Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib i
 n Patients With Advanced Lung Cancer Who Progressed on Osimertinib\nEstima
 ted primary completion: March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04486833
URL:https://assetmemo.bio/drug/quaratusugene-ozeplasmid#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05256290-2729@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Silevertinib: Phase 1/2 readout est. (NCT05256290)
DESCRIPTION:Silevertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma 
 or Non-Small Cell Lung Cancer With EGFR Mutations\nEstimated primary compl
 etion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/si
 levertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05256290
URL:https://assetmemo.bio/drug/silevertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807722-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07807722)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum
 -Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC\nEstimated p
 rimary completion: March 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07807722
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05684276-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05684276)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DUMAS
 : Neo-Adjuvant Immunotherapy for Pancoast Tumors\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05684276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653438-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07653438)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: In V
 ivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients Wi
 th Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemora
 diotherapy\nEstimated primary completion: 1 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07653438
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405190-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07405190)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ivo
 nescimab Alone And With Carboplatin/Pemetrexed For NSCLC\nEstimated primar
 y completion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07405190
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405190-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07405190)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC\nEstimate
 d primary completion: 1 March 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07405190
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in P
 articipants With Resectable EGFR-Mutated NSCLC\nEstimated primary completi
 on: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/laz
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07586202
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07586202)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in 
 Participants With Resectable EGFR-Mutated NSCLC\nEstimated primary complet
 ion: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/am
 ivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07586202
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07586202-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280302
DTEND;VALUE=DATE:20280303
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07586202)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemothe
 rapy in Participants With Resectable EGFR-Mutated NSCLC\nEstimated primary
  completion: 2 March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07586202
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063329-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280308
DTEND;VALUE=DATE:20280309
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT07063329)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemother
 apy in Patients With EGFR Mutation-positive\nEstimated primary completion:
  8 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/andame
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07063329
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07144280-2168@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280310
DTEND;VALUE=DATE:20280311
SUMMARY:Fetrastobart vedotin: Phase 3 readout est. (NCT07144280)
DESCRIPTION:Fetrastobart vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL
 1V Versus Docetaxel in Adult Participants With Previously-Treated Programm
 ed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: 10 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07144280
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07192068-2201@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280313
DTEND;VALUE=DATE:20280314
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07192068)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Trial Evaluating the Activity of Zanidatamab for the Treatment of Pa
 tients With Solid Tumors With an Alteration of the HER2 Gene.\nEstimated p
 rimary completion: 13 March 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07192068
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06616766-2815@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:YH42946: Phase 1/2 readout est. (NCT06616766)
DESCRIPTION:YH42946\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2\, Open-label\, Multicenter\, FIH Study to Evaluate Safety\, Tolerab
 ility\, PK and Anti-tumor Activity of YH42946\nEstimated primary completio
 n: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/yh4
 2946#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06616766
URL:https://assetmemo.bio/drug/yh42946#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871214-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07871214)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Assess The Safety and Tolerability of Pumitamig-Based Therapy Admini
 stered Before Surgery in Participants With Early-Stage Non-Small Cell Lung
  Cancer (ROSETTA Lung-220)\nEstimated primary completion: 15 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07871214
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07871214-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07871214)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Assess The Safety and Tolerability of Pumitamig-Based Ther
 apy Administered Before Surgery in Participants With Early-Stage Non-Small
  Cell Lung Cancer (ROSETTA Lung-220)\nEstimated primary completion: 15 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07871
 214
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908993-2033@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280315
DTEND;VALUE=DATE:20280316
SUMMARY:Tepmetko (Tepotinib): Phase 3 readout est. (NCT06908993)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 1
 4 Mutated Non-Small Cell Lung Cancer Previously Treated\nEstimated primary
  completion: 15 March 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tepotinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06908993
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06350097-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280321
DTEND;VALUE=DATE:20280322
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06350097)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label Study of First-line Osimertinib With or Wit
 hout Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-s
 mall Cell Lung Cancer\nEstimated primary completion: 21 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06350097
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03412877-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280323
DTEND;VALUE=DATE:20280324
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03412877)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 dministration of Autologous T-Cells Genetically Engineered to Express T-Ce
 ll Receptors Reactive Against Neoantigens in People With Metastatic Cancer
 \nEstimated primary completion: 23 March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03412877
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354061-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280325
DTEND;VALUE=DATE:20280326
SUMMARY:Ensacove (Ensartinib): Phase 1/2 readout est. (NCT07354061)
DESCRIPTION:Ensacove (Ensartinib)\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy fo
 r ALK-positive Non - Small Cell Lung Cancer (NSCLC)\nEstimated primary com
 pletion: 25 March 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/ensartinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07354061
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644768-2791@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Ezharmia (valemetostat tosylate): Phase 1/2 readout est. (NCT066447
 68)
DESCRIPTION:Ezharmia (valemetostat tosylate)\, phase 1/2\, Non-Small Cell L
 ung Cancer.\nStudy: A Study of Valemetostat Tosylate Plus Pembrolizumab Ve
 rsus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Al
 terations\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06644768
URL:https://assetmemo.bio/drug/valemetostat-tosylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of HS-20093 Injection Combined With Adebrelimab Versus HS-20
 093 Injection in Previously Treated Patients With Advanced or Metastatic N
 on-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterati
 ons\nEstimated primary completion: 30 March 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07824882-2501@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Risvutatug rezetecan: Phase 2 readout est. (NCT07824882)
DESCRIPTION:Risvutatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase II Study of HS-20093 Injection Combined With Adebrelimab Ver
 sus HS-20093 Injection in Previously Treated Patients With Advanced or Met
 astatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic
  Alterations\nEstimated primary completion: 30 March 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07824882
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718737-2088@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:AMT-116: Phase 2/3 readout est. (NCT07718737)
DESCRIPTION:AMT-116\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Globa
 l\, Multicenter Study of AMT-116 Versus Investigator's Choice in Participa
 nts With Advanced or Metastatic Non-squamous EGFR-Wildtype Non-Small Cell 
 Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemothera
 py and Anti-PD-1/PD-L1 Immunotherapy\nEstimated primary completion: 30 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/amt-116#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07718737
URL:https://assetmemo.bio/drug/amt-116#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412262-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07412262)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Chidamide Combined With Ivonescimab in the Treatment of Advanced N
 on-Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherap
 y and High Yes-associated Protein (YAP) Expression\nEstimated primary comp
 letion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07412262
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07412262-2286@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Chidamide: Phase 2 readout est. (NCT07412262)
DESCRIPTION:Chidamide\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non
 -Small Cell Lung Cancer (NSCLC) With Acquired Resistance to Immunotherapy 
 and High Yes-associated Protein (YAP) Expression\nEstimated primary comple
 tion: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 chidamide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07412262
URL:https://assetmemo.bio/drug/chidamide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 llogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in 
 Advanced Solid Tumors\nEstimated primary completion: April 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Allogeneic NK Cell Therapy Combined With Standard Maintenance Treat
 ment in Advanced Solid Tumors\nEstimated primary completion: April 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551778-2242@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:S-1: Phase 1/2 readout est. (NCT07551778)
DESCRIPTION:S-1\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Allogenei
 c NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced
  Solid Tumors\nEstimated primary completion: April 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/s-1#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07551778
URL:https://assetmemo.bio/drug/s-1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Ivonescimab in Combination With Dato-DXd or Osimertin
 ib in People With Non-Small Cell Lung Cancer\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimert
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07535437
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Ivonescimab in Combination With Dato-DXd or Osimertin
 ib in People With Non-Small Cell Lung Cancer\nEstimated primary completion
 : April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopot
 amab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07535437
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535437-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07535437)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in Peopl
 e With Non-Small Cell Lung Cancer\nEstimated primary completion: April 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07535437
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07535463-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07535463)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab\, Chemotherapy\, and Stereotactic Radiosurgery for P
 eople With Non-Small Cell Lung Cancer\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075354
 63
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04940325-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT04940325)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd\, DS-1062a) in Advanced and/or Un
 resectable Non-Small Cell Lung Cancer\nEstimated primary completion: April
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04940325
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818304-994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Envafolimab: Phase 2 readout est. (NCT07818304)
DESCRIPTION:Envafolimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SRT
  Combined With Envafolimab and Endostar in the First-line Treatment of Adv
 anced NSCLC\nEstimated primary completion: April 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/envafolimab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07818304
URL:https://assetmemo.bio/drug/envafolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The 
 Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small 
 Cell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06885840-2050@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 2 readout est. (NCT06885840)
DESCRIPTION:Pamvatamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with
  AGA and MET Amplification.\nEstimated primary completion: April 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pamvatamig#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06885840
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-2157@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Oleclumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Oleclumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The S
 elective Personalized Radio-Immunotherapy for Locally Advanced Non-Small C
 ell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/oleclumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818304-2160@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Endostar: Phase 2 readout est. (NCT07818304)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SRT Co
 mbined With Envafolimab and Endostar in the First-line Treatment of Advanc
 ed NSCLC\nEstimated primary completion: April 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/endostar#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07818304
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-2257@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Monalizumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Monalizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small
  Cell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/monalizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06767514-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT06767514)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients With High PD-L1\nEstimated primary completion: April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06767514
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712680-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT06712680)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced 
 Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treatin
 g Patients With Advanced NSCLC Positive for Driver Genes\nEstimated primar
 y completion: 10 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/osimertinib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06712680
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04789486-2333@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:AGuIX: Phase 1/2 readout est. (NCT04789486)
DESCRIPTION:AGuIX\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Nano-SM
 ART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors an
 d Pancreatic Cancer\nEstimated primary completion: 10 April 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/aguix#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04789486
URL:https://assetmemo.bio/drug/aguix#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712680-2763@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:HYP-6589: Phase 1/2 readout est. (NCT06712680)
DESCRIPTION:HYP-6589\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors a
 nd in Combination With Tyrosine Kinase Inhibitors in Treating Patients Wit
 h Advanced NSCLC Positive for Driver Genes\nEstimated primary completion: 
 10 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hyp-65
 89#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6712680
URL:https://assetmemo.bio/drug/hyp-6589#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360132-2128@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07360132)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pe
 mbrolizumab Combined With Chemotherapy for the First-Line Treatment of Adv
 anced Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotibur
 afusp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07360132
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2128@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Sotiburafusp alfa: Phase 3 readout est. (NCT07383116)
DESCRIPTION:Sotiburafusp alfa\, phase 3\, Non-Small Cell Lung Cancer.\nStud
 y: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Ti
 slelizumab Combined With Chemotherapy as First-Line Treatment for Advanced
  Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 10 
 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sotiburaf
 usp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07383116
URL:https://assetmemo.bio/drug/sotiburafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07383116-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07383116)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus 
 Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanc
 ed Nonsquamous Non-Small Cell Lung Cancer\nEstimated primary completion: 1
 0 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07383116
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06907615-2039@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280420
DTEND;VALUE=DATE:20280421
SUMMARY:HLX43: Phase 2 readout est. (NCT06907615)
DESCRIPTION:HLX43\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Phase I
 I Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cel
 l Lung Cancer (NSCLC)\nEstimated primary completion: 20 April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/hlx43#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06907615
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518160-2047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:JS111: Phase 2 readout est. (NCT07518160)
DESCRIPTION:JS111\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS212 Plu
 s JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study\nEstimated primary
  completion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07518160
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07518160-2571@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280423
DTEND;VALUE=DATE:20280424
SUMMARY:JS212: Phase 2 readout est. (NCT07518160)
DESCRIPTION:JS212\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: JS212 Plu
 s JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study\nEstimated primary
  completion: 23 April 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/js212#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07518160
URL:https://assetmemo.bio/drug/js212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930432-2050@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pamvatamig: Phase 1/2 readout est. (NCT04930432)
DESCRIPTION:Pamvatamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of MCLA-129\, a Human Bispecific EGFR and cMet Antibody\, in Patients 
 With Advanced NSCLC and Other Solid Tumors\nEstimated primary completion: 
 30 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pamvat
 amig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04930432
URL:https://assetmemo.bio/drug/pamvatamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07841106-2160@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Endostar: Phase 2 readout est. (NCT07841106)
DESCRIPTION:Endostar\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Early 
 Prophylactic Versus Late Salvage Recombinant Human Endostatin in Managing 
 Radiosurgery-Induced Brain Injury for NSCLC Brain Metastases\nEstimated pr
 imary completion: 30 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/endostar#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07841106
URL:https://assetmemo.bio/drug/endostar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06041776-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Befotertinib: Phase 3 readout est. (NCT06041776)
DESCRIPTION:Befotertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Posit
 ive EGFR Sensitive Mutations\nEstimated primary completion: 30 April 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06041776
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268210-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06268210)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mut
 ated Resectable Non-small Cell Lung Cancer\nEstimated primary completion: 
 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lazertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0626
 8210
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06268210-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06268210)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With
  EGFR-mutated Resectable Non-small Cell Lung Cancer\nEstimated primary com
 pletion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 metrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06268210
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418931-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07418931)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Mu
 lticenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy\, Sele
 cted on the Basis of Baseline Cytidine Deaminase Activity\, in Advanced Sq
 uamous Non-small Cell Lung Cancer\nEstimated primary completion: May 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07418931
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06861218-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06861218)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Cerebrospinal Fluid Cytology-guided Intrathecal Chemo-holiday Therapy
  for EGFR-positive NSCLC Leptomeningeal Metastases\nEstimated primary comp
 letion: May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06861218
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07418931-7671@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07418931)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A M
 ulticenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy\, Sel
 ected on the Basis of Baseline Cytidine Deaminase Activity\, in Advanced S
 quamous Non-small Cell Lung Cancer\nEstimated primary completion: May 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07418931
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06378892-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT06378892)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy 
 Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Ex
 clusively Extracranial Disease Progression on Lorlatinib\nEstimated primar
 y completion: May 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lorlatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06378892
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06472245-2663@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:OSE2101: Phase 3 readout est. (NCT06472245)
DESCRIPTION:OSE2101\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Trial o
 f Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung 
 Cancer and Secondary Resistance to Immune Checkpoint Inhibitor\nEstimated 
 primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/ose2101#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06472245
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07594522-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280512
DTEND;VALUE=DATE:20280513
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07594522)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Ivonescimab in People With Non-Small Cell Lung Cancer\nEstimated
  primary completion: 12 May 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07594522
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744529-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07744529)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
 mivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated L
 ung Adenocarcinoma\nEstimated primary completion: 28 May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07744529
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744529-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280528
DTEND;VALUE=DATE:20280529
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07744529)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-M
 utated Lung Adenocarcinoma\nEstimated primary completion: 28 May 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07744529
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05009836-2032@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Orpathys (Savolitinib): Phase 3 readout est. (NCT05009836)
DESCRIPTION:Orpathys (Savolitinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+
 /MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 
 30 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/savoliti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05009836
URL:https://assetmemo.bio/drug/savolitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463677-2487@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Dupert (Fulzerasib): Phase 2 readout est. (NCT07463677)
DESCRIPTION:Dupert (Fulzerasib)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally
  Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary comp
 letion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 fulzerasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07463677
URL:https://assetmemo.bio/drug/fulzerasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031688-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT06031688)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tar
 geted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exo
 n 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)\nEstimate
 d primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06031688
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06116682-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06116682)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tar
 geted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased
  Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)\nEstimated 
 primary completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/amivantamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06116682
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051695-2311@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:A2B543: Phase 1/2 readout est. (NCT06051695)
DESCRIPTION:A2B543\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated 
 CAR T\, in Participants With Solid Tumors That Express MSLN and Have Lost 
 HLA-A*02 Expression\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/a2b543#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06051695
URL:https://assetmemo.bio/drug/a2b543#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06051695-2312@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:A2B694: Phase 1/2 readout est. (NCT06051695)
DESCRIPTION:A2B694\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated 
 CAR T\, in Participants With Solid Tumors That Express MSLN and Have Lost 
 HLA-A*02 Expression\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/a2b694#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06051695
URL:https://assetmemo.bio/drug/a2b694#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malign
 ancies\nEstimated primary completion: June 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-1979@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignanc
 ies\nEstimated primary completion: June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/trametinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertin
 ib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07079475
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2251@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:DZD6008: Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:DZD6008\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Wh
 o Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nEstimated primary 
 completion: June 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dzd6008#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07079475
URL:https://assetmemo.bio/drug/dzd6008#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602842-2537@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:IDP-001: Phase 1/2 readout est. (NCT07602842)
DESCRIPTION:IDP-001\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of IDP-001 in Advanced or Metastatic Solid Tumors\nEstimated primary co
 mpletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 idp-001#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07602842
URL:https://assetmemo.bio/drug/idp-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05786924-2719@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:S241656: Phase 1/2 readout est. (NCT05786924)
DESCRIPTION:S241656\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Phase
  1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
 \nEstimated primary completion: June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/s241656#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05786924
URL:https://assetmemo.bio/drug/s241656#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03767348)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03767348
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-2713@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Vusolimogene oderparepvec (Tudriqev): Phase 2 readout est. (NCT0376
 7348)
DESCRIPTION:Vusolimogene oderparepvec (Tudriqev)\, phase 2\, Non-Small Cell
  Lung Cancer.\nStudy: Study of RP1 Monotherapy and RP1 in Combination With
  Nivolumab (IGNYTE)\nEstimated primary completion: June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqe
 v#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 767348
URL:https://assetmemo.bio/drug/vusolimogene-oderparepvec-tudriqev#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07704645-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07704645)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The
  Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a 
 Treatment for Resectable Non-small Cell Lung Cancer\nEstimated primary com
 pletion: June 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 debrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07704645
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680050-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06680050)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stag
 e III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACI
 FIC Regimen\nEstimated primary completion: June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06680050
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502237-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT05502237)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pemb
 rolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: June 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05502237
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05502237-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT05502237)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus
  Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non
 -Small Cell Lung Cancer\nEstimated primary completion: June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05502237
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04995523-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT04995523)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participan
 ts With Advanced or Metastatic NSCLC\nEstimated primary completion: 1 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0499
 5523
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07603661-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07603661)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sint
 ilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC 
 NSCLC\nEstimated primary completion: 1 June 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07603661
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07408635-2254@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:IBI363: Phase 2 readout est. (NCT07408635)
DESCRIPTION:IBI363\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IBI363 (
 PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy 
 in Initially Unresectable Stage III Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 6 June 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ibi363#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07408635
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410975-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280610
DTEND;VALUE=DATE:20280611
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07410975)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as 
 Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer
 \nEstimated primary completion: 10 June 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07410975
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06902272-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280611
DTEND;VALUE=DATE:20280612
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06902272)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: c
 tDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residua
 l Disease in Non-Small Cell Lung Cancer\nEstimated primary completion: 11 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06902272
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06779539-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280612
DTEND;VALUE=DATE:20280613
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06779539)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III N
 on-Small Cell Lung Cancer\nEstimated primary completion: 12 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06779539
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623642-2037@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:GV20-0251: Phase 2 readout est. (NCT07623642)
DESCRIPTION:GV20-0251\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodi
 es in Patients With Unresectable\, Locally Advanced\, or Metastatic Solid 
 Tumors.\nEstimated primary completion: 15 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/gv20-0251#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07623642
URL:https://assetmemo.bio/drug/gv20-0251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic S
 quamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 
 15 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pac
 litaxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07845786
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Z
 anzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Sq
 uamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1
 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845786
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07845786-2819@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Zanzalintinib: Phase 2 readout est. (NCT07845786)
DESCRIPTION:Zanzalintinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Z
 anzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Sq
 uamous Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1
 5 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zanzalin
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07845786
URL:https://assetmemo.bio/drug/zanzalintinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623356-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07623356)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non
 -Small Cell Lung Cancer\nEstimated primary completion: 18 June 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07623356
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623356-2335@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280618
DTEND;VALUE=DATE:20280619
SUMMARY:AK138D1: Phase 1/2 readout est. (NCT07623356)
DESCRIPTION:AK138D1\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: 18 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ak138d1#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07623356
URL:https://assetmemo.bio/drug/ak138d1#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or 
 Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0497
 7453
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2493@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Efdelikofusp alfa: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:Efdelikofusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nSt
 udy: GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab
  or Lenvatinib in Advanced Solid Tumors\nEstimated primary completion: 30 
 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/efdelikofu
 sp-alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT04977453
URL:https://assetmemo.bio/drug/efdelikofusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04977453-2494@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:GI-101A: Phase 1/2 readout est. (NCT04977453)
DESCRIPTION:GI-101A\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: GI-10
 1/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvat
 inib in Advanced Solid Tumors\nEstimated primary completion: 30 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/gi-101a#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04977453
URL:https://assetmemo.bio/drug/gi-101a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03110978-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03110978)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stere
 otactic Body Radiation Therapy With or Without Nivolumab in Treating Patie
 nts With Stage I-IIA or Recurrent Non-small Cell Lung Cancer\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03110978
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375316-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07375316)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A ctDNA-guided Phase II Trial of Osimertinib in Combination With S
 acituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positi
 ve ctDNA After lead-in Osimertinib Monotherapy\nEstimated primary completi
 on: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osi
 mertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07375316
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822543-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06822543)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Single Arm\, Phase 2 Study of Datopotamab Deruxtecan\, Carboplatin\, and 
 Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small C
 ell Lung Cancer)\nEstimated primary completion: 30 June 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06822543
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06822543-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT06822543)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Single Arm\, Phase 2 Study of Datopotamab Deruxtecan\, Carboplat
 in\, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (No
 n-small Cell Lung Cancer)\nEstimated primary completion: 30 June 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06822
 543
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07375316-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07375316)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A ctDNA-guided Phase II Trial of Osimertinib in Combination With 
 Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Posit
 ive ctDNA After lead-in Osimertinib Monotherapy\nEstimated primary complet
 ion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sa
 cituzumab-tirumotecan#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07375316
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06281964-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Andamertinib: Phase 3 readout est. (NCT06281964)
DESCRIPTION:Andamertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ef
 ficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCL
 C Harboring EGFR Exon 20 Insertion.\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/andamertinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06281
 964
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07197853-2137@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Huaier Granule: Phase 3 readout est. (NCT07197853)
DESCRIPTION:Huaier Granule\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Clinical Efficacy and Safety of Microwave Ablation Combined With Huaier Gr
 anules in Patients With Inoperable Stage IA Non-Small Cell Lung Cancer: A 
 Prospective\, Single-Center\, Randomized Controlled Clinical Trial\nEstima
 ted primary completion: 30 June 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/huaier-granule#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07197853
URL:https://assetmemo.bio/drug/huaier-granule#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339176-2630@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:N17350: Phase 1/2 readout est. (NCT07339176)
DESCRIPTION:N17350\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Intrat
 umoral N17350 in Advanced Solid Tumors\nEstimated primary completion: July
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/n17350#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07339176
URL:https://assetmemo.bio/drug/n17350#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619911-2061@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07619911)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : SHR-1701 for Induction and Consolidation Therapy in Unresectable Stage I
 II Non-Small Cell Lung Cancer\nEstimated primary completion: July 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07619911
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882174-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06882174)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 his Study is Comparing Morning vs Random Scheduling of Standard of Care Pe
 mbrolizumab Checkpoint Inhibitor Immunotherapy Infusions in Patients With 
 Metastatic Non-small Cell Lung Cancer\nEstimated primary completion: July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06882
 174
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158489-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158489)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ove
 rcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab
  in Advanced NSCLC\nEstimated primary completion: July 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07158489
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915037-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07915037)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: E
 valuation of the Effect of Time of Administration on the Activity on First
  Line of Pembrolizumab in Association With Carboplatin-pemetrexed in Metas
 tatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III Trial\n
 Estimated primary completion: July 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07915037
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915037-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07915037)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Evaluation of the Effect of Time of Administration on the Activity on
  First Line of Pembrolizumab in Association With Carboplatin-pemetrexed in
  Metastatic Non-squamous Lung Cancer. A Randomised Multicenter Phase III T
 rial\nEstimated primary completion: July 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07915037
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951646-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT06951646)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ctD
 NA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC Wi
 th Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)\nEst
 imated primary completion: 1 July 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06951646
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06951646-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06951646)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced
  NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adapt
 ive)\nEstimated primary completion: 1 July 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06951646
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415005-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07415005)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small
  Cell Lung Cancer\nEstimated primary completion: 22 July 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07415005
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489066-1989@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280729
DTEND;VALUE=DATE:20280730
SUMMARY:PF-08634404: Phase 2 readout est. (NCT07489066)
DESCRIPTION:PF-08634404\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination
  in Early-stage or Locally Advanced NSCLC\nEstimated primary completion: 2
 9 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pf-08634
 404#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07489066
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940401-2047@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:JS111: Phase 1/2 readout est. (NCT06940401)
DESCRIPTION:JS111\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: JS111 i
 n Patients With Advanced NSCLC Harboring EGFR Mutations\nEstimated primary
  completion: 30 July 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/js111#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06940401
URL:https://assetmemo.bio/drug/js111#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07374419-2363@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:atamparib: Phase 1/2 readout est. (NCT07374419)
DESCRIPTION:atamparib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ata
 mparib in Patients With Advanced Solid Tumors\nEstimated primary completio
 n: 31 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/atam
 parib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07374419
URL:https://assetmemo.bio/drug/atamparib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987826-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT05987826)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB
  EGFR Sensitive Mutant NSCLC\nEstimated primary completion: August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05987826
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697586-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07697586)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07697586
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07809256-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07809256)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective\, Single-center\, Non-randomized\, Interventional Study on th
 e Effectiveness and Safety of Combined Immunotargeted Therapy in Patients 
 With Metastatic Non-small Cell Cancer With a RET Gene Translocation\nEstim
 ated primary completion: August 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07809256
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEst
 imated primary completion: 1 August 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05800587)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
 \nEstimated primary completion: 1 August 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-7671@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT05800587)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Dos
 e Attenuated Chemotherapy in Compromised Patients With Lung Cancer\nEstima
 ted primary completion: 1 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/gemcitabine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800587-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05800587)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Dose Attenuated Chemotherapy in Compromised Patients With Lung Cance
 r\nEstimated primary completion: 1 August 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT05800587
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Pa
 rticipants With Solid Tumors\nEstimated primary completion: 4 August 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05797168-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280804
DTEND;VALUE=DATE:20280805
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05797168)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Part
 icipants With Solid Tumors\nEstimated primary completion: 4 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05797168
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07855965-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07855965)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mul
 ticenter\, Single-Arm\, Prospective Phase II Study of Neoadjuvant Cryo-The
 rmal Ablation Combined With Toripalimab and Chemotherapy for Resectable St
 age IB-IIIB Non-Small Cell Lung Cancer\nEstimated primary completion: 5 Au
 gust 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/toripalima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 855965
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984588-2193@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280805
DTEND;VALUE=DATE:20280806
SUMMARY:Uliledlimab: Phase 2/3 readout est. (NCT06984588)
DESCRIPTION:Uliledlimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Compare Uliledlimab Combined With Toripalimab\, Toripalimab Mono
 therapy\, and Pembrolizumab Monotherapy in Patients With Previously Untrea
 ted Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 5 August 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/uliledlimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06984588
URL:https://assetmemo.bio/drug/uliledlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07030257-2438@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:CP-383: Phase 1/2 readout est. (NCT07030257)
DESCRIPTION:CP-383\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 of CP-383 in Patients With Advanced or Metastatic Solid Tumors\nEstimated 
 primary completion: 15 August 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cp-383#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07030257
URL:https://assetmemo.bio/drug/cp-383#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 reatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Inter
 stitial Lung Disease\nEstimated primary completion: 15 August 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Treat
 ment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstit
 ial Lung Disease\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tre
 atment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interst
 itial Lung Disease\nEstimated primary completion: 15 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06007937-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Lorlatinib: Phase 1/2 readout est. (NCT06007937)
DESCRIPTION:Lorlatinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Lorlatinib in Combination With Ramucirumab in People With Lung Ca
 ncer\nEstimated primary completion: 17 August 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/lorlatinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06007937
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06007937-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06007937)
DESCRIPTION:Ramucirumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Lorlatinib in Combination With Ramucirumab in People With Lung C
 ancer\nEstimated primary completion: 17 August 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ramucirumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06007937
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06305754-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280817
DTEND;VALUE=DATE:20280818
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06305754)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplat
 in Combination Therapy in Participants With Epidermal Growth Factor (EGFR)
 -Mutated\, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Hav
 e Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)\nEstim
 ated primary completion: 17 August 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06305754
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224152-2634@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:NBTXR3: Phase 1/2 readout est. (NCT07224152)
DESCRIPTION:NBTXR3\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: NBTXR3
  With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung Can
 cer\nEstimated primary completion: 30 August 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nbtxr3#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07224152
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05967689-2070@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT05967689)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer
  With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other 
 Uncommon Mutation.\nEstimated primary completion: 31 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/zipalertinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05967689
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416994-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Beruzatatug pelitecan: Phase 3 readout est. (NCT07416994)
DESCRIPTION:Beruzatatug pelitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Pivotal Study to Evaluate YL202 Versus Docetaxel in Patients With L
 ocally Advanced or Metastatic EGFR Sensitive Mutation Non-Squamous Non-Sma
 ll Cell Lung Cancer\nEstimated primary completion: 31 August 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/beruzatatug-pelitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07416994
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158840-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07158840)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: AK1
 12 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actiona
 ble Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase 
 Inhibitor (TKI) Treatment\nEstimated primary completion: September 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07158840
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for 
 Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEs
 timated primary completion: September 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for P
 atients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEst
 imated primary completion: September 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06656598-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06656598)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiother
 apy in Unfit or Elderly Patients With Stage III Lung Cancer\nEstimated pri
 mary completion: September 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06656598
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05613413-2031@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Cabozantinib: Phase 2 readout est. (NCT05613413)
DESCRIPTION:Cabozantinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Pa
 tients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEsti
 mated primary completion: September 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cabozantinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05613413
URL:https://assetmemo.bio/drug/cabozantinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020065-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07020065)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemipli
 mab Monotherapy in Treatment Naive Older and Frail Patients With Metastati
 c NSCLC With PD-L1 <50%\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07020065
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020065-7671@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Gemcitabine: Phase 2 readout est. (NCT07020065)
DESCRIPTION:Gemcitabine\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Red
 uced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Mono
 therapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC 
 With PD-L1 <50%\nEstimated primary completion: September 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gemcitabine#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07020065
URL:https://assetmemo.bio/drug/gemcitabine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT06486142)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Stud
 y\nEstimated primary completion: September 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1969@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Dacomitinib PF-00299804: Phase 3 readout est. (NCT06486142)
DESCRIPTION:Dacomitinib PF-00299804\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Stu
 dy\nEstimated primary completion: September 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/dacomitinib-pf-00299804#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06486142-1976@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Gilotrif (Afatinib): Phase 3 readout est. (NCT06486142)
DESCRIPTION:Gilotrif (Afatinib)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study\n
 Estimated primary completion: September 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/afatinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06486142
URL:https://assetmemo.bio/drug/afatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745908-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT06745908)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cl
 inical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint 
 Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With 
 Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resist
 ance to Immune Checkpoint Inhibitor Therapy\nEstimated primary completion:
  September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tisl
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06745908
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745908-2051@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 3 readout est. (NCT06
 745908)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 3\, Non-Small Ce
 ll Lung Cancer.\nStudy: Clinical Trial of N-803 Plus Tislelizumab or Prior
  Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monothe
 rapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cance
 r Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy\nEst
 imated primary completion: September 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06745908
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174908-2138@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ifebemtinib: Phase 3 readout est. (NCT07174908)
DESCRIPTION:Ifebemtinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy
  for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mut
 ation\nEstimated primary completion: September 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07174908
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174908-2488@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Anfangning (Garsorasib): Phase 3 readout est. (NCT07174908)
DESCRIPTION:Anfangning (Garsorasib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase 3 Study of IN10018 in Combination With D-1553 Versus Stan
 dard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With K
 RAS G12C Mutation\nEstimated primary completion: September 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07174908
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06758401-2267@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280905
DTEND;VALUE=DATE:20280906
SUMMARY:Sigvotatug Vedotin: Phase 3 readout est. (NCT06758401)
DESCRIPTION:Sigvotatug Vedotin\, phase 3\, Non-Small Cell Lung Cancer.\nStu
 dy: This is a Study to Learn About How the Combination of the Study Medici
 nes Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small C
 ell Lung Cancer With High Levels of PD-L1.\nEstimated primary completion: 
 5 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sig
 votatug-vedotin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06758401
URL:https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614231-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280908
DTEND;VALUE=DATE:20280909
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT06614231)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oajuvant Tislelizumab Combined with Chemotherapy for Initially Unresectabl
 e Stage IIIA/N2 Non-small Cell Lung Cancer\nEstimated primary completion: 
 8 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tis
 lelizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06614231
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Pumitamig: Phase 2 readout est. (NCT07680764)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy To Assess the Safety\, Tolerability\, and Efficacy of Imzokitug in Comb
 ination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pum
 itamig and PDCT as First-line Treatment for Participants With Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pumitamig#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07680764)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study To Assess the Safety\, Tolerability\, and Efficacy of Imzokit
 ug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) 
 Versus Pumitamig and PDCT as First-line Treatment for Participants With Lo
 cally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated
  primary completion: 15 September 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680764-2544@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:Imzokitug: Phase 2 readout est. (NCT07680764)
DESCRIPTION:Imzokitug\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy To Assess the Safety\, Tolerability\, and Efficacy of Imzokitug in Comb
 ination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pum
 itamig and PDCT as First-line Treatment for Participants With Locally Adva
 nced or Metastatic Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 15 September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/imzokitug#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07680764
URL:https://assetmemo.bio/drug/imzokitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780578-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Andamertinib: Phase 2 readout est. (NCT07780578)
DESCRIPTION:Andamertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Th
 e Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced o
 r Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 30 
 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/andam
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07780578
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253871-2528@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:IAM1363: Phase 1/2 readout est. (NCT06253871)
DESCRIPTION:IAM1363\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1/2 Study of IAM1363 in HER2 Cancers\nEstimated primary completion: Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iam1363#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062538
 71
URL:https://assetmemo.bio/drug/iam1363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609251-2178@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:SCTB41: Phase 2 readout est. (NCT07609251)
DESCRIPTION:SCTB41\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Clinic
 al Study of SCTB41 Combined With Docetaxel in Patients With Previously Tre
 ated Locally Advanced or Metastatic Non-Small Cell Lung Cancer（Phase II 
 Study Ongoing）\nEstimated primary completion: October 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07609251
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609251-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07609251)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Clinical Study of SCTB41 Combined With Docetaxel in Patients With 
 Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Canc
 er（Phase II Study Ongoing）\nEstimated primary completion: October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07609251
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841055-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06841055)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Preliminary Efficacy of Pumitamig (BNT327)\, an Investigational Ther
 apy for Patients With Non-small Cell Lung Cancer in Combination With Chemo
 therapy as First-line or Second-line Treatment\nEstimated primary completi
 on: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pum
 itamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06841055
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2061@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumo
 r Treatments in Non-small Cell Lung Cancer Subjects\nEstimated primary com
 pletion: October 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/retlirafusp-alfa#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07175220
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2064@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Notiretatug rezetecan: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Notiretatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti
 -tumor Treatments in Non-small Cell Lung Cancer Subjects\nEstimated primar
 y completion: October 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/notiretatug-rezetecan#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07175220
URL:https://assetmemo.bio/drug/notiretatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175220-2727@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Zeprumetostat: Phase 2 readout est. (NCT07175220)
DESCRIPTION:Zeprumetostat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor T
 reatments in Non-small Cell Lung Cancer Subjects\nEstimated primary comple
 tion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 eprumetostat#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07175220
URL:https://assetmemo.bio/drug/zeprumetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06841055-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06841055)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Safety and Preliminary Efficacy of Pumitamig (BNT327)\, an Investiga
 tional Therapy for Patients With Non-small Cell Lung Cancer in Combination
  With Chemotherapy as First-line or Second-line Treatment\nEstimated prima
 ry completion: October 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06841055
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06335355-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Adebrelimab: Phase 2/3 readout est. (NCT06335355)
DESCRIPTION:Adebrelimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemot
 herapy in Advanced or Metastatic NSCLC Patients\nEstimated primary complet
 ion: October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ad
 ebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06335355
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06335355-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06335355)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Phase II/III Study of Adebrelimab in Combination With SHR-8068 an
 d Chemotherapy in Advanced or Metastatic NSCLC Patients\nEstimated primary
  completion: October 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06335355
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07177105-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07177105)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Prim
 ary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC\nEs
 timated primary completion: 1 October 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sintilimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07177105
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Resp
 onse and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cel
 l Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07288
 034
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Imm
 unotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Res
 ponse and Selection of Second-line Treatment in Stage IIIB-IV Non-small Ce
 ll Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Octo
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 88034
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-2015@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Im
 munotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Re
 sponse and Selection of Second-line Treatment in Stage IIIB-IV Non-small C
 ell Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7288034
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-9865
 23 Alone and in Combination With Anti-Cancer Agents in Participants With A
 dvanced Solid Malignancies\nEstimated primary completion: 13 October 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-98652
 3 Alone and in Combination With Anti-Cancer Agents in Participants With Ad
 vanced Solid Malignancies\nEstimated primary completion: 13 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223047-2412@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281013
DTEND;VALUE=DATE:20281014
SUMMARY:BMS-986523: Phase 1/2 readout est. (NCT07223047)
DESCRIPTION:BMS-986523\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Evaluate the Safety\, Tolerability\, and Efficacy of BMS-986523 A
 lone and in Combination With Anti-Cancer Agents in Participants With Advan
 ced Solid Malignancies\nEstimated primary completion: 13 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/bms-986523#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07223047
URL:https://assetmemo.bio/drug/bms-986523#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07206498-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281014
DTEND;VALUE=DATE:20281015
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07206498)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With
  Osimertinib for NSCLC\nEstimated primary completion: 14 October 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07206498
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-2616@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:MDNA11: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:MDNA11\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Beta
 -only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 October 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/mdna11#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05086692
URL:https://assetmemo.bio/drug/mdna11#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432984-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07432984)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fe
 cal Microbiota Transplant(FMT) Combination With Tislelizumab in Advanced o
 r Metastatic NSCLC\nEstimated primary completion: 30 October 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07432984
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936578-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07936578)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in t
 he Treatment of Advanced Non-small Cell Lung Cancer\nEstimated primary com
 pletion: 30 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ivonescimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07936578
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07294261-2488@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Anfangning (Garsorasib): Phase 2 readout est. (NCT07294261)
DESCRIPTION:Anfangning (Garsorasib)\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NS
 CLC\nEstimated primary completion: 30 October 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/garsorasib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07294261
URL:https://assetmemo.bio/drug/garsorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911449-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07911449)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Plus Stereotactic Radiosurgery/Radiotherapy for EGFR-M
 utant Non-Small Cell Lung Cancer With Symptomatic Brain Metastases\nEstima
 ted primary completion: 30 October 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07911449
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385262-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06385262)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: TOP 
 2301: Neoadjuvant Chemo for NSCLC\nEstimated primary completion: 30 Octobe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT063852
 62
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07561983-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07561983)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ti
 slelizumab Plus Chemotherapy and BACE for Unresectable NSCLC\nEstimated pr
 imary completion: 31 October 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07561983
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04613596-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT04613596)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizu
 mab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRA
 S G12C Mutation KRYSTAL-7\nEstimated primary completion: 31 October 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04613596
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131319-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tislelizumab: Phase 2/3 readout est. (NCT07131319)
DESCRIPTION:Tislelizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: 
 SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC\n
 Estimated primary completion: 31 October 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tislelizumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07131319
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04613596-2025@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Krazati (Adagrasib): Phase 2/3 readout est. (NCT04613596)
DESCRIPTION:Krazati (Adagrasib)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pemb
 rolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With
  a KRAS G12C Mutation KRYSTAL-7\nEstimated primary completion: 31 October 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/adagrasib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04613596
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131319-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07131319)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III 
 NSCLC\nEstimated primary completion: 31 October 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07131319
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833154-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT03833154)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Plac
 ebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC)
  Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresec
 ted NSCLC Harboring an EGFR Mutation\nEstimated primary completion: 31 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertini
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 833154
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833154-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT03833154)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Durv
 alumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBR
 T in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ O
 simertinib Following SBRT in Patients With Early Stage Unresected NSCLC Ha
 rboring an EGFR Mutation\nEstimated primary completion: 31 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03833154
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010419-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07010419)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo f
 or Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Unco
 mmon Epidermal Growth Factor Receptor (EGFR) Mutations\, Following Complet
 e Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）\nE
 stimated primary completion: 31 October 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/furmonertinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07010419
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111520-1982@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Beruzatatug pelitecan: Phase 1/2 readout est. (NCT07111520)
DESCRIPTION:Beruzatatug pelitecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Trial to Test if an Investigational Combination Therap
 y With BNT326 and BNT327 is Safe and Potentially Beneficial for People Wit
 h Advanced Non-small Cell Lung Cancer (NSCLC)\nEstimated primary completio
 n: November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ber
 uzatatug-pelitecan#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07111520
URL:https://assetmemo.bio/drug/beruzatatug-pelitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07111520-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07111520)
DESCRIPTION:Pumitamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A C
 linical Trial to Test if an Investigational Combination Therapy With BNT32
 6 and BNT327 is Safe and Potentially Beneficial for People With Advanced N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: November 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07111520
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07181499)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Canc
 er (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimate
 d primary completion: November 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07181499-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07181499)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Se
 quential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSC
 LC) Patients With Resistance to Third-Generation EGFR-TKI\nEstimated prima
 ry completion: November 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/befotertinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07181499
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07217301-2254@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:IBI363: Phase 3 readout est. (NCT07217301)
DESCRIPTION:IBI363\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
 \nEstimated primary completion: 1 November 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ibi363#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07217301
URL:https://assetmemo.bio/drug/ibi363#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Amivantamab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Amivantamab and Olomorasib Combination Therapy in Participants W
 ith Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 3
 0 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/amiv
 antamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07227025
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227025-2053@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT07227025)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Amivantamab and Olomorasib Combination Therapy in Participants Wi
 th Metastatic Non-Small Cell Lung Cancer\nEstimated primary completion: 30
  November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olomo
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07227025
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706219-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06706219)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combin
 ation With Toripalimab in Patients With Initially Unresectable Stage III N
 SCLC\nEstimated primary completion: 30 November 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06706219
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706219-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Toripalimab: Phase 2 readout est. (NCT06706219)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Eff
 icacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With T
 oripalimab in Patients With Initially Unresectable Stage III NSCLC\nEstima
 ted primary completion: 30 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06706219
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393555-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT07393555)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Treatment for Advanced Non-small Cell Lung Cancer With Actionable G
 enomic Alterations After Targeted Treatment and Chemotherapy (An Expanded 
 Lung-MAP Treatment Trial)\nEstimated primary completion: 30 November 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-goviteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 393555
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07393555-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07393555)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tre
 atment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alt
 erations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP T
 reatment Trial)\nEstimated primary completion: 30 November 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07393555
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793215-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06793215)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab V
 ersus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Partici
 pants With Previously Untreated\, KRAS G12C-Mutated\, Advanced or Metastat
 ic Non-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 
 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06793215
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793215-2217@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Divarasib: Phase 3 readout est. (NCT06793215)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versu
 s Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participant
 s With Previously Untreated\, KRAS G12C-Mutated\, Advanced or Metastatic N
 on-Squamous Non-Small Cell Lung Cancer\nEstimated primary completion: 30 N
 ovember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divaras
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6793215
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tu
 mors\nEstimated primary completion: December 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumo
 rs (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tum
 ors\nEstimated primary completion: December 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-1997@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Elironrasib and Daraxonrasib as Monotherapies and Combination Ther
 apy in Participants With Advanced KRAS G12C Mutant Solid Tumors\nEstimated
  primary completion: December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/elironrasib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: R
 inatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Advanced Solid Tumors
  (GCT1184-01/ PRO1184-001)\nEstimated primary completion: December 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06128551-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT06128551)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Elironrasib and Daraxonrasib as Monotherapies and Comb
 ination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumor
 s\nEstimated primary completion: December 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/daraxonrasib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06128551
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Sol
 id Tumors\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07020221-2279@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:GFH375: Phase 1/2 readout est. (NCT07020221)
DESCRIPTION:GFH375\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors\nEs
 timated primary completion: December 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/gfh375#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07020221
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05579366-2708@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rinatabart sesutecan (Rina-S): Phase 1/2 readout est. (NCT05579366)
DESCRIPTION:Rinatabart sesutecan (Rina-S)\, phase 1/2\, Non-Small Cell Lung
  Cancer.\nStudy: Rinatabart Sesutecan (Rina-S\, PRO1184\, GEN1184) for Adv
 anced Solid Tumors (GCT1184-01/ PRO1184-001)\nEstimated primary completion
 : December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rina
 tabart-sesutecan-rina-s#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05579366
URL:https://assetmemo.bio/drug/rinatabart-sesutecan-rina-s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06657222-2784@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:TUB-030: Phase 1/2 readout est. (NCT06657222)
DESCRIPTION:TUB-030\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: First
  in Human Study of TUB-030 in Patients With Advanced Solid Tumors\nEstimat
 ed primary completion: December 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/tub-030#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06657222
URL:https://assetmemo.bio/drug/tub-030#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827261-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07827261)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 Combined With Glecirasib in Patients With KRA
 S G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer\n
 Estimated primary completion: December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07827261
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07827261-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Glecirasib: Phase 2 readout est. (NCT07827261)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutate
 d Locally Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/glecirasib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07827261
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567326-2061@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Retlirafusp alfa: Phase 2 readout est. (NCT07567326)
DESCRIPTION:Retlirafusp alfa\, phase 2\, Non-Small Cell Lung Cancer.\nStudy
 : Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Re
 sectable NSCLC\nEstimated primary completion: December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07567326
URL:https://assetmemo.bio/drug/retlirafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802834-2070@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT07802834)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ad
 juvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical E
 GFR-Mutant NSCLC\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07802834
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07567326-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07567326)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resecta
 ble NSCLC\nEstimated primary completion: December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07567326
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360743-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07360743)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 mmunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With H
 igh PD-L1 Levels\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07360743
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07360743-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07360743)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Without Chemotherapy for Advanced Lung Cancer Patients With High
  PD-L1 Levels\nEstimated primary completion: December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07360743
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06838273-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT06838273)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of BL-B01D1 in Combination With Osimertinib Versus Osimer
 tinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanc
 ed or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)\nEstimated prima
 ry completion: December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06838273
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04928846-2230@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telisotuzumab Vedotin: Phase 3 readout est. (NCT04928846)
DESCRIPTION:Telisotuzumab Vedotin\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Disease Activity and Adverse Events of Intravenou
 s (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participant
 s With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04928846
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099172-2723@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Hyrnuo (Sevabertinib): Phase 1/2 readout est. (NCT05099172)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: First in Human Study of BAY2927088 in Participants Who Have Advan
 ced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epid
 ermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor R
 eceptor 2 (HER2)\nEstimated primary completion: 1 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sevabertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05099172
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04969315-2782@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:TT-10: Phase 1/2 readout est. (NCT04969315)
DESCRIPTION:TT-10\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TT-4 an
 d TT-10 as Single Agents and in Combination in Subjects With Advanced Sele
 cted Solid Tumors and Pleural Mesothelioma\nEstimated primary completion: 
 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tt-1
 0#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 969315
URL:https://assetmemo.bio/drug/tt-10#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04969315-2783@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:TT-4: Phase 1/2 readout est. (NCT04969315)
DESCRIPTION:TT-4\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TT-4 and
  TT-10 as Single Agents and in Combination in Subjects With Advanced Selec
 ted Solid Tumors and Pleural Mesothelioma\nEstimated primary completion: 1
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tt-4#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0496
 9315
URL:https://assetmemo.bio/drug/tt-4#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819578-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07819578)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy f
 or Resectable NSCLC\nEstimated primary completion: 1 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781957
 8
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07819578-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07819578)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectabl
 e NSCLC\nEstimated primary completion: 1 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07819578
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017829-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07017829)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: G
 T103 in Combination With Pembrolizumab for the Treatment of Advanced or Me
 tastatic STK11 Mutant Non-Small Cell Lung Cancer\nEstimated primary comple
 tion: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07017829
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100080-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07100080)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-b
 ased Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small C
 ell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)\nEsti
 mated primary completion: 15 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07100080
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Dato-DXd-based Combinations 
 in Participants With TROP2 NMR+ NSCLC\nEstimated primary completion: 16 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7941609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Investigate the Efficacy and Safety of Dato-DXd-based C
 ombinations in Participants With TROP2 NMR+ NSCLC\nEstimated primary compl
 etion: 16 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/datopotamab-deruxtecan#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07941609
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07435038-2419@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281228
DTEND;VALUE=DATE:20281229
SUMMARY:BPI-572270: Phase 1/2 readout est. (NCT07435038)
DESCRIPTION:BPI-572270\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specifi
 c Mutations in RAS\nEstimated primary completion: 28 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bpi-572270#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07435038
URL:https://assetmemo.bio/drug/bpi-572270#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855771-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT06855771)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Study of Navlimetostat (BMS-986504) Alone or in Combination Wit
 h Izalontamab Brengitecan in Participants With Pre-treated Advanced or Met
 astatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion o
 r MTAP Loss (MountainTAP-9)\nEstimated primary completion: 29 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengi
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06855771
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855771-2283@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281229
DTEND;VALUE=DATE:20281230
SUMMARY:Navlimetostat: Phase 2 readout est. (NCT06855771)
DESCRIPTION:Navlimetostat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalonta
 mab Brengitecan in Participants With Pre-treated Advanced or Metastatic No
 n-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Los
 s (MountainTAP-9)\nEstimated primary completion: 29 December 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855771
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055465-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06055465)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: 30 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06055465
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06055465-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT06055465)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable 
 Non-Small Cell Lung Cancer\nEstimated primary completion: 30 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6055465
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated pr
 imary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07304739-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07304739)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 urmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radio
 therapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and L
 eptomeningeal Metastases\nEstimated primary completion: 30 December 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07304739
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prim
 ary completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/bevacizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07039656-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Toripalimab: Phase 2 readout est. (NCT07039656)
DESCRIPTION:Toripalimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tor
 ipalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell
  Lung Cancer With or Without Prior Neoadjuvant Therapy\nEstimated primary 
 completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/toripalimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07039656
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164170-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Glecirasib: Phase 2 readout est. (NCT07164170)
DESCRIPTION:Glecirasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164170
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863167-2181@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 2 readout est. (NCT07863167)
DESCRIPTION:Ruzaltatug rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: An Open\, Multicenter Phase II Clinical Trial of SHR-A2009 Combined 
 With Other Anti-tumor Therapies for Perioperative Treatment of Resectable 
 Non-small Cell Lung Cancer.\nEstimated primary completion: 30 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/ruzaltatug-rezetec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7863167
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07164170-2323@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT07164170)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib\nE
 stimated primary completion: 30 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lumipodlin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07164170
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895992-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07895992)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: SHR
 -A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or M
 etastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlle
 d\, Open\, Multicenter Phase III Study\nEstimated primary completion: 30 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevaciz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07895992
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895992-2181@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07895992)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Adva
 nced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized 
 Controlled\, Open\, Multicenter Phase III Study\nEstimated primary complet
 ion: 30 December 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/ruzaltatug-rezetecan#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07895992
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816380-2440@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Fudotinib: Phase 3 readout est. (NCT07816380)
DESCRIPTION:Fudotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously 
 Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung
  Cancer\nEstimated primary completion: 30 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fudotinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07816380
URL:https://assetmemo.bio/drug/fudotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058428-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07058428)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: FSR
 T Combines With Bevacizumab for Multiple Brain Metastases in Lung Adenocar
 cinoma\nEstimated primary completion: 30 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/bevacizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07058428
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07917767-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07917767)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Pr
 ospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimuma
 b N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small 
 Cell Lung Cancer\nEstimated primary completion: 31 December 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/ipilimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07917767
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631884-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07631884)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetec
 an in the Treatment of HER2-Expressiong Advanced Solid Tumor\nEstimated pr
 imary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07631884
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07622186)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of SKB571 Combination Therapy in Participants With Non-Sma
 ll Cell Lung Cancer (NSCLC)\nEstimated primary completion: 31 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06667908)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of JNJ-90301900 in Combination With Chemoradiation Followed by Consoli
 dation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated pri
 mary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06667908
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07622186)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB571 Combination Therapy in Participants With Non-Small Cell L
 ung Cancer (NSCLC)\nEstimated primary completion: 31 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07622186)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of SKB571 Combination Therapy in Participants With Non-Small Cell L
 ung Cancer (NSCLC)\nEstimated primary completion: 31 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624487-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Almonertinib: Phase 2 readout est. (NCT07624487)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Au
 molertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarc
 inoma\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/almonertinib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07624487
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622186-2066@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:SKB571: Phase 2 readout est. (NCT07622186)
DESCRIPTION:SKB571\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Can
 cer (NSCLC)\nEstimated primary completion: 31 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/skb571#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07622186
URL:https://assetmemo.bio/drug/skb571#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624487-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07624487)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Ad
 enocarcinoma\nEstimated primary completion: 31 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07624487
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-2634@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:NBTXR3: Phase 2 readout est. (NCT06667908)
DESCRIPTION:NBTXR3\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidati
 on Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nbtxr3#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06667908
URL:https://assetmemo.bio/drug/nbtxr3#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908772-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT06908772)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: Glumetinib Combined With Osimertinib Treatment for Non-Small Cel
 l Lung Cancer Patients\nEstimated primary completion: 31 December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06908772
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908772-2222@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Glumetinib: Phase 2/3 readout est. (NCT06908772)
DESCRIPTION:Glumetinib\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Gl
 umetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cance
 r Patients\nEstimated primary completion: 31 December 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/glumetinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06908772
URL:https://assetmemo.bio/drug/glumetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04092283-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04092283)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Test
 ing the Addition of an Antibody to Standard Chemoradiation Followed by the
  Antibody for One Year to Standard Chemoradiation Followed by One Year of 
 the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung C
 ancer\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04092283
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05899608-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ivonescimab: Phase 3 readout est. (NCT05899608)
DESCRIPTION:Ivonescimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Cli
 nical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Pa
 tients\nEstimated primary completion: 31 December 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05899608
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04092283-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04092283)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of an Antibody to Standard Chemoradiation Follow
 ed by the Antibody for One Year to Standard Chemoradiation Followed by One
  Year of the Antibody in Patients With Unresectable Stage III Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 31 December 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04092283
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464327-2501@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Risvutatug rezetecan: Phase 3 readout est. (NCT07464327)
DESCRIPTION:Risvutatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase III Study of HS-20093 Injection Combined With Adebrelimab Ve
 rsus Docetaxel in Previously Treated Patients With Advanced or Metastatic 
 Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterat
 ions\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07464327
URL:https://assetmemo.bio/drug/risvutatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of STK-012 Alone and With Other Treatments in Patients With Advance
 d Lung Cancer and Other Cancers\nEstimated primary completion: January 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05098132
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of STK-012 Alone and With Other Treatments in Patients With A
 dvanced Lung Cancer and Other Cancers\nEstimated primary completion: Janua
 ry 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05098
 132
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098132-2743@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:STK-012: Phase 1/2 readout est. (NCT05098132)
DESCRIPTION:STK-012\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of STK-012 Alone and With Other Treatments in Patients With Advanced Lung
  Cancer and Other Cancers\nEstimated primary completion: January 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/stk-012#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05098132
URL:https://assetmemo.bio/drug/stk-012#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045767-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06045767)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: T
 -Cell Repertoire Sequencing: Assessing Pembrolizumab Efficacy in Advanced 
 Non-small Lung Cancer\nEstimated primary completion: January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06045767
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06206850-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06206850)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resista
 nce to Neoadjuvant Osimertinib\nEstimated primary completion: January 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06206850
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712316-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pumitamig: Phase 2/3 readout est. (NCT06712316)
DESCRIPTION:Pumitamig\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety\, Efficacy\, and Pharmacokinetics of BNT327 in Combination With Chemot
 herapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)\
 nEstimated primary completion: January 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pumitamig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06712316
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712316-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06712316)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Safety\, Efficacy\, and Pharmacokinetics of BNT327 in Combination W
 ith Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA
  Lung-02)\nEstimated primary completion: January 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06712316
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564324-2075@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT06564324)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Pos
 itive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients\n
 Estimated primary completion: January 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/taletrectinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06564324
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03202940-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Alecensa (Alectinib): Phase 1/2 readout est. (NCT03202940)
DESCRIPTION:Alecensa (Alectinib)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase IB/II Study of Alectinib Combined With Cobimetinib in Adva
 nced ALK-Rearranged (ALK+) NSCLC\nEstimated primary completion: 1 January 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03202940
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699328-2801@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:VRN110755: Phase 1/2 readout est. (NCT07699328)
DESCRIPTION:VRN110755\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer\
 nEstimated primary completion: 1 January 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/vrn110755#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07699328
URL:https://assetmemo.bio/drug/vrn110755#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885709-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07885709)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC\n
 Estimated primary completion: 1 January 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07885709
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07885709-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07885709)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NS
 CLC\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07885709
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323732-2395@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290106
DTEND;VALUE=DATE:20290107
SUMMARY:BIO 300: Phase 2 readout est. (NCT07323732)
DESCRIPTION:BIO 300\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell L
 ung Cancer and Interstitial Lung Disease\nEstimated primary completion: 6 
 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/bio-300
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 23732
URL:https://assetmemo.bio/drug/bio-300#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT
 \; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-
 2870-023]\nEstimated primary completion: 12 January 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT\
 ; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2
 870-023]\nEstimated primary completion: 12 January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06422143-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290112
DTEND;VALUE=DATE:20290113
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06422143)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan
  (Sac-TMT\; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NS
 CLC) [MK-2870-023]\nEstimated primary completion: 12 January 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06422143
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780839-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290115
DTEND;VALUE=DATE:20290116
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06780839)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with 
 Ensartinib Guided by MRD\nEstimated primary completion: 15 January 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ensartinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780839
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058519-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290124
DTEND;VALUE=DATE:20290125
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07058519)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EG
 FRm+ Monitoring in NSCLC\nEstimated primary completion: 24 January 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07058519
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291037-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290129
DTEND;VALUE=DATE:20290130
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT07291037)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Prev
 iously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Wi
 thout Actionable Genomic Alterations\nEstimated primary completion: 29 Jan
 uary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/datopotama
 b-deruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07291037
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706076-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06706076)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of BH-30643 in Subjects With Locally Advanced or Metastatic
  NSCLC Harboring EGFR and/or HER2 Mutations\nEstimated primary completion:
  31 January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 etrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06706076
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06706076-2391@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:BH-30643: Phase 1/2 readout est. (NCT06706076)
DESCRIPTION:BH-30643\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harb
 oring EGFR and/or HER2 Mutations\nEstimated primary completion: 31 January
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/bh-30643#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06706076
URL:https://assetmemo.bio/drug/bh-30643#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185997-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT07185997)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Efficacy and Safety of Firmonertinib Compared With Invest
 igator's Choice of EGFR Inhibitor as First-Line Treatment in Participants 
 Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C
 -Helix Compressing (PACC) Uncommon Mutations\nEstimated primary completion
 : February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/furm
 onertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07185997
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06930794-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Vebreltinib: Phase 3 readout est. (NCT06930794)
DESCRIPTION:Vebreltinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Vebreltinib and Platinum-Containing Double Agents in Subjects With
  MET-Positive\nEstimated primary completion: February 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06930794
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primar
 y completion: 23 February 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary
  completion: 23 February 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Ramucirumab: Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Ramucirumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A
  Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated primary c
 ompletion: 23 February 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ramucirumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996782-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290223
DTEND;VALUE=DATE:20290224
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT06996782)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Platform Study in Non-Small Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 23 February 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06996782
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222566-1989@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:PF-08634404: Phase 3 readout est. (NCT07222566)
DESCRIPTION:PF-08634404\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Sym
 biotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634
 404 in Combination With Chemotherapy in Adult Participants With Locally Ad
 vanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary complet
 ion: 27 February 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pf-08634404#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07222566
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Bevacizumab: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Bevacizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 YS6090 Combination Therapy in Advanced Lung Cancer\nEstimated primary comp
 letion: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/bevacizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07472647
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:CPO301: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:CPO301\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SYS609
 0 Combination Therapy in Advanced Lung Cancer\nEstimated primary completio
 n: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cpo301#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07472647
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: SYS6090 Combination Therapy in Advanced Lung Cancer\nEstimated prim
 ary completion: 28 February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07472647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-2751@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SYS6090: Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:SYS6090\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: SYS60
 90 Combination Therapy in Advanced Lung Cancer\nEstimated primary completi
 on: 28 February 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sys6090#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07472647
URL:https://assetmemo.bio/drug/sys6090#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472647-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07472647)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: SYS6090 Combination Therapy in Advanced Lung Cancer\nEstimated pri
 mary completion: 28 February 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07472647
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699952-1984@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Almonertinib: Phase 2 readout est. (NCT07699952)
DESCRIPTION:Almonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Fi
 rst-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inh
 ibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-smal
 l Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human 
 Epidermal Growth Factor Receptor 2(HER2) Alterations\nEstimated primary co
 mpletion: March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /almonertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07699952
URL:https://assetmemo.bio/drug/almonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699952-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07699952)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine K
 inase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced
  Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant Wi
 th Human Epidermal Growth Factor Receptor 2(HER2) Alterations\nEstimated p
 rimary completion: March 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07699952
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07831863-2299@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:7MW3711: Phase 3 readout est. (NCT07831863)
DESCRIPTION:7MW3711\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study
  of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior
  Chemoimmunotherapy\nEstimated primary completion: March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/7mw3711#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07831863
URL:https://assetmemo.bio/drug/7mw3711#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06931717-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT06931717)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemipli
 mab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Hav
 e Not Received Prior Chemotherapy\nEstimated primary completion: March 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06931717
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970639-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Furmonertinib: Phase 3 readout est. (NCT06970639)
DESCRIPTION:Furmonertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy V
 ersus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR)
  Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NS
 CLC) and Brain Metastases\nEstimated primary completion: March 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06970639
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06970639-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06970639)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemothe
 rapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor 
 (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Canc
 er (NSCLC) and Brain Metastases\nEstimated primary completion: March 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06970639
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07661173)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided 
 by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-muta
 ted Non-small Cell Lung Cancer\nEstimated primary completion: 6 March 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07661173
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07661173)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 rospective Study of Firmonertinib as First-line Adaptive Therapy Guided by
  Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutate
 d Non-small Cell Lung Cancer\nEstimated primary completion: 6 March 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07661173
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07661173-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290306
DTEND;VALUE=DATE:20290307
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07661173)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Prospective Study of Firmonertinib as First-line Adaptive Therapy G
 uided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGF
 R-mutated Non-small Cell Lung Cancer\nEstimated primary completion: 6 Marc
 h 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076611
 73
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-1989@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:PF-08634404: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:PF-08634404\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 ymbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-0863
 4404 in Combination With Different Anticancer Agents in Advanced Cancers\n
 Estimated primary completion: 8 March 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pf-08634404#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/pf-08634404#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-2168@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:Fetrastobart vedotin: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:Fetrastobart vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Calle
 d PF-08634404 in Combination With Different Anticancer Agents in Advanced 
 Cancers\nEstimated primary completion: 8 March 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/fetrastobart-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227298-2267@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290308
DTEND;VALUE=DATE:20290309
SUMMARY:Sigvotatug Vedotin: Phase 1/2 readout est. (NCT07227298)
DESCRIPTION:Sigvotatug Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called 
 PF-08634404 in Combination With Different Anticancer Agents in Advanced Ca
 ncers\nEstimated primary completion: 8 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07227298
URL:https://assetmemo.bio/drug/sigvotatug-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495125-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290317
DTEND;VALUE=DATE:20290318
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06495125)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Defac
 tinib\, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractor
 y LKB1-Mutant Advanced Non-Small Cell Lung Cancer\nEstimated primary compl
 etion: 17 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06495125
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682793-2309@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:A2B395: Phase 1/2 readout est. (NCT06682793)
DESCRIPTION:A2B395\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B395\, an Allogeneic Logic-gate
 d CAR T\, in Participants With Solid Tumors That Express EGFR and Have Los
 t HLA-A*02 Expression\nEstimated primary completion: 31 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/a2b395#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06682793
URL:https://assetmemo.bio/drug/a2b395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772610-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT06772610)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage 
 I ALK-positive NSCLC Patients with High Risk Factors\nEstimated primary co
 mpletion: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ensartinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06772610
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098988-2796@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Visugromab: Phase 2 readout est. (NCT07098988)
DESCRIPTION:Visugromab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l Investigating Visugromab in Combination With Immunochemotherapy in 1L Tr
 eatment of Participants With Metastatic NSCLC\nEstimated primary completio
 n: 31 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vis
 ugromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07098988
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07833202-2138@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Ifebemtinib: Phase 3 readout est. (NCT07833202)
DESCRIPTION:Ifebemtinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Th
 erapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12
 C Mutation\nEstimated primary completion: April 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/ifebemtinib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07833202
URL:https://assetmemo.bio/drug/ifebemtinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07169734-2339@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290405
DTEND;VALUE=DATE:20290406
SUMMARY:ALE.P03: Phase 1/2 readout est. (NCT07169734)
DESCRIPTION:ALE.P03\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected A
 dvanced or Metastatic CLDN1+ Solid Tumors\nEstimated primary completion: 5
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ale-p03#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0716
 9734
URL:https://assetmemo.bio/drug/ale-p03#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC
 )\nEstimated primary completion: 6 April 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Rilvegostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nEstima
 ted primary completion: 6 April 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098338-2013@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290406
DTEND;VALUE=DATE:20290407
SUMMARY:Ramucirumab: Phase 2 readout est. (NCT07098338)
DESCRIPTION:Ramucirumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)\nEstimate
 d primary completion: 6 April 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ramucirumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07098338
URL:https://assetmemo.bio/drug/ramucirumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Atezolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Co
 mparing Impact of Treatment Before or After Surgery in Patients With Stage
  II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary completi
 on: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/at
 ezolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06632327
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: C
 omparing Impact of Treatment Before or After Surgery in Patients With Stag
 e II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary complet
 ion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06632327
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Compa
 ring Impact of Treatment Before or After Surgery in Patients With Stage II
 -IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary completion:
  30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06632327
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06632327)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Comparing Impact of Treatment Before or After Surgery in Patients Wit
 h Stage II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary c
 ompletion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06632327
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06632327)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: Comparing Impact of Treatment Before or After Surgery in Patients Wi
 th Stage II-IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary 
 completion: 30 April 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06632327
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-1997@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Elironrasib: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Elironrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/elironrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/elironrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Ivonescimab: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Ivonescimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ivonescimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2216@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Rasonque (Daraxonrasib): Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Rasonque (Daraxonrasib)\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in 
 Patients With Solid Tumors\nEstimated primary completion: May 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/daraxonrasib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/daraxonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Pati
 ents With Solid Tumors\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07610798-2553@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:INV-8989: Phase 1/2 readout est. (NCT07610798)
DESCRIPTION:INV-8989\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Safety\, Tolerability\, Pharmacokinetics\, and Prelimi
 nary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors
  Harboring KRAS G12D Mutations\nEstimated primary completion: May 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/inv-8989#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07610798
URL:https://assetmemo.bio/drug/inv-8989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397338-2827@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Zoldonrasib: Phase 1/2 readout est. (NCT07397338)
DESCRIPTION:Zoldonrasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients Wit
 h Solid Tumors\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07397338
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05318573-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05318573)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Evaluate Safety\, Efficacy of FF-10832 in Combo With Pembrolizum
 ab in Urothelial & Non-small Cell Lung Cancer\nEstimated primary completio
 n: May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05318573
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05318573-2482@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Gemcitabine (FF-10832): Phase 2 readout est. (NCT05318573)
DESCRIPTION:Gemcitabine (FF-10832)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study to Evaluate Safety\, Efficacy of FF-10832 in Combo With Pe
 mbrolizumab in Urothelial & Non-small Cell Lung Cancer\nEstimated primary 
 completion: May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /gemcitabine-ff-10832#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05318573
URL:https://assetmemo.bio/drug/gemcitabine-ff-10832#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07946848)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebime
 tinib in Participants With Advanced or Metastatic NSCLC.\nEstimated primar
 y completion: May 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07946848
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07946848)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity o
 f Atebimetinib in Participants With Advanced or Metastatic NSCLC.\nEstimat
 ed primary completion: May 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07946848
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07946848-2540@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Atebimetinib: Phase 2 readout est. (NCT07946848)
DESCRIPTION:Atebimetinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ph
 ase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebi
 metinib in Participants With Advanced or Metastatic NSCLC.\nEstimated prim
 ary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/atebimetinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07946848
URL:https://assetmemo.bio/drug/atebimetinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806773-2785@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:TUB-040: Phase 2 readout est. (NCT07806773)
DESCRIPTION:TUB-040\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study o
 f TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-
 small Cell Lung Cancer\nEstimated primary completion: May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tub-040#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07806773
URL:https://assetmemo.bio/drug/tub-040#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07608159-2018@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Toripalimab: Phase 3 readout est. (NCT07608159)
DESCRIPTION:Toripalimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-
 III NSCLC.\nEstimated primary completion: May 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/toripalimab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07608159
URL:https://assetmemo.bio/drug/toripalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890598-2053@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Olomorasib: Phase 3 readout est. (NCT06890598)
DESCRIPTION:Olomorasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y of Olomorasib (LY3537982) in Combination With Standard of Care in Partic
 ipants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung 
 Cancer\nEstimated primary completion: May 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06890598
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: D
 atopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinu
 m Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\nEstimate
 d primary completion: 11 May 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05555732-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290511
DTEND;VALUE=DATE:20290512
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05555732)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Withou
 t Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)\
 nEstimated primary completion: 11 May 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05555732
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486648-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT07486648)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alt
 erations Following Prior 1L Osimertinib\nEstimated primary completion: 15 
 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074
 86648
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Comb
 ination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fac
 tor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lazertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Amivantamab: Phase 2 readout est. (NCT06667076)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Amivantamab in Combination With Lazertinib\, or Amivantamab in Com
 bination With Platinum-Based Chemotherapy\, for Common Epidermal Growth Fa
 ctor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667076-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290523
DTEND;VALUE=DATE:20290524
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06667076)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Amivantamab in Combination With Lazertinib\, or Amivantama
 b in Combination With Platinum-Based Chemotherapy\, for Common Epidermal G
 rowth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Sm
 all Cell Lung Cancer (NSCLC)\nEstimated primary completion: 23 May 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06667076
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295821-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07295821)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib Induction and Maintenance for Chemo-ineligible Stage I
 II Unresectable EGFR+ NSCLC: Single-arm Study\nEstimated primary completio
 n: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/osime
 rtinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07295821
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889232-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07889232)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic No
 n-Small Cell Lung Cancer\nEstimated primary completion: 31 May 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07889232
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07609121-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07609121)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hy
 pofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unr
 esectable Stage III NSCLC\nEstimated primary completion: 31 May 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07609121
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06436144-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT06436144)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Etoposide as First-Line Treatment in Osimertinib-R
 esistant Advanced EGFR-Mutant NSCLC\nEstimated primary completion: June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06436144
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07729670-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07729670)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mu
 ltimodal Ablation Combined With Perioperative Tislelizumab and Chemotherap
 y for Resectable II-IIIB NSCLC\nEstimated primary completion: June 2029. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07729670
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452224-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07452224)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 LKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07452224
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07452224-2538@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:ILKN421H: Phase 2 readout est. (NCT07452224)
DESCRIPTION:ILKN421H\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ILKN42
 1H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer\nEstimated pr
 imary completion: June 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ilkn421h#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07452224
URL:https://assetmemo.bio/drug/ilkn421h#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07562581-7648@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Luvometinib: Phase 2 readout est. (NCT07562581)
DESCRIPTION:Luvometinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC\
 nEstimated primary completion: June 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/luvometinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07562581
URL:https://assetmemo.bio/drug/luvometinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05690945-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab and tuvonralimab: Phase 3 readout est. (NCT05690945)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 3\, Non-Small Cell Lung Ca
 ncer.\nStudy: A Study of QL1706 in Combination With Chemotherapy in PD-L1-
 Negative Non-small Cell Lung Cancer\nEstimated primary completion: June 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/iparomlimab-and-t
 uvonralimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05690945
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543172-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Sotorasib: Phase 2 readout est. (NCT07543172)
DESCRIPTION:Sotorasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: CIMAv
 ax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced\, KRAS G12C 
 Mutated Non Small Cell Lung Cancer\nEstimated primary completion: 1 June 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sotorasib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07543172
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229339-2070@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Zipalertinib: Phase 2 readout est. (NCT07229339)
DESCRIPTION:Zipalertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Zi
 palertinib With Carboplatin and Pemetrexed for the Treatment of Resectable
 \, Stage II-IIIB\, Non-Small Cell Lung Cancer\nEstimated primary completio
 n: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/zipal
 ertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07229339
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07229339-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07229339)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Res
 ectable\, Stage II-IIIB\, Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 1 June 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07229339
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361484-2260@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Plinabulin: Phase 3 readout est. (NCT07361484)
DESCRIPTION:Plinabulin\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Doce
 taxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non
 -Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN
 -4)\nEstimated primary completion: 1 June 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/plinabulin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07361484
URL:https://assetmemo.bio/drug/plinabulin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468071-1979@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Trametinib: Phase 1/2 readout est. (NCT07468071)
DESCRIPTION:Trametinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ro
 llover Study for Participants Who Have Been Treated With and Are Continuin
 g to Benefit From Opnurasib as a Single Agent or in Combination With Other
  Study Treatments\nEstimated primary completion: 11 June 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/trametinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07468071
URL:https://assetmemo.bio/drug/trametinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07468071-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290611
DTEND;VALUE=DATE:20290612
SUMMARY:Tislelizumab: Phase 1/2 readout est. (NCT07468071)
DESCRIPTION:Tislelizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Rollover Study for Participants Who Have Been Treated With and Are Continu
 ing to Benefit From Opnurasib as a Single Agent or in Combination With Oth
 er Study Treatments\nEstimated primary completion: 11 June 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07468071
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120698-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:Sintilimab: Phase 2 readout est. (NCT07120698)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)\nEstimated pri
 mary completion: 26 June 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sintilimab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07120698
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07538804-2347@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:ANS02: Phase 1/2 readout est. (NCT07538804)
DESCRIPTION:ANS02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Study
  to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Smal
 l Cell Lung Cancer\nEstimated primary completion: 30 June 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ans02#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07538804
URL:https://assetmemo.bio/drug/ans02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06060613-2650@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:OBX-115: Phase 1/2 readout est. (NCT06060613)
DESCRIPTION:OBX-115\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safet
 y and Efficacy of OBX-115 in Advanced Solid Tumors\nEstimated primary comp
 letion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /obx-115#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06060613
URL:https://assetmemo.bio/drug/obx-115#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05546866-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05546866)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in
  NSCLC With Uncommon EGFRm\nEstimated primary completion: 30 June 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05546866
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379398-2261@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Iparomlimab and tuvonralimab: Phase 2 readout est. (NCT07379398)
DESCRIPTION:Iparomlimab and tuvonralimab\, phase 2\, Non-Small Cell Lung Ca
 ncer.\nStudy: Iparomlimab and Tuvonralimab Injection Combined With SBRT in
  Patients With Early-Stage Non-Small Cell Lung Cancer\nEstimated primary c
 ompletion: 30 June 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/iparomlimab-and-tuvonralimab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07379398
URL:https://assetmemo.bio/drug/iparomlimab-and-tuvonralimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemothe
 rapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEstimat
 ed primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemother
 apy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEstimate
 d primary completion: 2 July 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221474-2042@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290702
DTEND;VALUE=DATE:20290703
SUMMARY:Intismeran Autogene: Phase 2 readout est. (NCT07221474)
DESCRIPTION:Intismeran Autogene\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Che
 motherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)\nEs
 timated primary completion: 2 July 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07221474
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086456-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290719
DTEND;VALUE=DATE:20290720
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07086456)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 mbination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizuma
 b in Patients With Locally Advanced Non-Small Cell Lung Cancer\nEstimated 
 primary completion: 19 July 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07086456
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579221-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT07579221)
DESCRIPTION:Pumitamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Ph1
 /2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: 1 August 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07579221
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579221-2283@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:Navlimetostat: Phase 1/2 readout est. (NCT07579221)
DESCRIPTION:Navlimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced No
 n-Small Cell Lung Cancer\nEstimated primary completion: 1 August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07579221
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581419-2529@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:IAP0971: Phase 1/2 readout est. (NCT06581419)
DESCRIPTION:IAP0971\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Cli
 nical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malign
 ant Tumors\nEstimated primary completion: 1 August 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/iap0971#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06581419
URL:https://assetmemo.bio/drug/iap0971#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120282-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07120282)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-R
 isk Stage I NSCLC\nEstimated primary completion: 15 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tislelizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07120282
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1981@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small C
 ell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxte
 can#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07286149
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Calderasib: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Calderasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Ca
 ncer (MK-3475-01F)\nEstimated primary completion: 17 August 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07286149
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07286149-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290817
DTEND;VALUE=DATE:20290818
SUMMARY:Sacituzumab Tirumotecan: Phase 1/2 readout est. (NCT07286149)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: A Clinical Study of MK-1084 With Other Treatments for Non-small
  Cell Lung Cancer (MK-3475-01F)\nEstimated primary completion: 17 August 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tiru
 motecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07286149
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606446-9082@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290827
DTEND;VALUE=DATE:20290828
SUMMARY:Prifetrastat: Phase 2 readout est. (NCT04606446)
DESCRIPTION:Prifetrastat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of PF-07248144 in Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: 27 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/prifetrastat#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04606446
URL:https://assetmemo.bio/drug/prifetrastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07781202-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290830
DTEND;VALUE=DATE:20290831
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07781202)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Multicenter\, Single-Arm\, Prospective Phase II Clinical Study of
  Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mu
 tated Oligoprogressive Advanced Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: 30 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07781202
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QU
 ILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pre
 viously Received Treatment With Immune Checkpoint Inhibitors\nEstimated pr
 imary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-2051@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 2 readout est. (NCT03
 228667)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 2\, Non-Small Ce
 ll Lung Cancer.\nStudy: QUILT-3.055: A Study of Combination Immunotherapie
 s in Patients Who Have Previously Received Treatment With Immune Checkpoin
 t Inhibitors\nEstimated primary completion: 31 August 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiv
 a#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 228667
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03228667)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who 
 Have Previously Received Treatment With Immune Checkpoint Inhibitors\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : A 2-part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary comple
 tion: September 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07563738
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 2
 -part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion:
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivo
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07563738
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1987@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sotorasib: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Sotorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 2
 -part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion:
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/soto
 rasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07563738
URL:https://assetmemo.bio/drug/sotorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 2-part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipi
 limumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07563738
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629960-2404@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:BLU-924: Phase 1/2 readout est. (NCT07629960)
DESCRIPTION:BLU-924\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fir
 st-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harborin
 g KRAS Mutations\nEstimated primary completion: September 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/blu-924#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07629960
URL:https://assetmemo.bio/drug/blu-924#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633667-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Govitecan: Phase 2 readout est. (NCT05633667)
DESCRIPTION:Sacituzumab Govitecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Study of Novel Treatment Combinations in Patients With Lung Cancer\
 nEstimated primary completion: September 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05633667
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05633667-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05633667)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Study of Novel Treatment Combinations in Patients With Lung Cancer\nE
 stimated primary completion: September 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05633667
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750704-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Lorlatinib: Phase 2 readout est. (NCT07750704)
DESCRIPTION:Lorlatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as Firs
 t-Line Therapy for ALK Fusion-Positive NSCLC\nEstimated primary completion
 : September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lor
 latinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07750704
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07750704-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07750704)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Gui
 dance as First-Line Therapy for ALK Fusion-Positive NSCLC\nEstimated prima
 ry completion: September 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07750704
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182682-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zegfrovy (Sunvozertinib): Phase 3 readout est. (NCT07182682)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Ther
 apy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR
  Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery\nEsti
 mated primary completion: September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07182682
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06875310-2025@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:Krazati (Adagrasib): Phase 3 readout est. (NCT06875310)
DESCRIPTION:Krazati (Adagrasib)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo
  Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untr
 eated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRY
 STAL-4)\nEstimated primary completion: 7 September 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/adagrasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT06875310
URL:https://assetmemo.bio/drug/adagrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670312-2811@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290915
DTEND;VALUE=DATE:20290916
SUMMARY:XYA02: Phase 1/2 readout est. (NCT07670312)
DESCRIPTION:XYA02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Evaluat
 ion of XYA02 in Patients With Advanced Solid Tumors\nEstimated primary com
 pletion: 15 September 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/xya02#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07670312
URL:https://assetmemo.bio/drug/xya02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07481786-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290915
DTEND;VALUE=DATE:20290916
SUMMARY:Bevacizumab: Phase 3 readout est. (NCT07481786)
DESCRIPTION:Bevacizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Bev
 acizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma
  With Extensive Brain Metastases\nEstimated primary completion: 15 Septemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0748
 1786
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04
  (TP04)]\nEstimated primary completion: 30 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Datopotamab Deruxtecan: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Datopotamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-P
 anTumor04 (TP04)]\nEstimated primary completion: 30 September 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-2053@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Olomorasib: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Olomorasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (T
 P04)]\nEstimated primary completion: 30 September 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/olomorasib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/olomorasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890714-2121@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Enfortumab Vedotin: Phase 1/2 readout est. (NCT07890714)
DESCRIPTION:Enfortumab Vedotin\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTu
 mor04 (TP04)]\nEstimated primary completion: 30 September 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07890714
URL:https://assetmemo.bio/drug/enfortumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04892953)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Loca
 l Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogre
 ssive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy\nEstimat
 ed primary completion: 30 September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT04892953)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polypr
 ogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy\nEst
 imated primary completion: 30 September 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106802-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Lazertinib: Phase 2 readout est. (NCT06106802)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Laze
 rtinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified
  Who Progressed After Lazertinib Treatment\nEstimated primary completion: 
 30 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/la
 zertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06106802
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06106802-2033@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Tepmetko (Tepotinib): Phase 2 readout est. (NCT06106802)
DESCRIPTION:Tepmetko (Tepotinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or
  Amplified Who Progressed After Lazertinib Treatment\nEstimated primary co
 mpletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/tepotinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06106802
URL:https://assetmemo.bio/drug/tepotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT04892953)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Local Consolidative Therapy and Durvalumab for Oligoprogressive and P
 olyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy
 \nEstimated primary completion: 30 September 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2045@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Glecirasib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Glecirasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: JAB-
 21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment 
 of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstimate
 d primary completion: 30 September 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/glecirasib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/glecirasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672223-2211@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:CPO301: Phase 3 readout est. (NCT07672223)
DESCRIPTION:CPO301\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therapy in N
 on-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 Septem
 ber 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07672223
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06416410-2238@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Sitneprotafib: Phase 3 readout est. (NCT06416410)
DESCRIPTION:Sitneprotafib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: J
 AB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatme
 nt of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation\nEstim
 ated primary completion: 30 September 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/sitneprotafib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06416410
URL:https://assetmemo.bio/drug/sitneprotafib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07672223-2291@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Enlonstobart: Phase 3 readout est. (NCT07672223)
DESCRIPTION:Enlonstobart\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of SYS6010 Plus Anti-PD-(L)-1 Monoclonal Antibody as Adjuvant Therap
 y in Non-small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 30 
 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enlon
 stobart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07672223
URL:https://assetmemo.bio/drug/enlonstobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284317-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06284317)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Benefit of Adding Durvalumab After Chemotherapy\, Durv
 alumab and Surgery in Patients With Early-stage\, Operable\, Non-small Cel
 l Lung Cancer.\nEstimated primary completion: October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06284317
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07777822-2827@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Zoldonrasib: Phase 3 readout est. (NCT07777822)
DESCRIPTION:Zoldonrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Z
 oldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mut
 ated NSCLC\nEstimated primary completion: October 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/zoldonrasib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07777822
URL:https://assetmemo.bio/drug/zoldonrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246863-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07246863)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trial
  Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Tr
 eatment of Participants With Metastatic NSCLC\nEstimated primary completio
 n: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 volumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07246863
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246863-2796@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Visugromab: Phase 2 readout est. (NCT07246863)
DESCRIPTION:Visugromab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L T
 reatment of Participants With Metastatic NSCLC\nEstimated primary completi
 on: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 isugromab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07246863
URL:https://assetmemo.bio/drug/visugromab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128199-2070@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Zipalertinib: Phase 3 readout est. (NCT07128199)
DESCRIPTION:Zipalertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Assess Zipalertinib Versus Placebo in Participants With Early Sta
 ge NSCLC With Uncommon EGFR Mutations\, Following Complete Tumor Resection
 \nEstimated primary completion: 1 October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/zipalertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07128199
URL:https://assetmemo.bio/drug/zipalertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115043-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:Rilvegostomig: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:Rilvegostomig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate Safety of AZD6750 in Adult Participants With Selec
 t Advanced or Metastatic Solid Tumors\nEstimated primary completion: 2 Oct
 ober 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rilvegosto
 mig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07115043
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07115043-2374@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291002
DTEND;VALUE=DATE:20291003
SUMMARY:AZD6750: Phase 1/2 readout est. (NCT07115043)
DESCRIPTION:AZD6750\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate Safety of AZD6750 in Adult Participants With Select Adva
 nced or Metastatic Solid Tumors\nEstimated primary completion: 2 October 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/azd6750#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07115043
URL:https://assetmemo.bio/drug/azd6750#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688577-2810@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:XTX501: Phase 1/2 readout est. (NCT07688577)
DESCRIPTION:XTX501\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: XTX501
  in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid
  Tumors\nEstimated primary completion: November 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/xtx501#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07688577
URL:https://assetmemo.bio/drug/xtx501#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06644313-2213@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Vebreltinib: Phase 2 readout est. (NCT06644313)
DESCRIPTION:Vebreltinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Veb
 reltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cel
 l Lung Cancer (NSCLC)\nEstimated primary completion: 1 November 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/vebreltinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06644313
URL:https://assetmemo.bio/drug/vebreltinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Tagrisso (Osimertinib): Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 1/2\, Non-Small Cell Lung Cancer
 .\nStudy: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumor
 s\nEstimated primary completion: 2 November 2029. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated 
 primary completion: 2 November 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated
  primary completion: 2 November 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors\n
 Estimated primary completion: 2 November 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-2803@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:VT3989: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:VT3989\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Study 
 to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated pri
 mary completion: 2 November 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/vt3989#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/vt3989#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: K
 EYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Partici
 pants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Vir
 al Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)\nEst
 imated primary completion: 15 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Calderasib: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Calderasib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: KEYM
 AKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participan
 ts With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral 
 Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)\nEstima
 ted primary completion: 15 November 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/calderasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07252739-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291115
DTEND;VALUE=DATE:20291116
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT07252739)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 
 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat S
 arcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-
 U01J)\nEstimated primary completion: 15 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07252739
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05526755-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291122
DTEND;VALUE=DATE:20291123
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT05526755)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of 5 Years of Adjuvant Osimertinib in Completely Resected 
 Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carc
 inoma (NSCLC)\nEstimated primary completion: 22 November 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05526755
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632262-2323@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT06632262)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Clinical Study of ABSK061 and ABSK043\nEstimated primary completion:
  30 November 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lu
 mipodlin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06632262
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632262-2324@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Lavengratinib: Phase 2 readout est. (NCT06632262)
DESCRIPTION:Lavengratinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase 2 Clinical Study of ABSK061 and ABSK043\nEstimated primary completi
 on: 30 November 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lavengratinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06632262
URL:https://assetmemo.bio/drug/lavengratinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07285148-2208@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Andamertinib: Phase 1/2 readout est. (NCT07285148)
DESCRIPTION:Andamertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/andamertinib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07285148
URL:https://assetmemo.bio/drug/andamertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07439094-2430@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:CKD-703: Phase 1/2 readout est. (NCT07439094)
DESCRIPTION:CKD-703\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fir
 st-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell L
 ung Cancer\nEstimated primary completion: December 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/ckd-703#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07439094
URL:https://assetmemo.bio/drug/ckd-703#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751798-2663@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:OSE2101: Phase 1/2 readout est. (NCT05751798)
DESCRIPTION:OSE2101\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Dose-
 finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Soli
 d Tumors or Lymphomas\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ose2101#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05751798
URL:https://assetmemo.bio/drug/ose2101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05751798-2667@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:OSE-279: Phase 1/2 readout est. (NCT05751798)
DESCRIPTION:OSE-279\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Dose-
 finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Soli
 d Tumors or Lymphomas\nEstimated primary completion: December 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/ose-279#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05751798
URL:https://assetmemo.bio/drug/ose-279#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836543-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07836543)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tra
 stuzumab Rezetecan and Adebrelimab\, Alone or in Combination\, After Chemo
 radiotherapy for HER2-Altered Unresectable Stage III Lung Cancer\nEstimate
 d primary completion: December 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07836543
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836543-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Trastuzumab rezetecan: Phase 2 readout est. (NCT07836543)
DESCRIPTION:Trastuzumab rezetecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Trastuzumab Rezetecan and Adebrelimab\, Alone or in Combination\, A
 fter Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer
 \nEstimated primary completion: December 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07836543
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739186-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739186)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bis
 pecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as
  First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-
 small Cell Lung Cancer(PANKU-Lung06)\nEstimated primary completion: Decemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab-
 brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07739186
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739199-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07739199)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispec
 ific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific
  Antibody in First-line Patients With Locally Advanced or Metastatic Squam
 ous Non-small Cell Lung Cancer(PANKU-Lung05)\nEstimated primary completion
 : December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izal
 ontamab-brengitecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07739199
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756645-2698@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:RC148: Phase 3 readout est. (NCT07756645)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study t
 o Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembroliz
 umab Combined With Chemotherapy for the First Line Treatment of Locally Ad
 vanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants\nEstima
 ted primary completion: December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07756645
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06765109-10952@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:neladalkib: Phase 3 readout est. (NCT06765109)
DESCRIPTION:neladalkib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nela
 dalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC\n
 Estimated primary completion: December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/neladalkib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06765109
URL:https://assetmemo.bio/drug/neladalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06043817-2746@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Elticertinib: Phase 1/2 readout est. (NCT06043817)
DESCRIPTION:Elticertinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advan
 ced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 2
 0 Insertion Mutations\nEstimated primary completion: 1 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elticertinib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06043817
URL:https://assetmemo.bio/drug/elticertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07808138-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07808138)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: RADI
 CAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly
  InOperable Stage I Non-small Cell Lung Cancer\nEstimated primary completi
 on: 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07808138
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890636-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Adebrelimab: Phase 2 readout est. (NCT07890636)
DESCRIPTION:Adebrelimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ade
 brelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC\nEstimated pr
 imary completion: 1 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07890636
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771764-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291201
DTEND;VALUE=DATE:20291202
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07771764)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: A Multicenter Exploratory Clinical Study of Iruplaltinib Combined Wit
 h Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamo
 us Non-Small Cell Lung Cancer\nEstimated primary completion: 1 December 20
 29. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07771764
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06465329)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Pl
 us Other Cancer Treatments for Adult Patients With Operable Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 4 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465329-2176@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291204
DTEND;VALUE=DATE:20291205
SUMMARY:Marlotamig: Phase 2 readout est. (NCT06465329)
DESCRIPTION:Marlotamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Pl
 us Other Cancer Treatments for Adult Patients With Operable Non-Small Cell
  Lung Cancer (NSCLC)\nEstimated primary completion: 4 December 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/marlotamig#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06465329
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190248-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Calderasib: Phase 3 readout est. (NCT07190248)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Study of Calderasib (MK-1084) and Other Treatments for Participants
  With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)\nEstimated pr
 imary completion: 7 December 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/calderasib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07190248
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07190248-2259@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291207
DTEND;VALUE=DATE:20291208
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07190248)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Non-Small Cell Lung Cancer.\nStudy: A Clinical Study of Calderasib (MK-1
 084) and Other Treatments for Participants With Non-Small Cell Lung Cancer
  (MK-1084-007/KANDLELIT-007)\nEstimated primary completion: 7 December 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab-bera
 hyaluronidase-alfa#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07190248
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Phase III\, Open-label\, Study of First-line Dato-DXd in Combinati
 on With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expr
 ession (TC ≥ 50%) and Without Actionable Genomic Alterations\nEstimated 
 primary completion: 28 December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06357533-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291228
DTEND;VALUE=DATE:20291229
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06357533)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase III\, Open-label\, Study of First-line Dato-DXd in Combination With R
 ilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (T
 C ≥ 50%) and Without Actionable Genomic Alterations\nEstimated primary c
 ompletion: 28 December 2029. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/rilvegostomig#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06357533
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182708-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07182708)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: H
 igh-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resecta
 ble EGFRm Stage II-IIIB NSCLC\nEstimated primary completion: 30 December 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071827
 08
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182708-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT07182708)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hig
 h-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectabl
 e EGFRm Stage II-IIIB NSCLC\nEstimated primary completion: 30 December 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/bevacizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07182708
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07622706-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291230
DTEND;VALUE=DATE:20291231
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07622706)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-m
 utated Lung Adenocarcinoma\nEstimated primary completion: 30 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07622706
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902921-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07902921)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: STA
 R0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castr
 ate-Resistant Prostate Cancer\, and STAR0602 Alone in Thymic Carcinoma\nEs
 timated primary completion: 31 December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07902921
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902921-2742@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Invikafusp alfa: Phase 1/2 readout est. (NCT07902921)
DESCRIPTION:Invikafusp alfa\, phase 1/2\, Non-Small Cell Lung Cancer.\nStud
 y: STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic
  Castrate-Resistant Prostate Cancer\, and STAR0602 Alone in Thymic Carcino
 ma\nEstimated primary completion: 31 December 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07902921
URL:https://assetmemo.bio/drug/invikafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710612-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07710612)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase 2 Study of ABSK043 Combined With Osimertinib\nEstimated pr
 imary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07710612
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274384-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07274384)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Hype
 rprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial\nEst
 imated primary completion: 31 December 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07274384
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07710612-2323@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Lumipodlin: Phase 2 readout est. (NCT07710612)
DESCRIPTION:Lumipodlin\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase 2 Study of ABSK043 Combined With Osimertinib\nEstimated primary comple
 tion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/lumipodlin#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07710612
URL:https://assetmemo.bio/drug/lumipodlin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810609-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06810609)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 nochemotherapy\, Surgery or Chemoradiation\, and Durvalumab for Stage IIIA
 /B NSCLC\nEstimated primary completion: 31 December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06810609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-1995@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Sintilimab: Phase 2 readout est. (NCT03872661)
DESCRIPTION:Sintilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Followed by
  Surgery in Unresectable Stage III NSCLC\nEstimated primary completion: 31
  December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sinti
 limab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03872661
URL:https://assetmemo.bio/drug/sintilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-2008@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Bevacizumab: Phase 2 readout est. (NCT03872661)
DESCRIPTION:Bevacizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Followed b
 y Surgery in Unresectable Stage III NSCLC\nEstimated primary completion: 3
 1 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/beva
 cizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT03872661
URL:https://assetmemo.bio/drug/bevacizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03872661-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT03872661)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant IBI308\, Bevacizumab\, Plus Pemetrexed and Carboplatin Fo
 llowed by Surgery in Unresectable Stage III NSCLC\nEstimated primary compl
 etion: 31 December 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03872661
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06219317-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06219317)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Consolidation After Radical Treatment of Synchronous Oligo-metas
 tatic NSCLC\nEstimated primary completion: January 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06219317
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06745882)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Prospective Trial Assessing Real World Outcomes Response to Pembro in Blac
 k Patients w/ NSCLC\nEstimated primary completion: January 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06745882)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 rospective Trial Assessing Real World Outcomes Response to Pembro in Black
  Patients w/ NSCLC\nEstimated primary completion: January 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745882-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06745882)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Prospective Trial Assessing Real World Outcomes Response to Pembro in
  Black Patients w/ NSCLC\nEstimated primary completion: January 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06745882
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459751-1999@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300115
DTEND;VALUE=DATE:20300116
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07459751)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of
  HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in 
 Advanced or Metastatic Squamous Non-Small Cell Lung Cancer\nEstimated prim
 ary completion: 15 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pimurutamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07459751
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459751-2039@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300115
DTEND;VALUE=DATE:20300116
SUMMARY:HLX43: Phase 2/3 readout est. (NCT07459751)
DESCRIPTION:HLX43\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A Globa
 l Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43
  Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanc
 ed or Metastatic Squamous Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 15 January 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/hlx43#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07459751
URL:https://assetmemo.bio/drug/hlx43#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Cemiplimab: Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Cemiplimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemot
 herapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult 
 Patients With Advanced Non-small Cell Lung Cancer\nEstimated primary compl
 etion: 16 January 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05800015
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05800015-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300116
DTEND;VALUE=DATE:20300117
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT05800015)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Trial to Learn How the Combination of Fianlimab With Cemiplimab a
 nd Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treati
 ng Adult Patients With Advanced Non-small Cell Lung Cancer\nEstimated prim
 ary completion: 16 January 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05800015
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06868277-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300117
DTEND;VALUE=DATE:20300118
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06868277)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for 
 First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer\n
 Estimated primary completion: 17 January 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06868277
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lu
 ng Cancer\nEstimated primary completion: 24 January 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-2178@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:SCTB41: Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:SCTB41\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: SCTB41
  Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cance
 r\nEstimated primary completion: 24 January 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/sctb41#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/sctb41#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662395-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300124
DTEND;VALUE=DATE:20300125
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07662395)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Ce
 ll Lung Cancer\nEstimated primary completion: 24 January 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07662395
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718243-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07718243)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Inv
 estigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours\
 , Melanoma and NSCLC\nEstimated primary completion: 31 January 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07718243
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718243-2934@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Bexmarilimab: Phase 1/2 readout est. (NCT07718243)
DESCRIPTION:Bexmarilimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumou
 rs\, Melanoma and NSCLC\nEstimated primary completion: 31 January 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/bexmarilimab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07718243
URL:https://assetmemo.bio/drug/bexmarilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04267848-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT04267848)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: T
 esting the Addition of a Type of Drug Called Immunotherapy to the Usual Ch
 emotherapy Treatment for Non-small Cell Lung Cancer\, an ALCHEMIST Treatme
 nt Trial (Chemo-IO [ACCIO])\nEstimated primary completion: 31 January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04267848
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04267848-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT04267848)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Testing the Addition of a Type of Drug Called Immunotherapy to the Us
 ual Chemotherapy Treatment for Non-small Cell Lung Cancer\, an ALCHEMIST T
 reatment Trial (Chemo-IO [ACCIO])\nEstimated primary completion: 31 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT042678
 48
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07573696-2016@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300208
DTEND;VALUE=DATE:20300209
SUMMARY:Alecensa (Alectinib): Phase 2 readout est. (NCT07573696)
DESCRIPTION:Alecensa (Alectinib)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant
  Alectinib and Chemotherapy\nEstimated primary completion: 8 February 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/alectinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07573696
URL:https://assetmemo.bio/drug/alectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410611-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07410611)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: ct
 DNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined Wi
 th Radiotherapy\nEstimated primary completion: 28 February 2030. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/befotertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07410611
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04683250-2757@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Vepafestinib: Phase 1/2 readout est. (NCT04683250)
DESCRIPTION:Vepafestinib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors
  With RET Gene Abnormalities\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/vepafestinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04683250
URL:https://assetmemo.bio/drug/vepafestinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858410-1970@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Lorlatinib: Phase 3 readout est. (NCT06858410)
DESCRIPTION:Lorlatinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Lorl
 atinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III
  ALK Positive Lung Adenocarcinoma\nEstimated primary completion: March 203
 0. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/lorlatinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06858410
URL:https://assetmemo.bio/drug/lorlatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821684-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07821684)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Comp
 ared to Standard of Care in Adult Participants Previously Treated\, EGFR W
 ildtype\, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Can
 cer\nEstimated primary completion: March 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07821684
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-li
 ne Treatment of Subjects With Advanced or Metastatic NSCLC Without Actiona
 ble Genomic Alterations\nEstimated primary completion: 4 March 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05215340
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05215340-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300304
DTEND;VALUE=DATE:20300305
SUMMARY:Datopotamab Deruxtecan: Phase 3 readout est. (NCT05215340)
DESCRIPTION:Datopotamab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the
  First-line Treatment of Subjects With Advanced or Metastatic NSCLC Withou
 t Actionable Genomic Alterations\nEstimated primary completion: 4 March 20
 30. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/datopotamab-derux
 tecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05215340
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926790-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06926790)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)\nEstimated
  primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06926790
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926790-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT06926790)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)\nEstimate
 d primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06926790
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06322108-2380@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Balstilimab: Phase 2 readout est. (NCT06322108)
DESCRIPTION:Balstilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ass
 essment of the Safety and Efficacy of Balstilimab in Combination With Bote
 nsilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)\nEst
 imated primary completion: April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/balstilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06322108
URL:https://assetmemo.bio/drug/balstilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06322108-2415@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Botensilimab: Phase 2 readout est. (NCT06322108)
DESCRIPTION:Botensilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: As
 sessment of the Safety and Efficacy of Balstilimab in Combination With Bot
 ensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008)\nEs
 timated primary completion: April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/botensilimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06322108
URL:https://assetmemo.bio/drug/botensilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04564157-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04564157)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: New A
 djuvant Trial of Chemotherapy vs Chemo-immunotherapy\nEstimated primary co
 mpletion: 1 April 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04564157
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-based Chemot
 herapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer\nEstim
 ated primary completion: 24 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06899126-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300424
DTEND;VALUE=DATE:20300425
SUMMARY:Trastuzumab Deruxtecan: Phase 3 readout est. (NCT06899126)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Trastuzumab Deruxtecan\, Pembrolizumab\, and Platinum-bas
 ed Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Canc
 er\nEstimated primary completion: 24 April 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06899126
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274761-2163@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT07274761)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung C
 ancer Harboring EGFR Exon 20 Insertion Mutation.\nEstimated primary comple
 tion: 1 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sun
 vozertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07274761
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nE
 stimated primary completion: 28 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1980@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Datopotamab Deruxtecan: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Datopotamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lu
 ng Cancer\nEstimated primary completion: 28 May 2030. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/datopotamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1985@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Volrustomig: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Volrustomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\n
 Estimated primary completion: 28 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/volrustomig#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Rilvegostomig: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Rilvegostomig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: N
 eoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
 \nEstimated primary completion: 28 May 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2157@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Oleclumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Oleclumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nEs
 timated primary completion: 28 May 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/oleclumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/oleclumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT05061550)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung 
 Cancer\nEstimated primary completion: 28 May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2257@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Monalizumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Monalizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neo
 adjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\n
 Estimated primary completion: 28 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/monalizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/monalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-2371@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Falbikitug: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Falbikitug\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nE
 stimated primary completion: 28 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/falbikitug#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/falbikitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822542-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07822542)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy With or 
 Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Line Thera
 py in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer\n
 Estimated primary completion: 31 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/adebrelimab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07822542
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07822542-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07822542)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study Evaluating HS-10370 Plus Platinum-based Doublet Chemotherapy 
 With or Without Adebrelimab vs. Tislelizumab Plus Chemotherapy as First-Li
 ne Therapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung 
 Cancer\nEstimated primary completion: 31 May 2030. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07822542
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941583-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07941583)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase II Study of Ivonescimab Combined With Iza-bren in Patients With Advan
 ced Non-Small Cell Lung Cancer.\nEstimated primary completion: 1 June 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07941583
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941583-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Izalontamab brengitecan: Phase 2 readout est. (NCT07941583)
DESCRIPTION:Izalontamab brengitecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: A Phase II Study of Ivonescimab Combined With Iza-bren in Patient
 s With Advanced Non-Small Cell Lung Cancer.\nEstimated primary completion:
  1 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/izalont
 amab-brengitecan#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07941583
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154290-2176@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Marlotamig: Phase 2 readout est. (NCT07154290)
DESCRIPTION:Marlotamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Ad
 ult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCL
 C)\nEstimated primary completion: 10 June 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/marlotamig#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07154290
URL:https://assetmemo.bio/drug/marlotamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154290-2789@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300610
DTEND;VALUE=DATE:20300611
SUMMARY:Ubamatamab: Phase 2 readout est. (NCT07154290)
DESCRIPTION:Ubamatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Ad
 ult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCL
 C)\nEstimated primary completion: 10 June 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ubamatamab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07154290
URL:https://assetmemo.bio/drug/ubamatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06077760-2042@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300625
DTEND;VALUE=DATE:20300626
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06077760)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Ve
 rsus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung C
 ancer (V940-002)\nEstimated primary completion: 25 June 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/intismeran-autogene#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06077760
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073365-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07073365)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Bolstering Outcomes After Induction With Osimertinib Plus Chemothe
 rapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial)\n
 Estimated primary completion: 30 June 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07073365
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775040-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Tislelizumab: Phase 2 readout est. (NCT07775040)
DESCRIPTION:Tislelizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Sp
 atially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for B
 ulky Stage III NSCLC: A Phase II Trial\nEstimated primary completion: 30 J
 une 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tislelizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 775040
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775040-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07775040)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherap
 y for Bulky Stage III NSCLC: A Phase II Trial\nEstimated primary completio
 n: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07775040
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07566052-2183@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Setidegrasib: Phase 3 readout est. (NCT07566052)
DESCRIPTION:Setidegrasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study to Compare Setidegrasib (ASP3082) With Docetaxel\, in People With No
 n-small Cell Lung Cancer With a KRAS G12D Mutation\nEstimated primary comp
 letion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /setidegrasib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07566052
URL:https://assetmemo.bio/drug/setidegrasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668752-2279@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:GFH375: Phase 3 readout est. (NCT07668752)
DESCRIPTION:GFH375\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study 
 to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lu
 ng Cancer With KRAS G12D Mutation\nEstimated primary completion: 30 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/gfh375#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07668752
URL:https://assetmemo.bio/drug/gfh375#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02493582-2014@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Apatinib: Phase 2 readout est. (NCT02493582)
DESCRIPTION:Apatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The St
 udy of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adeno
 carcinoma Patients With Wild-Type EGFR\nEstimated primary completion: July
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/apatinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT02493582
URL:https://assetmemo.bio/drug/apatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692738-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06692738)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemothera
 py for First-Line Treatment of Locally Advanced or Metastatic Squamous Non
 -small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1 July 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06692738
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692738-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06692738)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-
 small Cell Lung Cancer (NSCLC)\nEstimated primary completion: 1 July 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/rilvegostomig#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06692738
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy v
 s Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-
 small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary com
 pletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06561386
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-2059@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Relatlimab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Relatlimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy 
 vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non
 -small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary co
 mpletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/relatlimab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06561386
URL:https://assetmemo.bio/drug/relatlimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06561386)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chem
 otherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squ
 amous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated p
 rimary completion: 30 July 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06561386
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of DS-3939a in Participants With Solid Tumors\nEstimated primary 
 completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07739966
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of DS-3939a in Participants With Solid Tumors\nEstimated pr
 imary completion: 31 July 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07739966
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-7685@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:DS-3939a: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:DS-3939a\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of DS-3939a in Participants With Solid Tumors\nEstimated primary compl
 etion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ds-3939a#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07739966
URL:https://assetmemo.bio/drug/ds-3939a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07739966-7686@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:DS-1103a: Phase 1/2 readout est. (NCT07739966)
DESCRIPTION:DS-1103a\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of DS-3939a in Participants With Solid Tumors\nEstimated primary compl
 etion: 31 July 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 ds-1103a#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07739966
URL:https://assetmemo.bio/drug/ds-1103a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709585-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07709585)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy f
 or Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Pa
 tients\nEstimated primary completion: 31 July 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07709585
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07709585-2235@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Befotertinib: Phase 2 readout est. (NCT07709585)
DESCRIPTION:Befotertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Be
 fotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Trea
 tment Escalation and Response Optimization in EGFR-mutated NSCLC Patients\
 nEstimated primary completion: 31 July 2030. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/befotertinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07709585
URL:https://assetmemo.bio/drug/befotertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154706-2075@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300830
DTEND;VALUE=DATE:20300831
SUMMARY:Taletrectinib: Phase 3 readout est. (NCT07154706)
DESCRIPTION:Taletrectinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: P
 hase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Po
 sitive NSCLC (TRUST-IV)\nEstimated primary completion: 30 August 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/taletrectinib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07154706
URL:https://assetmemo.bio/drug/taletrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001618-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07001618)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Oral
  Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus B
 est Investigator's Choice in Patients With Resistance to Treatment Due to 
 Antibiotics Uptake With Advanced Non-small Cell Lung Cancer\nEstimated pri
 mary completion: September 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07001618
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155187-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT07155187)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Adverse Events and Change in Disease Activity 
 of Intravenous (IV) Telisotuzumab Adizutecan\, Monotherapy or in Combinati
 on With Osimertinib\, Compared to Standard of Care in Adult Participants W
 ith Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cel
 l Lung Cancer\nEstimated primary completion: September 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07155187
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155187-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07155187)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events and Change in Disease Activit
 y of Intravenous (IV) Telisotuzumab Adizutecan\, Monotherapy or in Combina
 tion With Osimertinib\, Compared to Standard of Care in Adult Participants
  With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small C
 ell Lung Cancer\nEstimated primary completion: September 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07155187
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746388-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300901
DTEND;VALUE=DATE:20300902
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07746388)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial\nEs
 timated primary completion: 1 September 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07746388
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361497-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20300918
DTEND;VALUE=DATE:20300919
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361497)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradia
 tion Therapy in Participants With Unresectable Stage III Non-small Cell Lu
 ng Cancer (NSCLC) (ROSETTA Lung-201)\nEstimated primary completion: 18 Sep
 tember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 361497
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620835-2024@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301001
DTEND;VALUE=DATE:20301002
SUMMARY:Brigatinib: Phase 2 readout est. (NCT06620835)
DESCRIPTION:Brigatinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Tria
 l for Local Ablative Treatment (LAT) Optimization in Patients With Advance
 d Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Ki
 nase (ALK) Rearrangement Treated by Brigatinib\nEstimated primary completi
 on: 1 October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 rigatinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06620835
URL:https://assetmemo.bio/drug/brigatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109402-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06109402)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable N
 on-small Cell Lung Cancer\nEstimated primary completion: 1 November 2030. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109402
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109402-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06109402)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resecta
 ble Non-small Cell Lung Cancer\nEstimated primary completion: 1 November 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06109402
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07322341-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301101
DTEND;VALUE=DATE:20301102
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07322341)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: SX
 -682 and Atezolizumab for the Treatment of Advanced or Metastatic\, Recurr
 ent Non-small Cell Lung Cancer\nEstimated primary completion: 1 November 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/atezolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0732234
 1
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627647-1986@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301118
DTEND;VALUE=DATE:20301119
SUMMARY:Rilvegostomig: Phase 3 readout est. (NCT06627647)
DESCRIPTION:Rilvegostomig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherap
 y for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous 
 NSCLC\nEstimated primary completion: 18 November 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rilvegostomig#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06627647
URL:https://assetmemo.bio/drug/rilvegostomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06627647-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301118
DTEND;VALUE=DATE:20301119
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06627647)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemo
 therapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squ
 amous NSCLC\nEstimated primary completion: 18 November 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06627647
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06172478-1981@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301119
DTEND;VALUE=DATE:20301120
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06172478)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic
  Solid Tumors\nEstimated primary completion: 19 November 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06172478
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07859592-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07859592)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: L
 abyrinthin Vaccination in Veterans With Lung Adenocarcinoma\nEstimated pri
 mary completion: 30 November 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07859592
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 atient Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimat
 ed primary completion: 30 November 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Patie
 nt Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimated p
 rimary completion: 30 November 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874490-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Tagrisso (Osimertinib): Phase 2 readout est. (NCT07874490)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NS
 CLC\nEstimated primary completion: December 2030. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07874490
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04614103-2048@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:LN-145: Phase 2 readout est. (NCT04614103)
DESCRIPTION:LN-145\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Autologo
 us LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer\nEstimate
 d primary completion: December 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ln-145#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04614103
URL:https://assetmemo.bio/drug/ln-145#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955325-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Ensacove (Ensartinib): Phase 3 readout est. (NCT06955325)
DESCRIPTION:Ensacove (Ensartinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk
  Stage IA-IB NSCLC: Focus on Driver Mutations\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ens
 artinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06955325
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955325-2011@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Icotinib: Phase 3 readout est. (NCT06955325)
DESCRIPTION:Icotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Umbrel
 la Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB 
 NSCLC: Focus on Driver Mutations\nEstimated primary completion: December 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/icotinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06955325
URL:https://assetmemo.bio/drug/icotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955325-2234@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Rezivertinib: Phase 3 readout est. (NCT06955325)
DESCRIPTION:Rezivertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Um
 brella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA
 -IB NSCLC: Focus on Driver Mutations\nEstimated primary completion: Decemb
 er 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/rezivertinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 55325
URL:https://assetmemo.bio/drug/rezivertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07640789-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07640789)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study Comparing BL-B01D1 in Combination With Osimertinib Versus
  Osimertinib Alone in Patients With Locally Advanced\, Unresectable EGFR-m
 utated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progres
 sed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung0
 8)\nEstimated primary completion: December 2030. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07640789
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06918132-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301202
DTEND;VALUE=DATE:20301203
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06918132)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cemi
 plimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non
 -Small Cell Lung Cancer\nEstimated primary completion: 2 December 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cemiplimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06918132
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929041-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301212
DTEND;VALUE=DATE:20301213
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT04929041)
DESCRIPTION:Nivolumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Tes
 ting the Addition of Radiation Therapy to the Usual Treatment (Immunothera
 py With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Ca
 ncer Patients Who Are PD-L1 Negative\nEstimated primary completion: 12 Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 29041
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929041-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301212
DTEND;VALUE=DATE:20301213
SUMMARY:Ipilimumab: Phase 2/3 readout est. (NCT04929041)
DESCRIPTION:Ipilimumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Addition of Radiation Therapy to the Usual Treatment (Immunother
 apy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung C
 ancer Patients Who Are PD-L1 Negative\nEstimated primary completion: 12 De
 cember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ipilimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4929041
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865910-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07865910)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Learn the Safety and Efficacy of HLX37 in Combination With Ch
 emotherapy for First-line Treatment in Adult Participants With Locally Adv
 anced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary completi
 on: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07865910
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07865910-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07865910)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn the Safety and Efficacy of HLX37 in Combination Wi
 th Chemotherapy for First-line Treatment in Adult Participants With Locall
 y Advanced or Metastatic Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07865910
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07897188)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: ASKC202 Plus Limertinib as the First-line Therapy for Patients With E
 GFRm+/MET+ Locally Advanced or Metastatic NSCLC\nEstimated primary complet
 ion: 30 December 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07897188
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-2356@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:ASKC202: Phase 3 readout est. (NCT07897188)
DESCRIPTION:ASKC202\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC202
  Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET+ L
 ocally Advanced or Metastatic NSCLC\nEstimated primary completion: 30 Dece
 mber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/askc202#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078971
 88
URL:https://assetmemo.bio/drug/askc202#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897188-7622@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301230
DTEND;VALUE=DATE:20301231
SUMMARY:Limertinib: Phase 3 readout est. (NCT07897188)
DESCRIPTION:Limertinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: ASKC
 202 Plus Limertinib as the First-line Therapy for Patients With EGFRm+/MET
 + Locally Advanced or Metastatic NSCLC\nEstimated primary completion: 30 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/limerti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07897188
URL:https://assetmemo.bio/drug/limertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890493-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07890493)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: I
 mmune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiot
 a Transplant in Advanced Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07890493
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298148-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07298148)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrat
 ing SD After 8 Week Induction With Firmonertinib 80 mg\nEstimated primary 
 completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/furmonertinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07298148
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07330076-2231@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Iruplinalkib: Phase 2 readout est. (NCT07330076)
DESCRIPTION:Iruplinalkib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ir
 uplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-posit
 ive NSCLC With High-risk Factors\nEstimated primary completion: 31 Decembe
 r 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/iruplinalkib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0733
 0076
URL:https://assetmemo.bio/drug/iruplinalkib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890493-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07890493)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Mic
 robiota Transplant in Advanced Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07890493
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07314216-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07314216)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Combined With Definitive Radiotherapy in Stage III Unresectab
 le EGFR Uncommon Mutant Pulmonary Adenocarcinoma\nEstimated primary comple
 tion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/furmonertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07314216
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07050043-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07050043)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Tre
 atment in Advanced or Metastatic NSCLC\nEstimated primary completion: 31 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7050043
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serp
 lulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or
  Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamo
 us Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-1999@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Pimurutamab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Pimurutamab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/pimurutamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/pimurutamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07318883-2161@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Serplulimab: Phase 2/3 readout est. (NCT07318883)
DESCRIPTION:Serplulimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A
  Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplul
 imab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pe
 mbrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous 
 Non-Small Cell Lung Cancer\nEstimated primary completion: January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/serplulimab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07318883
URL:https://assetmemo.bio/drug/serplulimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235306-1978@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Ensacove (Ensartinib): Phase 2 readout est. (NCT07235306)
DESCRIPTION:Ensacove (Ensartinib)\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC\n
 Estimated primary completion: 31 January 2031. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/ensartinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07235306
URL:https://assetmemo.bio/drug/ensartinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2019@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Lazertinib: Phase 2 readout est. (NCT07507188)
DESCRIPTION:Lazertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Coll
 aborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and
  Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Locally Adva
 nced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)\nEs
 timated primary completion: 31 January 2031. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lazertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/lazertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2020@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07507188)
DESCRIPTION:Amivantamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Col
 laborative Clinical-translational Cohort of Amivantamab Plus Lazertinib an
 d Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Locally Adv
 anced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)\nE
 stimated primary completion: 31 January 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/amivantamab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507188-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07507188)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Collaborative Clinical-translational Cohort of Amivantamab Plus Lazer
 tinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant\, Loc
 ally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR S
 tudy)\nEstimated primary completion: 31 January 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07507188
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of SHR-A1811 Combined With Adebrelimab for the First-line HER2-overex
 pressing Non-squamous Non-small Cell Lung Cancer\nEstimated primary comple
 tion: February 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 adebrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07896005
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896005-9096@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Trastuzumab rezetecan: Phase 3 readout est. (NCT07896005)
DESCRIPTION:Trastuzumab rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study of SHR-A1811 Combined With Adebrelimab for the First-line H
 ER2-overexpressing Non-squamous Non-small Cell Lung Cancer\nEstimated prim
 ary completion: February 2031. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/trastuzumab-rezetecan#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07896005
URL:https://assetmemo.bio/drug/trastuzumab-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07829549)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus C
 hemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung C
 ancer Without Actionable Genomic Alterations\nEstimated primary completion
 : April 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetre
 xed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07829549
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2698@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:RC148: Phase 3 readout est. (NCT07829549)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phase III
  Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as
  First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without 
 Actionable Genomic Alterations\nEstimated primary completion: April 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07829549
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07636785-2798@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:VMD-102: Phase 1/2 readout est. (NCT07636785)
DESCRIPTION:VMD-102\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tu
 mors\nEstimated primary completion: May 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/vmd-102#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07636785
URL:https://assetmemo.bio/drug/vmd-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946836-1994@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310501
DTEND;VALUE=DATE:20310502
SUMMARY:Cadonilimab: Phase 2 readout est. (NCT06946836)
DESCRIPTION:Cadonilimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Com
 parison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 
 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 
 Expression: A Single-Center\, Randomized\, Exploratory Clinical Study\nEst
 imated primary completion: 1 May 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cadonilimab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06946836
URL:https://assetmemo.bio/drug/cadonilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Nab-paclitaxel: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Nab-paclitaxel\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy
 : A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pe
 mbrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemoth
 erapy in First-line Metastatic Non-small Cell Lung Cancer Participants Wit
 h Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Pembrolizumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pem
 brolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemothe
 rapy in First-line Metastatic Non-small Cell Lung Cancer Participants With
  Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Compare the Combination of Navlimetostat (BMS-986504) Wi
 th Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Ch
 emotherapy in First-line Metastatic Non-small Cell Lung Cancer Participant
 s With Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2
 031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063745-2283@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310812
DTEND;VALUE=DATE:20310813
SUMMARY:Navlimetostat: Phase 2/3 readout est. (NCT07063745)
DESCRIPTION:Navlimetostat\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pem
 brolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemothe
 rapy in First-line Metastatic Non-small Cell Lung Cancer Participants With
  Homozygous MTAP Deletion\nEstimated primary completion: 12 August 2031. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/navlimetostat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07063745
URL:https://assetmemo.bio/drug/navlimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Pumitamig: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Pumitamig\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-2544@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Imzokitug: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Imzokitug\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/imzokitug#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/imzokitug#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-9029@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BMS-986340 as Monotherapy and as Combination Therapy in
  Participants With Advanced Solid Tumors\nEstimated primary completion: 31
  August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4895709
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06552234-2264@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Repotrectinib: Phase 2 readout est. (NCT06552234)
DESCRIPTION:Repotrectinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 hase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients W
 ith ROS1-rearranged Advanced NSCLC\nEstimated primary completion: Septembe
 r 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/repotrectinib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT065
 52234
URL:https://assetmemo.bio/drug/repotrectinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06236438-990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06236438)
DESCRIPTION:Budigalimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events\, Optimal Dose\, and Change in Disease Act
 ivity\, With Livmoniplimab in Combination With Budigalimab Plus Chemothera
 py Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants
  With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: October 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06236438
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06236438-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT06236438)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: Study to Evaluate Adverse Events\, Optimal Dose\, and Change in Dis
 ease Activity\, With Livmoniplimab in Combination With Budigalimab Plus Ch
 emotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Part
 icipants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer
  (NSCLC)\nEstimated primary completion: October 2031. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06236438
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07361510-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Pumitamig: Phase 3 readout est. (NCT07361510)
DESCRIPTION:Pumitamig\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participa
 nts With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L
 1 ≥ 50%. (ROSETTA Lung-202)\nEstimated primary completion: 14 October 20
 31. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07361510
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660094-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311022
DTEND;VALUE=DATE:20311023
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07660094)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
 glatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage
  IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)\nEstimated pr
 imary completion: 22 October 2031. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07660094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660094-2093@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311022
DTEND;VALUE=DATE:20311023
SUMMARY:Aglatimagene Besadenovec: Phase 3 readout est. (NCT07660094)
DESCRIPTION:Aglatimagene Besadenovec\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxe
 l for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)\nE
 stimated primary completion: 22 October 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07660094
URL:https://assetmemo.bio/drug/aglatimagene-besadenovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07715396-2010@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311030
DTEND;VALUE=DATE:20311031
SUMMARY:Tislelizumab: Phase 3 readout est. (NCT07715396)
DESCRIPTION:Tislelizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 dition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metasta
 tic Non-small Cell Lung Cancer With a High Tumor Burden\nEstimated primary
  completion: 30 October 2031. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tislelizumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07715396
URL:https://assetmemo.bio/drug/tislelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2073@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Vopimetostat: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:Vopimetostat\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: 
 TNG462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor A
 ctivity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Pa
 tients\nEstimated primary completion: November 2031. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/vopimetostat#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/vopimetostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07897734-2476@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:ERAS-0015: Phase 1/2 readout est. (NCT07897734)
DESCRIPTION:ERAS-0015\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: TNG
 462-C103: Study to Evaluate the Safety\, Tolerability\, and Antitumor Acti
 vity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patie
 nts\nEstimated primary completion: November 2031. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/eras-0015#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07897734
URL:https://assetmemo.bio/drug/eras-0015#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06431633-1992@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Sacituzumab Govitecan: Phase 3 readout est. (NCT06431633)
DESCRIPTION:Sacituzumab Govitecan\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: Study of Treatment With Sacituzumab and Zimberelimab for Patients W
 ith Lung Cancer Confined to the Chest and Previously Operated on Who Were 
 Not Disease-free.\nEstimated primary completion: 30 November 2031. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-govitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06431633
URL:https://assetmemo.bio/drug/sacituzumab-govitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878871-1983@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Furmonertinib: Phase 2 readout est. (NCT07878871)
DESCRIPTION:Furmonertinib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: F
 irmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III
  Lung Cancer: A Phase II Study\nEstimated primary completion: December 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/furmonertinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07878871
URL:https://assetmemo.bio/drug/furmonertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06837948-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Nab-paclitaxel: Phase 2 readout est. (NCT06837948)
DESCRIPTION:Nab-paclitaxel\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclon
 al Antibody in Locally Advanced NSCLC\nEstimated primary completion: 1 Dec
 ember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nab-pacli
 taxel#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06837948
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06837948-1990@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311201
DTEND;VALUE=DATE:20311202
SUMMARY:Pumitamig: Phase 2 readout est. (NCT06837948)
DESCRIPTION:Pumitamig\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal An
 tibody in Locally Advanced NSCLC\nEstimated primary completion: 1 December
  2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pumitamig#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06837948
URL:https://assetmemo.bio/drug/pumitamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247786-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07247786)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant
  in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)\n
 Estimated primary completion: 30 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07247786
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06917573-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT06917573)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: PALA
 CE: Cemiplimab Trial According to ctDNA Levels\nEstimated primary completi
 on: 30 December 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /cemiplimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06917573
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680790-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Tagrisso (Osimertinib): Phase 3 readout est. (NCT07680790)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 3\, Non-Small Cell Lung Cancer.\
 nStudy: Study of Izalontamab Brengitecan (BMS-986507) in Combination With 
 Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination W
 ith Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZA
 BRIGHT-Lung02)\nEstimated primary completion: 30 December 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/osimertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07680790
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680790-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Izalontamab brengitecan: Phase 3 readout est. (NCT07680790)
DESCRIPTION:Izalontamab brengitecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Study of Izalontamab Brengitecan (BMS-986507) in Combination With
  Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination 
 With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZ
 ABRIGHT-Lung02)\nEstimated primary completion: 30 December 2031. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07680790
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234877-2023@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Ivonescimab: Phase 2 readout est. (NCT07234877)
DESCRIPTION:Ivonescimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Pha
 se II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Ch
 emotherapy in NSCLC Brain Mets\nEstimated primary completion: January 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ivonescimab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07234877
URL:https://assetmemo.bio/drug/ivonescimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234877-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07234877)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivones
 cimab/Chemotherapy in NSCLC Brain Mets\nEstimated primary completion: Janu
 ary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0723
 4877
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study Evaluating the Safety\, Activity\, and Pharmacokinetics of Divara
 sib as a Single Agent or in Combination With Other Anti-Cancer Therapies i
 n Participants With Previously Untreated Advanced or Metastatic Non-Small 
 Cell Lung Cancer With a KRAS G12C Mutation\nEstimated primary completion: 
 29 January 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05789082
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-2217@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Divarasib: Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Divarasib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy Evaluating the Safety\, Activity\, and Pharmacokinetics of Divarasib 
 as a Single Agent or in Combination With Other Anti-Cancer Therapies in Pa
 rticipants With Previously Untreated Advanced or Metastatic Non-Small Cell
  Lung Cancer With a KRAS G12C Mutation\nEstimated primary completion: 29 J
 anuary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/divarasi
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 789082
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05789082-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320129
DTEND;VALUE=DATE:20320130
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT05789082)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: A Study Evaluating the Safety\, Activity\, and Pharmacokinetics of 
 Divarasib as a Single Agent or in Combination With Other Anti-Cancer Thera
 pies in Participants With Previously Untreated Advanced or Metastatic Non-
 Small Cell Lung Cancer With a KRAS G12C Mutation\nEstimated primary comple
 tion: 29 January 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/pemetrexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05789082
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07541170-2217@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320131
DTEND;VALUE=DATE:20320201
SUMMARY:Divarasib: Phase 3 readout est. (NCT07541170)
DESCRIPTION:Divarasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate the Efficacy and Safety of Divarasib Compared With Investig
 ator's Choice of Immunotherapy or Observation in Participants With Resecte
 d Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)\nEsti
 mated primary completion: 31 January 2032. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/divarasib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07541170
URL:https://assetmemo.bio/drug/divarasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943325-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Cemiplimab: Phase 3 readout est. (NCT07943325)
DESCRIPTION:Cemiplimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Dela
 yed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell
  Lung Cancer\nEstimated primary completion: February 2032. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07943325
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07943325-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320229
DTEND;VALUE=DATE:20320301
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07943325)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-S
 mall Cell Lung Cancer\nEstimated primary completion: February 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07943325
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: P
 embrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small
  Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated primary co
 mpletion: 6 February 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Sacituzumab Tirumotecan: Phase 2 readout est. (NCT06788912)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 2\, Non-Small Cell Lung Cancer.
 \nStudy: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable
  Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated 
 primary completion: 6 February 2032. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06788912-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320206
DTEND;VALUE=DATE:20320207
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT06788912)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non
 -small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)\nEstimated prim
 ary completion: 6 February 2032. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06788912
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK
 -3475) With or Without Chemotherapy When Used With Investigational Agents 
 in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer 
 (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 13 Febr
 uary 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04165070
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-1981@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Patritumab Deruxtecan: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Patritumab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembroliz
 umab (MK-3475) With or Without Chemotherapy When Used With Investigational
  Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung
  Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion:
  13 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pa
 tritumab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04165070
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-2106@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Boserolimab: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Boserolimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: K
 EYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3
 475) With or Without Chemotherapy When Used With Investigational Agents in
  Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (N
 SCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 13 Februa
 ry 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/boserolimab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0416
 5070
URL:https://assetmemo.bio/drug/boserolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizum
 ab (MK-3475) With or Without Chemotherapy When Used With Investigational A
 gents in Treatment-naïve Participants With Stage IV Non-small Cell Lung C
 ancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion: 1
 3 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peme
 trexed#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04165070
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165070-2527@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320213
DTEND;VALUE=DATE:20320214
SUMMARY:Ifinatamab Deruxtecan: Phase 1/2 readout est. (NCT04165070)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembroliz
 umab (MK-3475) With or Without Chemotherapy When Used With Investigational
  Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung
  Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)\nEstimated primary completion:
  13 February 2032. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/if
 inatamab-deruxtecan#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04165070
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195695-2274@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320226
DTEND;VALUE=DATE:20320227
SUMMARY:Hernexeos (Zongertinib): Phase 3 readout est. (NCT07195695)
DESCRIPTION:Hernexeos (Zongertinib)\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in Peo
 ple With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2
  TKD Mutations\nEstimated primary completion: 26 February 2032. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zongertinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07195695
URL:https://assetmemo.bio/drug/zongertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2527@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: Substudy 01I: A Study of Investigational Agents in Participants Wit
 h Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) 
 (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0678
 0098
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780098-2696@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320302
DTEND;VALUE=DATE:20320303
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06780098)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: Substudy 01I: A Study of Investigational Agents in Participants Wi
 th Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)
  (MK-3475-01I/KEYMAKER-U01I)\nEstimated primary completion: 2 March 2032. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxteca
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 780098
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2527@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Ifinatamab Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Ifinatamab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Investigational Agents in Participants With Previously T
 reated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01
 H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/ifinatamab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780085-2696@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Raludotatug Deruxtecan: Phase 2 readout est. (NCT06780085)
DESCRIPTION:Raludotatug Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of Investigational Agents in Participants With Previously 
 Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-0
 1H/KEYMAKER-U01)\nEstimated primary completion: 12 March 2032. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06780085
URL:https://assetmemo.bio/drug/raludotatug-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
  Study of Pembrolizumab With or Without Chemotherapy in Combination With A
 dditional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3
 475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06731907
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731907-1981@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320312
DTEND;VALUE=DATE:20320313
SUMMARY:Patritumab Deruxtecan: Phase 2 readout est. (NCT06731907)
DESCRIPTION:Patritumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study of Pembrolizumab With or Without Chemotherapy in Combinatio
 n With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCL
 C) (MK-3475-01G/KEYMAKER U01)\nEstimated primary completion: 12 March 2032
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/patritumab-deruxtec
 an#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6731907
URL:https://assetmemo.bio/drug/patritumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A
 nti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimat
 ed primary completion: 30 April 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimated p
 rimary completion: 30 April 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07355205)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Fir
 st-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803)
  in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 31 July 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07355205
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Ipilimumab: Phase 1/2 readout est. (NCT07355205)
DESCRIPTION:Ipilimumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Fi
 rst-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803
 ) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer\nEstim
 ated primary completion: 31 July 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/ipilimumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07355205
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-2051@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Nogapendekin alfa inbakicept (Anktiva): Phase 1/2 readout est. (NCT
 07355205)
DESCRIPTION:Nogapendekin alfa inbakicept (Anktiva)\, phase 1/2\, Non-Small 
 Cell Lung Cancer.\nStudy: First-Line Ipilimumab Plus Nivolumab and Nogapen
 dekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-S
 mall Cell Lung Cancer\nEstimated primary completion: 31 July 2032. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept
 -anktiva#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07355205
URL:https://assetmemo.bio/drug/nogapendekin-alfa-inbakicept-anktiva#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07388524-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Atezolizumab: Phase 3 readout est. (NCT07388524)
DESCRIPTION:Atezolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Te
 sting the Impact of an Anti-Cancer Drug\, Atezolizumab\, After Surgery to 
 Prevent Early Stage Non-small Cell Lung Cancer From Returning\, AASI-NSCLC
  Trial\nEstimated primary completion: 30 September 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/atezolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07388524
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07183189-2181@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Ruzaltatug rezetecan: Phase 3 readout est. (NCT07183189)
DESCRIPTION:Ruzaltatug rezetecan\, phase 3\, Non-Small Cell Lung Cancer.\nS
 tudy: A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib 
 for First-line Treatment in EGFR-mutated\, Advanced or Metastatic NSCLC\nE
 stimated primary completion: November 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07183189
URL:https://assetmemo.bio/drug/ruzaltatug-rezetecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07642024-2044@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Izalontamab brengitecan: Phase 2/3 readout est. (NCT07642024)
DESCRIPTION:Izalontamab brengitecan\, phase 2/3\, Non-Small Cell Lung Cance
 r.\nStudy: A Study of BL-B01D1 in Combination With Osimertinib as Perioper
 ative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung
  Cancer(PANKU-Lung09)\nEstimated primary completion: December 2032. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/izalontamab-brengitecan#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764202
 4
URL:https://assetmemo.bio/drug/izalontamab-brengitecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07554339-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20321215
DTEND;VALUE=DATE:20321216
SUMMARY:Calderasib: Phase 3 readout est. (NCT07554339)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Cl
 inical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Sma
 ll Cell Lung Cancer (MK-1084-015/KANDLELIT-015)\nEstimated primary complet
 ion: 15 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/calderasib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07554339
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895238-2166@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Adebrelimab: Phase 3 readout est. (NCT07895238)
DESCRIPTION:Adebrelimab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Perioperative Adebrelimab Plus Chemotherapy Versus Adjuvant Therap
 y in Patients With Resectable NSCLC\nEstimated primary completion: 31 Dece
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/adebrelima
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 895238
URL:https://assetmemo.bio/drug/adebrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07936422-2164@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Trastuzumab Deruxtecan: Phase 2 readout est. (NCT07936422)
DESCRIPTION:Trastuzumab Deruxtecan\, phase 2\, Non-Small Cell Lung Cancer.\
 nStudy: A Trial Evaluating the Anti-tumor Activity of Antibody-based Thera
 pies in Metastatic Cancer Patients\nEstimated primary completion: February
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/trastuzumab-de
 ruxtecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07936422
URL:https://assetmemo.bio/drug/trastuzumab-deruxtecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06623422-2042@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330516
DTEND;VALUE=DATE:20330517
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT06623422)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogen
 e (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpa
 th-009)\nEstimated primary completion: 16 May 2033. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/intismeran-autogene#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06623422
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Nab-paclitaxel: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Nab-paclitaxel\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keyt
 ruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexa
 valent OX40 Agonist)\nEstimated primary completion: July 2033. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Alimta (pemetrexed): Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Alimta (pemetrexed)\, phase 1/2\, Non-Small Cell Lung Cancer.\n
 Study: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab 
 (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors 
 (Hexavalent OX40 Agonist)\nEstimated primary completion: July 2033. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/pemetrexed#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-2546@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Ordastobart: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Ordastobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytrud
 a®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexaval
 ent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877584-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07877584)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line 
 Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%\nEstimate
 d primary completion: 30 November 2033. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07877584
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877584-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT07877584)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: PD-1 Blockade Alone Versus in Combination With Chemotherapy as First 
 Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%\nEst
 imated primary completion: 30 November 2033. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07877584
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07863999-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20331201
DTEND;VALUE=DATE:20331202
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT07863999)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Combined
  With Monoclonal Antibody in Locally Advanced NSCLC\nEstimated primary com
 pletion: 1 December 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07863999
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Study to Assess Efficacy and Safety of Pembrolizumab With or Without Saci
 tuzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non S
 mall Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response
  (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 2034. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06312137
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312137-1991@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340221
DTEND;VALUE=DATE:20340222
SUMMARY:Sacituzumab Tirumotecan: Phase 3 readout est. (NCT06312137)
DESCRIPTION:Sacituzumab Tirumotecan\, phase 3\, Non-Small Cell Lung Cancer.
 \nStudy: A Study to Assess Efficacy and Safety of Pembrolizumab With or Wi
 thout Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resect
 able Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complet
 e Response (pCR) (MK-2870-019)\nEstimated primary completion: 21 February 
 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/sacituzumab-tir
 umotecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06312137
URL:https://assetmemo.bio/drug/sacituzumab-tirumotecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07513376)
DESCRIPTION:Pembrolizumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A
  Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizuma
 b Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I
  Non-Small Cell Lung Cancer (V940-014)\nEstimated primary completion: 22 A
 ugust 2034. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07513376
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-2042@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Intismeran Autogene: Phase 3 readout est. (NCT07513376)
DESCRIPTION:Intismeran Autogene\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembro
 lizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk S
 tage I Non-Small Cell Lung Cancer (V940-014)\nEstimated primary completion
 : 22 August 2034. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/int
 ismeran-autogene#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07513376
URL:https://assetmemo.bio/drug/intismeran-autogene#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07513376-2259@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20340822
DTEND;VALUE=DATE:20340823
SUMMARY:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa): Phase 3 reado
 ut est. (NCT07513376)
DESCRIPTION:Keytruda Qlex (Pembrolizumab berahyaluronidase alfa)\, phase 3\
 , Non-Small Cell Lung Cancer.\nStudy: A Clinical Trial of Adjuvant Intisme
 ran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronida
 se Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-0
 14)\nEstimated primary completion: 22 August 2034. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07513376
URL:https://assetmemo.bio/drug/pembrolizumab-berahyaluronidase-alfa#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07153445-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20350502
DTEND;VALUE=DATE:20350503
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07153445)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Ne
 oadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for 
 the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)\nEstimated p
 rimary completion: 2 May 2035. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/atezolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07153445
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720167-1975@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:Cemiplimab: Phase 2 readout est. (NCT07720167)
DESCRIPTION:Cemiplimab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Cemi
 plimab for Clinical Stage I\, 2-3.9cm\, Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 1 August 2035. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/cemiplimab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07720167
URL:https://assetmemo.bio/drug/cemiplimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07720167-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20350801
DTEND;VALUE=DATE:20350802
SUMMARY:Alimta (pemetrexed): Phase 2 readout est. (NCT07720167)
DESCRIPTION:Alimta (pemetrexed)\, phase 2\, Non-Small Cell Lung Cancer.\nSt
 udy: Cemiplimab for Clinical Stage I\, 2-3.9cm\, Non-Small Cell Lung Cance
 r\nEstimated primary completion: 1 August 2035. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07720167
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365319-2115@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Resiquimod: Phase 2/3 readout est. (NCT07365319)
DESCRIPTION:Resiquimod\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: A 
 Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and
  Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.\nEs
 timated primary completion: 31 December 2035. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/resiquimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07365319
URL:https://assetmemo.bio/drug/resiquimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02201992-1966@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20360501
DTEND;VALUE=DATE:20360502
SUMMARY:Crizotinib: Phase 3 readout est. (NCT02201992)
DESCRIPTION:Crizotinib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Criz
 otinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer 
 That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Tr
 eatment Trial)\nEstimated primary completion: 1 May 2036. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/crizotinib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT02201992
URL:https://assetmemo.bio/drug/crizotinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-1958@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Tagrisso (Osimertinib): Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Tagrisso (Osimertinib)\, phase 2/3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity of
  Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as F
 irst-Line Treatment in Adult Participants With Locally Advanced Unresectab
 le or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nEst
 imated primary completion: November 2036. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/osimertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/osimertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Alimta (pemetrexed): Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Alimta (pemetrexed)\, phase 2/3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Adverse Events\, Change in Disease Activity of In
 travenous Telisotuzumab Adizutecan in Combination With Osimertinib as Firs
 t-Line Treatment in Adult Participants With Locally Advanced Unresectable 
 or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nEstima
 ted primary completion: November 2036. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-2270@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity 
 of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as
  First-Line Treatment in Adult Participants With Locally Advanced Unresect
 able or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nE
 stimated primary completion: November 2036. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05669846-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20361231
DTEND;VALUE=DATE:20370101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05669846)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory
  (R/R) PD-L1 Positive NSCLC\nEstimated primary completion: 31 December 203
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05669846
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096844-1963@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20390401
DTEND;VALUE=DATE:20390402
SUMMARY:Nab-paclitaxel: Phase 3 readout est. (NCT06096844)
DESCRIPTION:Nab-paclitaxel\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: 
 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Ol
 der Adults With Stage IIIB-IV Lung Cancer\, The ACHIEVE Trial\nEstimated p
 rimary completion: 1 April 2039. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nab-paclitaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06096844
URL:https://assetmemo.bio/drug/nab-paclitaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096844-2232@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20390401
DTEND;VALUE=DATE:20390402
SUMMARY:Alimta (pemetrexed): Phase 3 readout est. (NCT06096844)
DESCRIPTION:Alimta (pemetrexed)\, phase 3\, Non-Small Cell Lung Cancer.\nSt
 udy: Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone f
 or Older Adults With Stage IIIB-IV Lung Cancer\, The ACHIEVE Trial\nEstima
 ted primary completion: 1 April 2039. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pemetrexed#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06096844
URL:https://assetmemo.bio/drug/pemetrexed#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498635-1959@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20390715
DTEND;VALUE=DATE:20390716
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06498635)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy After Surgery for People Who Have No Remaining Cancer Cells Afte
 r Standard Treatment for Early-Stage Non-Small Cell Lung Cancer\, INSIGHT 
 Trial\nEstimated primary completion: 15 July 2039. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06498635
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431827-1988@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20391026
DTEND;VALUE=DATE:20391027
SUMMARY:Calderasib: Phase 3 readout est. (NCT07431827)
DESCRIPTION:Calderasib\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: MK-3
 475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS
  G12Cm NSCLC (MK-1084-013)\nEstimated primary completion: 26 October 2039.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/calderasib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07431827
URL:https://assetmemo.bio/drug/calderasib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1962@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Atezolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Atezolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiati
 on Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary com
 pletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/atezolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/atezolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1973@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 oncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiat
 ion Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary co
 mpletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1974@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Concu
 rrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation 
 Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary comple
 tion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07770100
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-2009@assetmemo.bio
DTSTAMP:20261121T005009Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Ipilimumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Ipilimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Conc
 urrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation
  Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary compl
 etion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/ipilimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07770100
URL:https://assetmemo.bio/drug/ipilimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
